Blue Cross and Blue Shield of Vermont
2025 Large Group Rating Program Filing
Actuarial Memorandum

1. PURPOSE ..... 2
2. OVERVIEW AND RATE IMPACT ..... 2
2.1. Overview ..... 2
2.2. Historical Financial Results ..... 2
2.3. Impact of Formula and Factor Changes ..... 3
3. FORMULA DESCRIPTION ..... 4
4. TREND FACTORS ..... 7
4.1. Medical Trend Development ..... 8
4.2. Retail Pharmacy Trend ..... 12
4.3. Overall Total Trend ..... 16
4.4. Leveraged Trends ..... 16
4.5. Medicare Secondary Trends ..... 16
4.6. Vision Trend ..... 17
4.7. Prior Experience Period Trend Factors ..... 17
5. BENEFIT FACTORS ..... 18
5.1. Models for Active Employees ..... 19
5.2. Tier Factors ..... 22
5.3. Models For Age 65+ Medicare Secondary Plans ..... 22
5.4. Formulary \& Pharmacy Options ..... 24
5.5. Riders ..... 24
5.6. Rate Smoothing Charges ..... 24
6. OTHER FACTORS APPLICABLE TO ALL LARGE GROUPS ..... 25
6.1. Manual Rate ..... 25
6.2. Large Claims Factors ..... 27
6.3. Administrative Charges ..... 28
6.4. Net Cost of Reinsurance ..... 29
6.5. Pharmacy Rebates ..... 30
6.6. Payment Reform Initiatives ..... 30
6.7. Contribution to Reserve ..... 30
6.8. State Mandates and Assessments ..... 31
6.9. Federal Assessments ..... 32
6.10. Hearing Aids ..... 32
7. MEDICAL LOSS RATIO PROJECTION ..... 32
8. ACT 193 INFORMATION. ..... 32
9. ACTUARIAL OPINION ..... 33
10. DISCLOSURES ..... 33

# Blue Cross and Blue Shield of Vermont 

2025 Large Group Rating Program Filing
Actuarial Memorandum

## 1. Purpose

Blue Cross and Blue Shield of Vermont (Blue Cross VT) performs large group rating on a case-by-case basis. We accomplish rating through a formulaic approach that blends recent group experience with a manual rate according to a credibility formula. We may adjust formula results for underwriting judgment and/or management decisions. This filing establishes the formula, manual rate, and accompanying factors that we will use for renewals beginning upon approval of this filing, most notably January 2025 renewals.

Once approved, we will use this filing for insured large group and grandfathered small group renewals (we will refer to them collectively as large groups for the remainder of the filing) until superseded by a subsequent filing ${ }^{1}$. In the event that renewals require factors with effective dates or experience periods beyond those explicitly presented in this filing, we will calculate appropriate factors using the same base data and methodology used in this filing. This filing will apply beginning with rates communicated within seven business days after the date of its approval and continuing until at most seven business days after the date of approval of the next Blue Cross VT Large Group Rating Program filing. The term "communicated," for this purpose, means a written proposal delivered to a large group account.

## 2. Overview and Rate Impact

### 2.1. Overview

This filing includes a description of the renewal formula and the development of each of the factors used in it. Blue Cross VT projects that this filing will affect 4,264 members ( 2,446 subscribers) in 33 groups. These totals are as of January 31, 2024.

We will describe in detail the formula used in the renewals. We will then detail the factors applicable to all insured large groups. The factors in the build-up of the projected claims cost include the trend factors, benefit relativities, manual rate, and large claims factors. In addition to the projected claims cost, we will explain the calculation of administrative charges, the net cost of reinsurance, contribution to reserve, and state and federal assessments, all of which we include in the rate development.

### 2.2. Historical Financial Results

Below is the experience for the prior five calendar years for Blue Cross VT and The Vermont Health Plan (TVHP). ${ }^{2}$ insured large group.

[^0]Blue Cross and Blue Shield of Vermont
2025 Large Group Rating Program Filing
Actuarial Memorandum

| Insured Large Group Experience |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year | Incurred Claims | Administrative Charges | Earned Premium | Gain/(Loss) |  <br> Expense Ratio | Target Loss and Expense Ratio | Member Months |
| 2019 | \$83,943,117 | \$10,154,503 | \$88,800,868 | (\$5,296,752) | 106.0\% | 98.5\% | 166,597 |
| 2020 | \$46,676,144 | \$9,376,855 | \$56,468,497 | \$415,498 | 99.3\% | 98.5\% | 97,941 |
| 2021 | \$41,511,340 | \$7,149,153 | \$43,451,198 | (\$5,209,294) | 112.0\% | 98.5\% | 71,773 |
| 2022 | \$56,188,326 | \$5,871,847 | \$54,947,032 | (\$7,113,141) | 112.9\% | 98.5\% | 88,273 |
| $2023{ }^{3}$ | \$43,959,865 | \$5,089,779 | \$47,210,141 | (\$1,839,503) | 103.9\% | 98.5\% | 66,570 |

The incurred claims, administrative expenses, and earned premium are from Blue Cross VT GAAP financials. The claims include capitations, fee-for-services claims, certain assessments, and other claims expenses. Overall, the performance of actual results to expected indicate a consistent absence of conservatism in the factors underlying the filing.

### 2.3. Impact of Formula and Factor Changes

To compute the impact of changes to the rating formula and the various factors in this filing on large group premium rates, we use the concept of a "pure manual premium," which is the premium that can be developed for each group in the existing block of business using none of their own experience data. ${ }^{4}$. We develop two renewals for each group: the first renewal applies the approved factors currently in force (BCVT-133551255 and BCVT-133676245) with an effective date of January 1, 2024. The second renewal uses the factors and formulas detailed in this filing with a January 1, 2025, effective date. By nature of the differing effective dates, the latter renewal includes an additional year of health care trend.

| Impact of Formula and Factor Changes |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: |
| Renewal Year | $\mathbf{2 0 2 4}$ | $\mathbf{2 0 2 5}$ | Component <br> Increase | Premium <br> Impact |
| Manual Claims (a) | $\$ 34,803,240$ | $\$ 37,941,327$ | $9.0 \%$ | $8.2 \%$ |
| Projected Rebates | $(\$ 2,204,366)$ | $(\$ 2,048,803)$ | $-7.1 \%$ | $0.4 \%$ |
| Admin | $\$ 2,862,709$ | $\$ 2,607,762$ | $-8.9 \%$ | $-0.7 \%$ |
| Reserve | $\$ 1,148,391$ | $\$ 1,244,333$ | $8.4 \%$ | $0.3 \%$ |
| Mandates and <br> Assessments | $\$ 803,177$ | $\$ 801,479$ | $-0.2 \%$ | $0.0 \%$ |
| Additional Items (b) | $\$ 866,549$ | $\$ 931,656$ | $7.5 \%$ | $0.2 \%$ |
| Total | $\$ 38,279,699$ | $\$ 41,477,754$ |  | $8.4 \%$ |

(a) The manual claims increase includes changes in the membership, industry, and update in benefit relativities from groups underlying the manual rate. We normalize the demographic factors, industry factors, and benefit factors to the membership in each respective filing.

[^1]
# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

(b) Additional Items include net cost of reinsurance, broker commissions, payment reform initiative costs, and fees paid to outside vendors.

We used the above approach to generate a proxy increase for a hypothetical group that is renewing with zero experience credibility, exactly average demographics and industry, and no underwriting judgment or management discretion applied to the proposed or in-force rates. The actual rate increase experienced by any specific group will be based on the group's own circumstances, including its claims data, demographic makeup, large claims experience, and so forth.

This total impact of formula and factor changes should not be interpreted as the new formula resulting in an 8.4 percent premium increase for any specific group.

## 3. Formula Description

We develop rates for active and Medicare Primary subscribers separately based on their own experience. Both the formula and factors described in this filing are the same for both populations except where noted. We do not offer Medicare Primary rate tiers on Blue Cross VT Managed Care networks.

## Benefit-Adjusted Projected Single Claims Rate

Exhibit 1A contains a sample calculation of the benefit-adjusted single claims rate. Page 1 of the exhibit applies to active members and page 2 applies to Medicare Primary members. For each case, we start the rating with a twelve-month experience period with at least two months of runout ${ }^{5}$. We include any fees charged by our pharmacy benefits manager or associated with claims subrogation in the claims total. We develop the experience rate for medical and pharmacy claims separately. We determine a pooling point based on the size of the case at the end of the runout period and split the experience period claims (line A) into amounts above (line B) and below (referred to as capped claims, line D) the pooling point. We exclude certain COVID-19 related claims incurred through June $2021{ }^{6}$ (line C) from the development. Exhibit 6C contains a list of excluded primary diagnosis and procedure codes.

We apply completion factors (line E) developed from the monthly financial reporting process (best estimates before margin) to capped claims to produce completed capped claims (line F). We use the formula and factors described in Milliman's 2023 Health Cost Guidelines - Reinsurance to calculate expected claims above the pooling limit (line G). We add the expected claims above the pooling limit to the completed capped claims to produce large-claim-adjusted experience period claims. Medicare Primary members generally do not have claims near the group's pooling point, so we do not pool their claims.

We then multiply the large-claim-adjusted experience claims by an adjustment factor (line H ) to reflect structural changes between the experience period and the rating period. This adjustment modifies the experience to reflect such things as mandated benefit changes, contractual provision changes,

[^2]
## Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum

mandated changes to provider payments, etc., that, in the judgment of the underwriter, are necessary to make the experience appropriate for the estimation of the expected claims in the rating period.

We divide the result (line I) by the number of member months during the experience period (line J) to produce the adjusted experience period claims per member per month (line K).

We then divide the adjusted experience period claims per member per month (PMPM) by a seasonallyadjusted benefit relativity value to neutralize any effect of seasonality and benefits on the paid claims. To determine this factor, we first determine a benefit relativity factor for each benefit plan (using the factors described in section 5) and contract tier type (single, 2-person, family, etc.). Based on the seasonal patterns observed as part of the reserving process for each calendar month, we determine seasonal factors for CDHPs and for non-CDHPs and normalize them so that they total to 12 . We combine these factors to calculate seasonal benefit relativity factors for each combination of benefit plan, contract tier type, and month. We apply these factors to the number of contracts for each benefit plan, contract tier type, and month in the experience period. We total the results and divide the resultant sum by the number of member months in the experience period. We apply the seasonal factors regardless of the length of experience period, but if there is a 12 -month experience period and there are no changes in benefits or enrollment, the normalization of the seasonality factors would cause the seasonal adjustment to be 1.000 . This produces the average experience period seasonally-adjusted benefit relativity factor (line L).

We adjust for any change in the demographics of the group between the experience period and the rating period by calculating the average demographic factor for each period and applying the ratio of projection to experience (line M). We multiply the adjusted experience period claims PMPM (line K) by the demographic normalization factor and divide by the average experience period seasonally-adjusted benefit relativity factor (line L ) to produce the benefit-adjusted experience period single claims rate (line N ), which is the expected cost for a single contract in the experience, neutral of benefit and seasonality. We then multiply this by a trend factor (line $Q$, as discussed in section 4) to project the claims from the experience period to the rating period.

We blend the projected single contract rate (line R) with the adjusted manual rate (line S, as described in section 6.1) using the credibility formula described below.

We calculate the credibility factor (line T ) as follows:
Credibility $=\sqrt{\frac{\text { Member Months }}{\text { Upper Bound }}}$
The pooling point determines the upper bound. We base the pooling limit on the group's membership in the current month as shown in the abbreviated table below for details. The underwriter may apply discretion in the event the current month's membership is not appropriate for determining a pooling limit (e.g., a material change in enrollment due to an acquisition or layoff).

Blue Cross and Blue Shield of Vermont
2025 Large Group Rating Program Filing
Actuarial Memorandum

| Membership <br> (Current Months) | Pooling Point | Upper Bound <br> Member Months |
| :---: | :---: | :---: |
| Medicare Primary |  | 8,325 |
| 0 to 299 | $\$ 100,000$ | 17,055 |
| 300 to 499 | $\$ 120,000$ | 18,745 |
| 500 to 999 | $\$ 140,000$ | 20,266 |

If member months are greater than the upper bound, the credibility factor will be 1. Exhibit 6A provides a complete list of upper bound member months by pooling point, while Exhibit 6B details pooling points by current month membership. To blend the projected single contract rate with the adjusted manual rate, we use the following equation:

Benefit-Adjusted Projected Single Claims Rate $=$ Projected Single Contract Rate $\times$ (Credibility) + Adjusted Manual Rate $\times$ ( 1 - Credibility)

## Multiple Experience Periods

Blue Cross VT uses multiple experience periods (when available) to develop the benefit-adjusted projected single claims rate. Following the methodology described above, we calculate an experience rate for the first and second year preceding the experience period. We then apply the credibility formula recursively to the residual portion of the rate. The table below provides a demonstration of the application of the credibility formula for a group with 50 percent credibility in each experience year.

| Experience Period | Proportion of <br> Rate |
| :--- | :---: |
| YE 202406 | $50.0 \%$ |
| YE 202306 | $25.0 \%$ |
| YE 202206 | $12.5 \%$ |
| Manual Rate | $12.5 \%$ |

Three years of experience is the maximum that we will use. In the absence of extenuating circumstances, all renewals will use the maximum number of years available. In the event we do not consider historical experience appropriate or reliable for rating periods (e.g., a significant change in enrollment due to an acquisition or layoff), the underwriter will use fewer years of experience and document the rationale for such a change.

Exhibit 1B provides a detailed sample calculation of the benefit-adjusted projected single claims rate using three years of experience.

If the credibility of the first year of experience is more than $66.67 \%$, the underwriter shall develop rates using a 3-2-1 blend of experience periods and not utilize the manual rate.

## Required premium by Plan, Tier Type

Exhibit 1C provides a sample calculation of premium. For each plan and contract tier type anticipated in the rating period, we calculate projected claims (line B1) as the product of the benefit-adjusted

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

projected single claims rate $(S$ ) and the benefit relativity factor (as described in section 5 ) for the plan and contract tier (line A). For any premium components that are exclusively applicable to either active or Medicare Primary members, we only include the component in the respective rate tier(s) to which it applies.

We use the members per contract tier during the last month of the runout period as the basis for the projected members per tier in the rating period. The underwriter will adjust this ratio if, in their opinion, the result is not representative of the expected values in the rating period. ${ }^{7}$

## Underwriting Judgment Adjustments

If, in the underwriter's professional judgment, the standard formula would not produce appropriate rates for the case they are rating, the underwriter will make such modifications as needed to produce appropriate rates. The underwriter will document in the case file the reason(s) for the adjustment(s) and the method of determining the appropriate adjustment(s).

## Management Discretionary Adjustments

For marketing or other reasons, management may decide to modify the rates on a specific case or block of cases. The underwriter will document in the case file the adjustment(s) made, along with a description of the nature of the adjustment(s).

## 4. Trend Factors

The source of data for trend development is the Blue Cross VT data warehouse, except where noted below. To ensure the accuracy of claims information, we reconcile the data used against internal reserving, enrollment, and other financial reports. The data includes claims from Blue Cross VT Cost Plus groups, Blue Cross VT self-funded groups of under 1,001 members, Blue Cross VT insured large groups, Blue Cross VT insured small groups with more than 10 members, Blue Cross VT insured association health plans, and TVHP insured large groups. The data also excludes insured large groups that left Blue Cross VT before September 2023, and any insured large groups new to Blue Cross VT in 2023. The above lines of business cover substantially similar populations under similar benefit packages. Combining these homogeneous populations creates greater consistency and credibility within the trend factor development.

We exclude large self-funded groups and self-funded groups with special pricing arrangements. We exclude claims from Medicare Primary members. We discuss Medicare Primary trend in section 4.5.

We use claims incurred from October 1, 2019, to September 30, 2023, paid through November 30, 2023. We apply completion factors to estimate the ultimate incurred claims for each period shown in the exhibits.

[^3]
# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

### 4.1. Medical Trend Development

Medical trend is composed of three pieces: cost, utilization, and intensity. In our analysis, we combine utilization and intensity within the utilization metric and analyze the unit cost separately. For fee-forservice claims, we combine plan payment with member cost sharing to calculate the allowed charges. For claims under a capitation arrangement, we combine a fee-for-service equivalent amount with the member cost sharing to calculate allowed charges.

### 4.1.1. Unit Cost

Observations of recent contracting and provider budgetary changes are the main source of unit cost trends. During the year ending September 2023, roughly 57 percent of total claims dollars were provided by Vermont facilities and providers directly affected by the hospital budget review process of the Green Mountain Care Board (GMCB). For hospitals under the jurisdiction of GMCB review, we start with the assumption that the GMCB will approve hospital budgets for October 1, 2024, and October 1, 2025, that support identical commercial increases as the five-year average of those approved for FY 2020 - FY $2024^{8}$. In the event that Blue Cross VT is made aware of budget increases that would materially diverge from this assumption, Blue Cross VT will file an interim trend filing to best align the cost trend used in pricing with expected cost trend.

For other providers within the Blue Cross VT service area, we work with the Blue Cross VT contracting team to include expected contract changes.

The provider contracting and actuarial departments worked together to assess the impact these increases would have on contracts for Blue Cross VT Managed Care, Blue Cross VT Non-Managed Care, and TVHP Managed Care contracts ${ }^{9}$. For marketing reasons, Blue Cross VT negotiates different unit cost increases for each of the contracts. To reflect these differences, we calculate a cost trend for each contract.

Finally, we derive unit cost increases for providers outside the Blue Cross VT service area from the Fall 2023 Blue Trend Survey, which is a proprietary and confidential dissemination of the BlueCross BlueShield Association.

Exhibit 2A shows the details of the cost increases by contract and type of claim.
We use the expected increases to trend the contract-normalized claims to the projection period.

The chart below summarizes the results of the analysis:

[^4]Blue Cross and Blue Shield of Vermont
2025 Large Group Rating Program Filing
Actuarial Memorandum

| Annualized Medical Unit Cost Trend - YE 202309 to CY 2024 |  |  |
| :--- | :---: | :---: |
|  | Blue Cross VT <br> Managed Care | Blue Cross VT Non- <br> Managed Care |
| Vermont facilities and providers impacted <br> by GMCB's Hospital Budget Review | $5.4 \%$ | $5.3 \%$ |
| Other facilities and providers | $5.7 \%$ | $5.7 \%$ |
| Total | $5.5 \%$ | $5.5 \%$ |


| Annualized Medical Unit Cost Trend - CY 2024 to CY 2025 |  |  |
| :--- | :---: | :---: |
|  | Blue Cross VT <br> Managed Care | Blue Cross VT Non- <br> Managed Care |
| Vermont facilities and providers impacted <br> by GMCB's Hospital Budget Review | $6.5 \%$ | $6.5 \%$ |
| Other facilities and providers | $5.4 \%$ | $5.4 \%$ |
| Total | $6.0 \%$ | $6.0 \%$ |

### 4.1.2. Utilization \& Intensity

To examine historical utilization trend patterns, we first normalize claims for unit cost increases. We measure contract changes for the entirety of the experience period explicitly for each facility within our service area as well as for major professional fee schedules. We normalize claims to the September 2023 contract at each unique provider by applying a factor equal to the product of the impact of each contracting change from the experience month through September 2023. We assume that the derived trend for other claims increases monthly on a continuous basis. This accounts for 85 percent of allowed claims dollars during the experience period. Costs for other claims are primarily for out-of-area services. To derive contracting changes for these claims, we use data from the Fall 2023 Blue Trend Survey, which is a proprietary and confidential dissemination of the BlueCross BlueShield Association.

To ensure that random high claims do not skew the trend calculation, we removed all claims of members who exceeded $\$ 500,000$ in allowed medical claims in a year ended September. As the utilization component includes intensity, an increase in high-cost claimants can disproportionately impact the year-over-over and regression calculations.

Exhibit 2B shows the resulting array of allowed PMPM claims costs both before and after normalization for contract changes. We also apply normalization factors to the array of allowed PMPM claim costs for:

- Changes in demographics, using factors from the SOA's report Health Care Costs - From Birth to Death ${ }^{10}$.
- Changes in paid-to-allowed ratio, using the induced utilization formula from HHS ${ }^{11}$.
- Normalizing each month to the average number of working days per month in the year ended September 2023, as defined by our reserving models.
- Programs to combat fraud, waste, and abuse (FWA).

[^5]
# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

Exhibit 2C shows the resulting time series and regressions.

## Facility Claims

Using the array of PMPM claim costs net of high claimants and adjusted for contract, aging, induced utilization, number of working days, and FWA, we performed 24-month regressions, 36 -month regressions, 48-month regressions, and time series calculations.

The deferral and return of care attributable to the COVID-19 pandemic unduly affected the 48-month regressions and time series, so we do not consider their results to be reliable projections of trend.

Claims in the year-ended September 2023, after the adjustments described above, are 2.9 percent higher than the year-ended September 2022. The year-over-year trend is slightly higher than other 24and 36 -month measures. We consider a 1.8 percent trend rate to be a reasonable selection through CY 2025 for these claims. FY 2024 hospital budget submissions noted some facilities had undertaken work to clear their backlogs and reduce wait times in 2022 and $20233^{12}$, which likely increased trend in the year ended September 2023. However, the University of Vermont Health Network noted it was undertaking an initiative to improve their case mix index ${ }^{13}$, which will result in higher commercial payments through the projection period. Any increases in the average severity will affect the intensity trend, which lends support to a modestly positive trend.

We provide the historical facility utilization trends through September 2023, and our selected trends for future periods in the table below.

| Facility Claims |  |  |
| :--- | :---: | :---: |
| Year Ending | PMPM | Annualized Trend |
| September 2020 | $\$ 338.06$ |  |
| September 2021 | $\$ 364.89$ | $7.9 \%$ |
| September 2022 | $\$ 366.82$ | $0.5 \%$ |
| September 2023 | $\$ 377.36$ | $2.9 \%$ |
| December 2024 | $\$ 385.88$ | $1.8 \%$ |
| December 2025 | $\$ 392.83$ | $1.8 \%$ |

Exhibit 2C, pages 7 to 9, shows the normalized facility time series and regressions.

## Professional and Ancillary

Similar to facility claims, we use the array of PMPM claim costs net of high claimants and adjusted for contract, aging, induced utilization, number of working days, and FWA, to perform 24-month regressions, 36 -month regressions, 48 -month regressions, and time series calculations.

Consistent with previous large group filings, we select separate utilization trends for mental health and substance use disorder (MHSUD) professional services and other professional services. After the

[^6]adjustments described above, professional MHSUD claims increased by 3.5 percent from year-ending September 2022 to year-ending September 2023, while all other professional claims increased by 2.1 percent over the same period.

MHSUD claims saw a significant increase in visits in the initial year of the COVID-19 pandemic but have since seen its trend rate dampen. We expect trend through CY 2025 will be aligned with the observed trend in recent years, and therefore select a utilization trend of 3.0 percent.

For all other professional services, an increase in evaluation and management visits and facility services underlie the high year-over-year trend. As with facility services, we consider the recent trends to be partially influenced by the work of providers to lessen their backlog. Considering this, we believe a selection of 1.8 percent, which is below the most recently observed of trend of 2.1 percent, best projects trend through CY 2025.

We provide the historical professional utilization trends through September 2023, and our selected trends for future periods in the table below.

| Professional Trend |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
|  | MHSUD |  | Non-MHSUD |  | Total Professional |  |
| Year Ending | PMPM | Annualized <br> Trend | PMPM | Annualized <br> Trend | PMPM | Annualized <br> Trend |
| September 2020 | $\$ 14.62$ |  | $\$ 122.54$ |  | $\$ 137.16$ |  |
| September 2021 | $\$ 16.44$ | $12.4 \%$ | $\$ 139.32$ | $13.7 \%$ | $\$ 155.76$ | $13.6 \%$ |
| September 2022 | $\$ 17.28$ | $5.1 \%$ | $\$ 143.07$ | $2.7 \%$ | $\$ 160.35$ | $2.9 \%$ |
| September 2023 | $\$ 17.88$ | $3.5 \%$ | $\$ 146.04$ | $2.1 \%$ | $\$ 163.93$ | $2.2 \%$ |
| December 2024 | $\$ 18.56$ | $3.0 \%$ | $\$ 149.34$ | $1.8 \%$ | $\$ 167.90$ | $1.9 \%$ |
| December 2025 | $\$ 19.11$ | $3.0 \%$ | $\$ 152.03$ | $1.8 \%$ | $\$ 171.15$ | $1.9 \%$ |

Exhibit 2C, pages 1 to 6, shows the normalized professional time series and regressions.

## Pharmaceuticals

The acceleration in cost for pharmaceuticals processed through the medical benefit warrants a separate analysis for these claims. Pharmaceuticals processed through the medical benefits include a wide variety of drugs. In prior filings, we included all types of pharmaceuticals in this separate analysis, but ultimately trended non-injections at the selected facility trend. To simplify the analysis, we only included specialty medications in this analysis and retained other medications in the respective facility or professional analysis.

The year ending September 2023 over year ending September 2022 annualized trend, after the adjustments described above, is 4.3 percent. We consider a 4.0 percent trend rate, which is aligned with and slightly lower than the average of the 24 - and 48 -months regressions, to be a reasonable selection for these claims.

Blue Cross and Blue Shield of Vermont
2025 Large Group Rating Program Filing
Actuarial Memorandum

| Pharmaceuticals |  |  |
| :--- | :---: | :---: |
| Year Ending | PMPM | Annualized Trend |
| September 2020 | $\$ 34.50$ |  |
| September 2021 | $\$ 37.93$ | $9.9 \%$ |
| September 2022 | $\$ 38.87$ | $2.5 \%$ |
| September 2023 | $\$ 40.54$ | $4.3 \%$ |
| December 2024 | $\$ 42.58$ | $4.0 \%$ |
| December 2025 | $\$ 44.28$ | $4.0 \%$ |

Exhibit 2C, pages 10 to 12 show the specialty pharmaceutical normalized time series and regressions.

### 4.1.3. Total Medical Trend

The total medical trend factors are the product of the utilization trend and the unit cost trend factors.

| YE 202309 to CY 2025 Annualized Medical Trend - Blue Cross VT Managed Care |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: |
| Category | Facility | Professional | Pharmaceuticals | Total |
| Unit Cost | $6.2 \%$ | $4.5 \%$ | $6.5 \%$ |  |
| Utilization | $1.8 \%$ | $1.9 \%$ | $4.0 \%$ |  |
| Total Medical Trend | $8.1 \%$ | $6.5 \%$ | $10.7 \%$ | $7.8 \%$ |


| Component | Blue Cross VT <br> Managed Care | Blue Cross VT Non- <br> Managed Care |
| :---: | :---: | :---: |
| Total Annual Medical Trend | $7.8 \%$ | $7.8 \%$ |

These represent the annualized trend from year-ending September 2023 to calendar year 2025. Due to the non-uniform trend assumptions for unit cost trend, we will apply monthly trend factors to bring the renewal experience period through the rating period. Exhibit 2G shows the monthly factors.

### 4.2. Retail Pharmacy Trend

For generic and brand drugs, we base our cost trend calculation on Average Wholesale Price (AWP) and apply a factor to the rating formula to account for the contracting changes. We exclude compound drugs from the development of AWP trend.

We separate glucagon-like peptide 1 (GLP-1) receptor agonists from brand cost trend and non-specialty utilization trend. This class of drugs experienced substantial growth in the year ending September 2023, and its inclusion in brand cost or non-specialty utilization would not reliably project future trends for either grouping.

We analyze the components of trend (cost and utilization) separately for brands, generics, and specialty drugs. We project the impact of brands going generic based on the brand drugs that are scheduled to lose patent in the projection period. Specialty drugs are very high-cost drugs with low utilization. Because of their relative infrequency, it is more appropriate to look at the overall PMPM trends for

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

these drugs rather than separate cost and utilization components. We calculate the overall pharmacy trend by combining the separate projections.

## Non-Specialty Drug Utilization

Exhibit 2D provides the monthly and the 12-month rolling data for non-specialty drugs, along with the corresponding year-over-year and exponential regression trends. There are separate developments for generic cost, brand cost, and overall non-specialty utilization. We use the number of days supply in the utilization development, rather than the number of scripts, to normalize for changes in the days supply per script (e.g., increased use of 90 -day fills). Because there are several popular brand drugs that have become generic during the experience period, or will become generic during the projection period, we combine the data for generic and brand drugs for the purpose of analyzing utilization patterns. We exclude vaccines, compound drugs, over the counter, GLP-1, and devices from the non-specialty trend calculations. We adjust the data for pharmacy working days, which are different from medical working days.

Due to the relaxation of clinical edits in response to COVID-19, many members refilled their prescription early in March 2020. This changed the pattern of monthly days supply per member. To adjust for this one-time event, we smooth monthly days supply per member for the periods from March 2020 to May 2020 and June 2020 to August 2020 by using the monthly spread from the same months in $2019{ }^{14}$. Blue Cross VT introduced Vermont Blue Rx in July 2021, which included a change in pharmacy benefit manager. Prior to the transition, we offered members the option to refill their prescriptions early to avoid potential disruptions. We smooth the monthly days supply for the period from June 2021 to August 2021 by using the monthly spread from the same months in 2019.

Exhibit 2D, page 3, shows monthly cost per day supply, adjustment calculation, the 24-month regressions and the 36 -month regressions. We select a 3.1 percent non-specialty utilization trend, which approximately corresponds to the average of the regressions on monthly, rolling costs, year-over-year and two-year trends.

The utilization of GLP-1 drugs in September 2023 more than double the observed amount in September 2022. Considering the dramatic increase in days supply for this class, we rebase our experience to be the annualized amount from May - September 2023 before trending at the same trend rate as all other nonspecialty drugs.

## Generic Cost Trend

Exhibit 2D, page 1, shows monthly AWP cost per days supply and the 24 -month regressions. We select 3.3 percent for the generic cost trend, which corresponds to the average of the 24-month regressions and the year over year result. We consider this to be a reasonable outlook for generic cost trend through CY 2025.

Brands that are going generic will become subject to generic discounts. We do not expect that the AWP for these drugs will significantly change from the experience period due to the lack of generic competition for the main drugs in this category. We adjust the price to reflect the different experienced effective discounts between brands and generics. We also adjust the price of the new generics to reflect

[^7]
# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

the difference in effective discounts as compared to the generics that have been in the market for at least three years.

## Brand Cost Trend

The mix of new and older brands affects the monthly AWP cost per day supply for brand drugs. Brands that have been in the market for one to two years are, on average, more expensive than older brands. To account for this change in mix, we perform a 24 -month regression on monthly AWP cost per day supply for brand drugs that have been in the experience for at least four years. We also exclude devices, vaccines, over the counter, compounds, GLP-1 drugs, COVID-19 drugs, and certain categories of drugs where we do not consider past experience to be representative of future trends from the trend analysis. We apply the selected trend to all brand drugs, including GLP-1, devices, and vaccines.

Exhibit 2D, page 2, shows the monthly cost per day supply and the 24 -month regressions.
We select 4.5 percent for the brand cost trend, which is slightly higher than the average of the 24-month regression result on monthly data, the 24 -month regression on rolling 12-month data, and the most recent year-over-year trend. The passage of the American Rescue Plan Act removed the cap which limited Medicaid rebates to 100 percent of the Average Manufacturer Price (AMP). In response to this, many manufacturers announced significant pricing changes. Although many of the pricing changes will not occur until to 2024, we observed minimal cost changes for drugs affected by the AMP cap, which dampened brand cost trend in the year ending September 2023. Given this, we believe the observed trend is likely understated and consider the selected trend of 4.5 percent to be an adequate, yet not excessive, outlook of future trends.

Compounds are one-off prescriptions that are constructed at the pharmacy from component ingredients. Because they are not sold on a wholesale basis, there is no official AWP. Therefore, the concept of cost trend does not apply to compounds. We also do not expect over the counter (OTC) to follow the overall brand cost trend, and we select a 0 percent cost trend for OTC drugs.

## Specialty Drugs

Exhibit 2E shows the calculation of specialty trend for all specialty drugs. We select a 14.0 percent specialty trend. This is informed by the average trend produced by a 24 -month regression on monthly cost, a 24 -month regression on rolling 12-month cost, the most recent year over year increase, and an expected reduction in costs due to the introduction of biosimilars. For our regressions, we chose 24 points of monthly data to best capture the most recent history of drug costs.

## Total Pharmacy Trend

Instead of explicitly projecting a generic dispensing rate, we separate the drugs into the following categories:

- Generics: Drugs that have been generic since at least October 2020
- New generics: Generic drugs that have been on the market for fewer than 36 months (launched October 2020 through September 2023)
- Brands going Generic: brands that we expect to become available in generic form in the projection period, based on a list from our pharmacy benefit manager
- Vaccines
- Over the Counter (OTC)


# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

- Compounds
- Devices, such as continuous glucose monitoring and insulin pens
- COVID-19 vaccines
- All other Brands

As shown on Exhibit 2F, we trend the days supply for each category forward at the same rate of 3.1 percent ${ }^{15}$ and calculate the total non-specialty allowed drug trend as 7.4 percent ${ }^{16}$.

Using the PMPM claims as weights between non-specialty and specialty claims for the 12 months ended September 2023, we apply the annual trends for 27 months. For drug claims in the year ended September 2023, we apply to AWP the contracted discounts and dispensing fees for both the experience period and CY 2025 to calculate the total effective trend based on anticipated discount improvements:

| Allowed Pharmacy Trend |  |
| :--- | :---: |
| Category | Annual Trend |
| Generic | $6.5 \%$ |
| Brand | $7.8 \%$ |
| Brands Going Generic | $-37.0 \%$ |
| Specialty | $14.0 \%$ |
| Total (Contract Adjusted) ${ }^{17}$ | $11.0 \%$ |

Please note that we apply contract changes separately from trend to accurately capture the timing for each renewal.

## AMP Cap

The passage of the American Rescue Plan Act removed the cap which limited Medicaid rebates to 100 percent of the Average Manufacturer Price (AMP). In response to this, many manufacturers announced significant pricing changes. Based on modeling provided by our PBM, we reduced non-specialty claims by $\$ 5.68$ PMPM due to anticipated reductions in the ingredient cost in drugs affected by the cap. To apply the reduction, we reduce the January 2024 PMPM cost used to calculate the monthly trend factor for January 2024 by $\$ 5.68$, which is when the majority of the reduction in pricing claims are expected to occur. Exhibit 2 H provides the development of the assumed reduction in ingredient costs and rebates.

After adjusting for the AMP cap, the effective non-specialty trend is 3.7 percent, and the effective total pharmacy trend is 9.4 percent.

## Contract Adjustment Factors

Exhibit 3 K contains the contract adjustment factors that we will apply to the drug claims in a group's renewal. These factors assume that both the experience period and rating period are 12 months. For cases where this is not true, or for periods not provided in the exhibit, we will calculate an appropriate factor using an analogous methodology.

[^8]
### 4.3. Overall Total Trend

Using the claims experience ${ }^{18}$ for the groups included in the manual rate (see section 6.1), we calculate the overall allowed trend as follows:

| Category | Allowed PMPM | Allowed Trend |
| :--- | :---: | :---: |
| Medical | $\$ 672.72$ | $7.8 \%$ |
| Pharmacy | $\$ 150.15$ | $9.4 \%$ |
| Total | $\$ 822.86$ | $8.1 \%$ |

### 4.4. Leveraged Trends

We will continue to use the leverage formulas from the Q3 2022 Large Group Filing. The formulas for leverage are below:

| Leverage Formulas |  |
| :--- | :--- |
| Medical | $-0.0631 \times(\mathrm{AV})+1.0641$ |
| Drug Card | $-0.0845 \times(\mathrm{AV})+1.0850$ |
| Drug - CDHP 100\% Wellness | $-0.0517 \times(\mathrm{AV})+1.0529$ |
| Drug - All Other CDHP | $-0.0802 \times(\mathrm{AV})+1.0805$ |

Exhibits 3 I and 3J provide examples of leverage factors.
Applying the leverage factors for benefits present in the year ended September 2023 for the groups included in the manual rate, we calculate the following paid trends:

| Category | Paid PMPM | Paid Trend |
| :--- | :---: | :---: |
| Medical | $\$ 548.88$ | $9.2 \%$ |
| Pharmacy | $\$ 135.65$ | $10.0 \%$ |
| Total | $\$ 684.53$ | $9.4 \%{ }^{19}$ |

### 4.5. Medicare Secondary Trends

Medicare Secondary plans cover two categories of services: Medicare-covered services which are subject to member cost share (deductible/coinsurance) and services which are not covered by Medicare. We do not adjust services subject to Medicare cost sharing for network, as Medicare sets the allowed charges, whereas we do adjust the services not covered by Medicare using the contract factors described above to bring all charges to a single network.

For Medicare claims, we use cost and utilization trends from the 2024 TVHP Medigap Blue Rate filing (BCVT-133710125).

[^9]Blue Cross and Blue Shield of Vermont
2025 Large Group Rating Program Filing
Actuarial Memorandum

| Category | Allowed Trend |
| :--- | :---: |
| Inpatient | $-2.6 \%$ |
| Outpatient | $11.3 \%$ |
| Professional | $2.6 \%$ |

The trends used for services not covered by Medicare are the same as the trends developed for use with active benefits. We use the same pharmacy trends for Medicare Secondary plans as we use for active plans.

### 4.6. Vision Trend

All large groups benefits include vision exams for both adult and children. Large groups can also purchase a rider to cover frames and lenses. Due to the different coverage options and limitation in the vision data to identify the cost of the exam and the materials, we calculate the trends for the large groups with exam only coverage.

| Year Ending | Paid PMPM |
| :---: | :---: |
| September 2020 | $\$ 0.42$ |
| September 2021 | $\$ 0.42$ |
| September 2022 | $\$ 0.44$ |
| September 2023 | $\$ 0.41$ |

Vision claims have remained relatively consistent over the past four years, with the cost oscillating around $\$ 0.42$. We expect 2024 and 2025 costs to remain consistent and therefore select a 0.0 percent overall vision paid trend.

While the data for groups with coverage for exam and materials is not fully credible for trend development, we observed the following PMPM paid claims results. We believe that the overall 0.0 percent trend for vision benefits is therefore reasonable for both exam and material benefits.

| Year Ended | Average Membership | Paid PMPM |
| :---: | :---: | :---: |
| September 2020 | 1,127 | $\$ 2.60$ |
| September 2021 | 1,567 | $\$ 2.34$ |
| September 2022 | 1,172 | $\$ 2.07$ |
| September 2023 | 1,194 | $\$ 2.13$ |

### 4.7. Monthly Trend Factors

We trend prior experience periods to the most current experience period using observed trends and apply the trend factors in section 4 to trend from the most current experience period to the rating period. Exhibit 2G contains the trend factors applicable to prior periods. For months following our trend base (that is, after September 2023), the observed trend is set to the trend factors in section 4. There are separate observed trend factors for active medical, Medicare Primary medical, and pharmacy.

To develop the observed medical trend factors, we calculate a monthly utilization trend. We apply actual cost increases to calculate the total observed medical trend. The observed pharmacy trend is the

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

allowed claims trend of the trend experience base described in section 4. Historical trend factors for Medicare Primary medical claims are the approved trends for prior periods from the filed 2024 TVHP Medigap Blue Rate filing (BCVT-133710125).

## 5. Benefit Factors

To determine standardized claims rate relationships, also called relativities, Blue Cross VT creates models that simulate the impact of member benefits for all types of plans. The models determine the allowed charges for the 12 months of claims included in the study and "re-adjudicate" the claims, thereby simulating the impact of member cost sharing for a given benefit plan.

The claims data used in the models is from the Blue Cross VT data warehouse. To ensure accuracy, the claims data has been reconciled against internal reserving, enrollment, and other financial reports. The starting point of the analysis is allowed charges as determined by the Blue Cross VT claims adjudication system. The claims data includes benefit service codes that enable us to identify the services and benefit structures (copays, deductibles, and coinsurance) for each claim.

We create separate models for active members and Medicare Primary members which use different experience periods. The models for active employees use incurred allowed charges from October 2022 to September 2023, paid through November 2023. We trend the allowed charges 27 months to the 12month period that begins January 1, 2025. The models for Medicare primary members use incurred allowed charges from January 2021 to December 2021, paid through November 2023. The majority of the Medicare primary experience comes from one group that changed coverage in January 2022; therefore, we used the most recent 12 months for which that group was present. We trend the allowed charges 48 months to the 12 -month period that begins January 1, 2025. The majority of the business that will be renewed using these relativity factors has a January 1 renewal date; the rating formula adjusts the trend for non-January renewals (see section 6.1).

The data includes claims from Blue Cross VT Cost Plus groups, Blue Cross VT self-funded groups of under 1,001 members, Blue Cross VT insured large groups, Blue Cross VT insured small groups with more than 10 members, Blue Cross VT insured association health plans, and TVHP insured large groups. The data also excludes insured large groups that left Blue Cross VT before September 2023, and any insured large groups new to Blue Cross VT in 2023. Combining these homogeneous populations creates greater consistency and credibility within the relativity factor development. We combine CDHP and non-CDHP claims. We exclude claims from groups that do not have pharmacy coverage through Blue Cross VT. We exclude claims from members with more than $\$ 500,000$ in total (medical and pharmacy) claims in the experience period.

For each benefit plan, the models produce the simulated PMPM values of the benefits. We divide the PMPM for each plan by the average trended paid claims rate from the model experience period to produce its benefit relativity value (BRV). We calculate relativities for medical-only plans, pharmacy-only plans, and integrated CDHP plans for both active and Medicare Primary members.

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

### 5.1. Models for Active Employees

## Benefit Relativity Model: Medical

We use the total medical trend by type of service to project to the rating period. We calculate cost trends for each type of service using the discrete unit cost trend method above, while applying the separate utilization trends developed for facility and professional services (see section 4.1.2).

Using the contracted reimbursement schedules, we calculate network factors that represent the different network contracts. Using these factors, we can include all claims in each of the three ${ }^{20}$ networks by adjusting each claim to the basis of a single network. This enables us to combine all the experience for each plan design.

We categorize claims according to how benefits are paid and generate one record for each member, date of service, and type of service. We assign each record a cost share (deductible/coinsurance, copay, covered in full) for each plan modeled. For all products, we assign claims for preventive mandated benefits a "covered in full" cost share independently of the product that is being modeled.

The model tests one benefit design at a time. It determines the member portion of the allowed charges, and from this, a total simulated paid PMPM for each benefit design. The model considers the impact of copay, deductible, coinsurance, out-of-pocket maximum, and preventive mandated benefits. If the average allowed cost of a category is less than the assigned copay, we assume that the member paid the full cost of the service.

Blue Cross VT offers products on several different networks based on the two provider contracts (Blue Cross VT Managed Care and Blue Cross VT Non-Managed Care). Depending on the network, there may be more than one tier of coverage (generally referred to as in-network and out-of-network) and different networks may have different providers in each tier. Below is a chart showing which providers are in which tiers on many of Blue Cross VT's common networks. Providers who accept the indicated provider contract are considered to be in-network. For providers who directly contract with other Blues plan (BlueCard ${ }^{\circledR}$ providers) and non-participating providers, 'In' indicates coverage for these providers on the in-network tier of coverage, and 'Out' indicates coverage for these providers on the out-ofnetwork tier of coverage.

| Network Name | Provider Contract | BlueCard <br> Providers | Non-Participating <br> Providers |
| :--- | :--- | :---: | :---: |
| VHP Select | Blue Cross VT Managed Care | N/A | N/A |
| VHP | Blue Cross VT Managed Care | Out | Out |
| EPO PCP | Blue Cross VT Managed Care | In | N/A |
| EPO | Blue Cross VT Non-Managed Care | In | N/A |
| PPO | Blue Cross VT Non-Managed Care | In | Out |
| Indemnity | Blue Cross VT Non-Managed Care | In | In |

[^10]
## Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum

If Blue Cross VT were to quote a product not on one of the networks listed above, or one featuring different provider networks for selected services, we would modify the base data in the BRV models to correspond to the desired changes (for example, excluding certain providers or modifying allowed amounts) before simulating the benefit impact. Similarly, if we were to modify the coverage parameters of a network in a certificate filing with DFR, we would modify the base data in the BRV models to correspond to the approved certificate changes.

We use BRVs in two places in the rating formula described in Section 3. We calculate the average experience period seasonally-adjusted benefit relativity factor (line $K$ in Exhibit 1A) using BRVs for the benefits in the experience period and the projected claims for the rating period (line B1 in Exhibit 1C) using BRVs for the benefits in the rating period.

Exhibits 3B and 3C display the relativities for active employees for some medical products currently in our book of business.

## Benefit Induced Utilization: Medical

We use factors for the impact of induced utilization (IU) developed by the federal Department of Health and Human Services (HHS) for use with Qualified Health Plans, to which we found the curve of best fit IU $=A V^{\wedge} 2-A V+1.24$, where $A V$ is the actuarial value of the benefit plan. HHS created their IU factors for combined medical/pharmacy AV, but as we develop BRVs separately for medical and pharmacy plans, we will apply the formula to medical-only AVs. We normalize the curve such that the average AV underlying the base $B R V$ experience period returns a utilization adjustment of 1.00 . In other words, if a simulated benefit has an AV less than the average AV, then utilization will be reduced (i.e., factor < 1.00). If a simulated benefit has an $A V$ greater than the average $A V$, then the benefit will have induced utilization (i.e., factor > 1.00).

## Benefit Relativity Model: Pharmacy

We use the total trend by type of drug, for brand, generic, and specialty drugs as described above (section 4.2) to project to the rating period.

Within the model, we assign all pharmacy scripts, including specialty, to one of six categories: retail generic, retail preferred brand, retail non-preferred brand, mail generic, mail preferred brand, and mail non-preferred brand. We apply flags to identify several categories of drugs that are either required to be covered in full (contraceptives and vaccines) or for which a group may purchase a rider to offer additional coverage (some fertility drugs) or exclusion (lifestyle drugs). We also flag drugs for which a group may offer special cost-sharing arrangements, such as diabetic medications and wellness drugs. We assign these flags by National Drug Codes as reported to us by our current PBM.

We adjust the experience period data to reflect the major brands that we expect to become generic between 2021 and 2025. The list comes from a report provided by an external pharmacy vendor.

For these brands, in the first six months (the exclusivity period), we reduce the AWP by 10 percent and keep the brand discount. For the months after the exclusivity period, we reduce the AWP by 10 percent and change the discount to the generic discount. The 10 percent reduction in AWP is based on industry standard assumptions, supported by our own analysis of AWP changes for drugs that have moved from brand to generic over the past several years.

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

We identify drugs affected by the AMP cap removal and adjust their allowed charges using factors provided by our PBM. As we account for the impact of the new allowed charges directly in the experience, we apply trends that do not include the impact of the AMP cap removal to trend to the experience period.

We generate one record for each member and date of service combination. One record can have more than one script category. The model tests one benefit design at a time. It determines the member portion of the allowed charges and a total simulated paid PMPM for each benefit design. The model considers the impact of the deductible, coinsurance, copays, and out-of-pocket maximum (OOPM). The model excludes contraceptives and vaccines from the cost sharing. If the average allowed cost of a category is less than the applied copay, we assume that the member pays only the full cost of the script. With Vermont Act 171, all pharmacy benefits effective January 1, 2024, or later will have an OOPM of $\$ 1,600$. It is possible that this limit will increase effective January 1, 2025, following the IRS rules for Health Savings Accounts and High Deductible Health Plans. The exhibits include the $\$ 1,600$ OOPM on pharmacy benefits.

Exhibit 3D displays the relativities for active employees for some pharmacy products currently in our book of business.

## Benefit Induced Utilization: Pharmacy

We performed an independent analysis to measure the correlation between the benefit design and the quantity of pharmacy prescriptions consumed. We adjust the pharmacy benefits in two ways. First, the generic utilization varies with the benefit design. We use claims and membership data from January 2020 through October 2023 to create a table to adjust the base generic utilization up or down depending on the difference in the generic and brand copays of the member's drug plan. Exhibit 3A displays the adjustments by brand/generic copay differential for generic and brand scripts.

Second, we perform a separate analysis to adjust for the overall pharmacy benefit. We assign a modeled actuarial value to every benefit in the experience period. The correlation uses the actuarial value as the independent variable and days supply as the dependent variable. A linear equation best fits the data. We normalize the curve such that the actuarial value underlying the base BRV benefit returns a utilization adjustment of 1.00. The resulting formula is Pharmacy Utilization

Although we use two steps to calculate the induced utilization, we are not adjusting the data twice. The adjustment for difference in generic/brand copays changes the mixture of scripts (i.e., generic dispensing rate) without adjusting the overall frequency of scripts. The richness or leanness of the plan, as measured by the actuarial value, drives an adjustment to the overall frequency of scripts without changing the mixture of scripts.

Claims incurred on a CDHP historically have a lower cost per script than claims incurred on a drug card, but the model includes claims from both CDHPs and drug cards. We calculate a factor for each benefit type by taking the ratio of the cost per script for that type and the cost per script from all claims in the model. For CDHPs, the factor for this filing is and for drug cards the factor is

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

## Benefit Relativity Model: Integrated (CDHP)

The CDHP model combines both the medical and pharmacy models described above. There is one record for each member, date of service and type of service combination. The model calculates separate medical and pharmacy actuarial values and makes the appropriate utilization adjustment for each.

Exhibit 3E displays the relativities for active employees for some CDHP products currently in our book of business.

### 5.2. Tier Factors

Each BRV model generates a BRV for different contract tiers as well as the overall PMPM described in the sections above. The models perform this calculation by re-adjudicating claims across families in addition to member-based readjudication. We apply the tiered BRVs to each benefit's member distribution by tier to calculate the average BRV for the experience benefits and to the group's member distribution by tier to calculate the average BRV for the rating benefits.

We use the same tier factors developed in the previous filing to spread the required premium across tiers. Exhibit 3L displays these factors.

There are separate factors for stacked plans with family multipliers of two, two-and-a-half, and three for deductibles and out-of-pocket maximums. The aggregate and hybrid factors assume a family multiplier of two. If a group requests a benefit with a non-standard multiplier, out-of-pocket maximum, tier structure, or individual out-of-pocket maximum (for a hybrid plan) that is not in the exhibit, we will use identical data, assumptions and methodology as described above to calculate appropriate tier factors for the requested benefit.

### 5.3. Models For Age 65+ Medicare Secondary Plans

## Benefit Relativity Model: Medical

Medicare Primary rate tiers are only available on the Blue Cross VT Non-Managed Care network. To develop benefit relativity values for Medicare Secondary plans, we use the same method as we do for the active factors. For the claims base, we use allowed charges incurred between January 2021 and December 2021, paid through October 2023, for members whose primary insurance is Medicare. Given the scarcity of Medicare Primary members in the BRV experience (fewer than 1,000 member months), we also include Medicare Primary members from groups who we exclude from the development of the active BRVs (e.g., large self-funded groups). If the underwriter believes that these claims are not representative of a given group's characteristics (for example, due to demographics or morbidity), we will develop relativities using an analogous method with more representative experience.

Medicare Secondary plans cover two categories of services: Medicare-covered services which are subject to member cost share (deductible/coinsurance) and services which are not covered by Medicare. We do not adjust services subject to Medicare cost sharing for network, as Medicare determines the allowed charges, whereas we adjust the services not covered by Medicare using the contract factors described above to bring all charges to a single network.

We trend the allowed charges to the 12-month period that begins January 1, 2025. Given the length of time between the experience period and the rating period, we use two types of trend factors. We use

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

observed trends from the TVHP Medigap Blue experience to trend from the 2021 experience period to the active BRV experience period (the year ending September 2023). From there, we use the total medical trend by type of service as described in section 4.5 to trend to 2025.

As with the active benefits, the model simulates the effects of a benefit design on the trended allowed charges and calculates a simulated paid PMPM. The model divides this paid PMPM by the Medicare Primary manual rate (without the adjustment for changes to the pharmacy contract) to produce the benefit relativity value. Unlike the active benefits, we do not make an adjustment for induced utilization due to the richness of the benefit. As Medicare is the primary insurance for these plans and Medicarecovered claims make up 89 percent of the trended allowed charges, we do not believe that the richness of the secondary insurance will have any influence on utilization.

Exhibit 3F displays the relativities for some Medicare Secondary medical products currently in our book of business.

## Benefit Relativity Model: Pharmacy

To calculate relativities for pharmacy benefits for plans that are secondary to Medicare, we use the same methodology as for active employees. We use allowed charges incurred between January 2021 and December 2021, paid through October 2022, for members whose primary insurance is Medicare (including members in large self-funded groups, as with the medical experience). If the underwriter believes that these claims are not representative of a given group's characteristics (for example, due to demographics or morbidity), we will develop relativities using an analogous method with more representative experience.

We trend the allowed charges to the 12-month period that begins January 1, 2025, using the same trends as used for active members. We use observed trend from the active experience to trend the 2021 experience to the year ended September 2023, then use the active trend factors to trend to 2025 . We assign pharmacy scripts to the same categories as for the active members and adjust allowed charges for brands going generic between the experience period and the rating period and for the removal of the AMP-cap. The model produces a simulated paid PMPM for each benefit design and adjusts for the impact of induced utilization on the mixture and frequency of scripts as described for the active relativities above. We divide the adjusted paid PMPM by the Medicare Primary manual rate (without the adjustment for changes to the pharmacy contract) to produce the relativity.

Exhibit 3G displays the relativities for some Medicare Secondary pharmacy products currently in our book of business.

## Benefit Relativity Model: Integrated (CDHP)

The Medicare Secondary CDHP model combines both the medical and pharmacy Medicare Secondary models described above. We create one record for each member, date of service, and type of service combination. The model calculates separate medical and pharmacy actuarial values and makes the appropriate utilization adjustments for each.

Exhibit 3H displays the relativities for some Medicare Secondary CDHP products currently in our book of business.

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

### 5.4. Formulary \& Pharmacy Options

Blue Cross VT offers groups a selection of formularies. Groups can select either the Blue Cross VT Formulary or the National Performance Formulary. Groups electing the National Performance Formulary receive greater rebates than those on the Blue Cross VT Formulary. To calculate the impact of the change, we identify rebate-eligible claims for the large groups impacted by this filing. We calculate rebate totals under the contracted terms of each formulary. For groups changing formularies, we apply the below factors to projected rebates. We adjust the factors proportionately if the experience period includes a mix of formularies.

| Experience Formulary | Rating Formulary | Rebate Multiplier |
| :--- | :--- | :---: |
| Blue Cross VT Formulary | National Performance |  |
| National Performance | Blue Cross VT Formulary |  |

The National Performance Formulary covers different drugs than the Blue Cross VT Formulary. To reflect the difference in covered drugs between the two formularies, we apply a factor to the drug BRV for the Blue Cross VT Formulary. Using the claims in the drug BRV model, we compare the average cost per script, including the impact of brand and generic dispensing rates, for both formularies. We compare the cost per script for each formulary to the cost per script for all claims in the model to calculate adjustment factors for each formulary.

| Formulary | Adjustment Factor |
| :--- | :--- |
| Blue Cross VT Formulary |  |
| National Performance Formulary |  |

If Blue Cross VT adds or changes a formulary, we will calculate the rebate multipliers and adjustment factors using the same methodology.

### 5.5. Riders

Blue Cross VT files riders with the Vermont Department of Financial Regulation (DFR) that allow large groups to add or modify covered services. These riders include, but are not limited to, the Benefit Enhancement Rider, Acupuncture Benefits Rider, and Wellness Drug Rider. For riders that modify covered services, we use the benefit relativity model to price the rider. For riders that cover an optional service, we develop allowed charges from groups offering that coverage and adjust to the group's benefit or use a reasonable approximation of allowed charges if no experience data exists. If, in the underwriter's professional judgment, the election of a rider will create material anti-selection, the underwriter will modify the rate as necessary to reflect appropriate rates for the rider they are rating, as described in section 3.

### 5.6. Rate Smoothing Charges

Blue Cross VT offers groups the option to apply the composite rate change to each tier's rate change. There is no charge to smooth rate changes by tier within a benefit if the change by tiers varies by less than two percentage points. If the tiered rate changes vary between two and five percentage points,

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

there is a charge of 0.2 percent applied to the total of the absolute values of the rate deviation by tier. We do not allow rate smoothing if the rate increases by tier vary by more than five percentage points.

If a group offering multiple benefits elects to apply the same rate change across benefits, the charge begins at 0.2 percent of the total of the absolute values of the rate deviation by benefit and increases continuously by 0.1 percent for every percentage point deviation. We do not allow benefit smoothing if the rate change by benefit varies by more than five percentage points.

## 6. Other Factors Applicable to All Large Groups

### 6.1. Manual Rate

We calculate the manual rate for active members from medical and pharmacy paid claims PMPM incurred between October 1, 2022, through September 30, 2023. Both medical and pharmacy claims include claims paid through November 30, 2023. We use claims from the groups impacted by this filing, trended to calendar year 2025 using the trends and pharmacy contract adjustments described in section 4. We cap claims at $\$ 120,000{ }^{21}$ and add expected claims above $\$ 120,000$. We calculate the expected large claims using the method described in section 6.2.

| Calculation of the Manual Rate (Actives) |  |  |  |
| :---: | :---: | :---: | :---: |
| Claim Type |  | Medical | Pharmacy |
| Incurred and Paid Experience Paid Claims, capped at $\$ 120,000$ | A | \$21,716,904 | \$5,734,911 |
| Estimated IBNR | B | \$172,258 | \$425 |
| Expected Claims above \$120,000 | C | \$3,964,518 | \$266,181 |
| Experience Adjustment Factor. ${ }^{22}$ | D | 0.9991 | 0.9991 |
| Demographic Normalization | E | 0.9966 | 0.9966 |
| Overall Paid Trend Factor | F | 1.2174 | 1.2484 |
| Projected Total Paid Claims | $\begin{gathered} G=(A-B+C) \times \\ E \times F \end{gathered}$ | \$31,341,451 | \$7,460,427 |
| Total Member Months | H | 47,479 | 47,479 |
| Medical/Pharmacy Manual Rate | $\mathrm{I}=\mathrm{H} / \mathrm{l}$ | \$660.11 | \$157.13 |
| 2025 Manual Rate | $\mathrm{K}=\mathrm{J}_{1}+\mathrm{J}_{2}$ | \$817.24 |  |
| 2024 Approved Manual Rate | L | \$762.72 |  |
| Manual Rate Increase | $\mathrm{M}=\mathrm{K} / \mathrm{L}-1$ | 7.1\% |  |

We calculate a separate manual rate for Medicare Primary members using the paid claims PMPM from the BRV experience period, trended to calendar year 2025 using the Medicare Primary trends described in section 4.5 and the pharmacy contract adjustments described in section 4.2. We make no adjustments to the Medicare Primary manual rate for large claims.

[^11]Blue Cross and Blue Shield of Vermont
2025 Large Group Rating Program Filing
Actuarial Memorandum

| Calculation of the Manual Rate (Medicare Primary) |  |  |  |
| :--- | :---: | :---: | :---: |
| Claim Type |  | Medical | Pharmacy |
| BRV Experience Paid Claims | A | $\$ 11,023,406$ | $\$ 19,266,918$ |
| Paid Trend Factor | B | 1.3428 | 1.5111 |
| Projected Total Paid Claims | $\mathrm{C}=\mathrm{A} \times \mathrm{B}$ | $\$ 14,802,349$ | $\$ 29,113,890$ |
| Total Member Months | D | 80,147 | 80,147 |
| Medical/Pharmacy Manual Rate | $\mathrm{E}=\mathrm{C} / \mathrm{D}$ | $\$ 187.51$ | $\$ 362.96$ |
| 2025 Manual Rate | $\mathrm{F}=\mathrm{E}_{1}+\mathrm{E}_{2}$ | $\$ 547.95$ |  |
| 2024 Approved Manual Rate | G | $\$ 536.24$ |  |
| Manual Rate Increase | $\mathrm{H}=\mathrm{G} / \mathrm{F}-1$ | $2.2 \%$ |  |

We use a different method of calculating the manual rate for active and Medicare Primary members. We develop the active manual rate from the experience of active members in the large groups covered by this filing. There are not enough Medicare Primary members in large groups to develop a credible manual rate with only large group experience, so we base the Medicare Primary manual rate on the larger set of claims in the BRV experience, which includes Medicare Primary members from self-funded groups as well as large groups.

For groups that only offer medical-only Medicare Primary coverage, we use the medical-only Medicare Primary manual rate in the table above and adjust the benefit relativity factor to be based only on medical claims.

Changes in the experience base, an update to the trends detailed in this filing, and an additional year of trend cause the changes in both manual rates.

| Active Manual Rate <br> Development | PMPM | PMPM <br> Change | Impact |
| :--- | :---: | :---: | :---: |
| 2024 Manual Rate | $\$ 762.72$ |  |  |
| Update Experience |  | $-\$ 10.24$ | $-1.3 \%$ |
| Update Trend |  | $-\$ 8.83$ | $-1.2 \%$ |
| Trend to 2025 |  | $\$ 73.59$ | $9.9 \%$ |
| 2025 Manual Rate | $\$ 817.24$ |  |  |


| Medicare Primary Manual <br> Rate Development | PMPM | PMPM <br> Change | Impact |
| :--- | :---: | :---: | :---: |
| 2024 Manual Rate | $\$ 536.24$ |  |  |
| Update Experience |  | $-\$ 51.14$ | $-9.5 \%$ |
| Update Trend |  | $\$ 11.54$ | $2.2 \%$ |
| Trend to 2025 |  | $\$ 51.31$ | $9.6 \%$ |
| 2024 Manual Rate | $\$ 547.95$ |  |  |

While the experience periods for the 2024 and 2025 Medicare Primary manual rates are identical, we identified drug claims with $\$ 2$ million in AWP that would move from brand to generic or specialty to nonspecialty cost sharing for the rating year 2025 compared to 2024 . These movements reduce the paid drug claims and, along with changes to the allowed cost for drugs affected by the removal of the AMP cap, account for the negative impact of the update to experience.

Blue Cross and Blue Shield of Vermont<br>2025 Large Group Rating Program Filing<br>Actuarial Memorandum

We adjust the manual rate to reflect a group's particular characteristics, as demonstrated in Exhibit 4A. We make an adjustment for the average age/gender factor (line B) of the group. For active and Medicare primary members, we use factors from the SOA's report Health Care Costs - From Birth to Death ${ }^{23}$. We normalize the factors such that the membership in the manual rate experience period has an age/gender factor of one. We assign an industry factor (line C) to each group based on the Standard Industrial Classification code. See Exhibit 4B for the schedule of industry factors. We normalize the industry factors such that the manual rate has a factor of one. We do not apply an industry adjustment to the manual rate for Medicare Primary members. We normalize for the average benefit relativity factor in the experience base by applying the ratio of the manual rate base average over the benefit relativity model average. In 2025, this factor is 0.9885 (line F).

We then multiply the manual rate by an adjustment factor to reflect structural changes between the experience period to the rating period. This adjustment modifies the manual claims to reflect such things as mandated benefit changes, contractual provision changes, etc., that, in the judgment of the underwriter, are necessary to make the manual rate appropriate for the estimation of the expected claims in the rating period.

For groups with a projection period other than calendar year 2025, we adjust the manual rate for trend to reflect the group's projection period (line D). Finally, we calculate a contract conversion factor (line E) based on member distribution and tier factors in order to convert from a PMPM to a single rate basis. This factor is necessary because the rating formula blends the adjusted manual rate (line $S$ of Exhibit 1A) with the projected single contract rate (line R of Exhibit 1A), which is not on a PMPM basis.

### 6.2. Large Claims Factors

Blue Cross VT uses the formula and factors in Milliman's 2023 Health Cost Guidelines - Reinsurance to calculate expected claims above the pooling limit. The contents of the Guidelines are proprietary and confidential. This filing provides a general description of the formula but will not include any of the factors.

The formula develops expected claim costs above a particular pooling point separately for children and adults on a PMPM basis. The basis for each rate is a starting claim cost that varies with the pooling point and the out-of-pocket limit for the benefit. Milliman calculates the starting claim costs using national data, and the formula applies factors to adjust to our Vermont service area and the details of our contracts with local providers. The formula applies an adjustment for demographics and a trend factor to adjust the starting claim costs for the experience period of the renewal. There are also adjustments to the starting claim costs for the network of the benefit to account for claims from out-of-network providers, if appropriate for the benefit. The formula includes an adjustment factor that controls for known, ongoing high claimants, which the underwriter may add to premium through underwriting judgment. To avoid double counting such claimants, we apply a five percent reduction to the estimated claims above the pooling point based on recent large group experience.

[^12]
# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

We multiply the adjusted adult and child claim rates by benefit by the number of adult and child member months in the experience for that benefit to develop the total expected claims above the pooling level.

### 6.3. Administrative Charges

The sources of administrative expense data in this filing are the Blue Cross VT data warehouse and accounting records. The experience period for this filing is January 2022 to December 2022. We use actual Blue Cross VT and TVHP administrative expenses for the experience period on a GAAP reporting basis.

The Blue Cross VT cost accounting system allocates administrative expenses to lines of business. We use Blue Cross VT insured large group, Blue Cross VT Cost Plus, and TVHP insured large group information for the base administrative charges.

The table below reflects reclassifications of the base data, including the removal of federal fees (we add these to premium rates separately; see section 6.9), GMCB billback (we add these to premium rates separately; see section 6.8), and fees paid to vendors for the administration of Health Savings Accounts and Health Reimbursement Accounts linked to our insurance products (participation in this service is optional; we assign these fees to groups who select the service). We also remove any expenses incurred due to one-time, non-recurring events, as these costs are not expected to continue to occur in the projection period. We are also reflecting the known savings from our affiliation with Blue Cross Blue Shield of Michigan (BCBSM) from processes and contracts already integrated. While there is still much to be done to fully integrate some functions with BCBSM, Blue Cross VT already started to experience lower costs of processing claims through NASCO (our claims processor) by accessing the lower fee schedule for BCBSM affiliates.

| Reconciliation of Experience Base Administrative Expense to <br> Reported GAAP Expenses |  |  |
| :--- | :---: | :---: |
|  | Total Dollars | PMPM |
| Reported Expenses | $\$ 6,111,243$ | $\$ 67.43$ |
| Commissions | $-\$ 1,066,147$ | $-\$ 11.76$ |
| Reclassification Items | $-\$ 400,912$ | $-\$ 4.42$ |
| Affiliation Savings | $-\$ 54,848$ | $-\$ 0.61$ |
| Total | $\$ 4,589,335$ | $\$ 50.64$ |

## Projection Factors

We project the base administrative charges to 2025 using a 4.0 percent annual trend. This projection factor is intended to make reasonable but modest provision for increases in overall operating costs PMPM.

We calculate PMPM admin charges with experience period enrollment and projected enterprise-wide 2024 enrollment. When projecting the 2024 enrollment, we include the observed membership changes, and expected growth due to the anticipated Medicaid redetermination initiative and its expected impact on ACA membership. Blue Cross VT variable costs represent approximately 30 percent of total administrative expenses. Blue Cross VT is committed to providing insurance coverage for our members

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing Actuarial Memorandum 

at the most affordable rates possible; as a result, even though it is impractical to react to enrollment shifts by immediately right-sizing staff, we nonetheless remove from our projection the entirety of variable costs associated with the changes in enrollment. We therefore apply a net decrease of 3.4 percent to the base PMPM charges to account for the growth in membership on core operating platform. The table below shows the calculation.

| Development of Enterprise Membership Adjustment |  |
| :--- | :---: |
|  | Members |
| Experience Period | $1,965,527$ |
| Projected 2024 Enrollment | $2,065,332$ |
| Adjustment for Enterprise Membership | $=1+0.7 \times(1,965,527 / 2,065,332-1)-1=-3.4 \%$ |

To calculate the projected base administrative charges, we increase the reweighted base experience PMPM by 4.0 percent for two years of trend and by -3.4 percent for the impact of membership.

| Projected Administrative Charges Calculation |  |  |
| :--- | :--- | :--- |
| Experience Base Administrative <br> Charges PMPM | A | $\$ 50.64$ |
| Trend Projection | B | 1.1249 |
| Impact of Membership changes | C | 0.9662 |
| Projected Base Administrative <br> Charges for January 2025 (Exhibit 5A) | D = A x B x C | $\$ 55.03$ |

## Charges for Group Accounts

Exhibit 5A shows the administrative charge PMPM values used by the rating formula to produce account-specific administrative charges.

The administrative charges do not include amounts for special items or unique services not part of Blue Cross VT's standard scope of administrative services (e.g., special booklets, certificates, or reports). Charges for such services will be determined and applied separately on an account-specific basis. The filed charges also do not include commissions based on the commission scale applicable to the account. The rating formula calculates and applies commissions separately.

### 6.4. Net Cost of Reinsurance

Blue Cross VT reinsures claims in excess of $\$ 1,000,000$ for 2024 , and we expect to purchase similar reinsurance in future years with limits approximately equal to the 2024 limit. We estimate that the target loss ratio for the reinsurance is 75 percent, which implies a cost of reinsurance of 33.3 percent of claims above the reinsurance limit. For each pricing period starting quarter, we use the total allowed trend from 2023 to 2025 and a leverage factor for the $\$ 1,000,000$ reinsurance limit from Milliman's 2023 Health Cost Guidelines - Reinsurance to calculate the expected annual claim cost above the reinsurance limit, then multiply the cost by 33.3 percent to determine the annual cost of reinsurance. We divide this by 12 to produce the PMPM cost of reinsurance. The table below shows these PMPM's based on pricing period starting quarter. If a renewal requires a factor for a pricing period not in the table, we will use identical data, assumptions, and methodology as described above to calculate the net cost of reinsurance.

# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

| Pricing Period Starting Quarter |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
| $\$ 2.83$ | $\$ 2.95$ | $\$ 3.08$ | $\$ 3.21$ | $\$ 3.35$ | $\$ 3.50$ | $\$ 3.65$ |

### 6.5. Pharmacy Rebates

We calculate pharmacy rebates by taking the experience period rebates and trending them using the total trend for brands eligible for rebates (see table below). There is a lag between the receipt of pharmacy rebates and the time of the original claims. For months in the experience for which we do not have detailed rebate information, we include an estimated rebate amount in the calculation.

| Claim Type | Experience Period <br> Allowed Charges | Projected Allowed <br> Charges after Contract <br> Changes |
| :--- | :---: | :---: |
| Brand Going Generic |  |  |
| Brand |  |  |
| Specialty |  |  |
| Total |  |  |
| Total Trend for Drugs Eligible for rebates |  |  |

As shown on Exhibit 2H, we identify drugs affected by the AMP cap removal and estimate the change in rebates using factors provided by our PBM. We estimate a reduction in rebates of $\$ 6.27$ PMPM. For experience in 2023 and or prior, we remove $\$ 6.27$ PMPM, trended to the projection period using the trend factor above, from the estimated rebate. For experience in 2024 and beyond, we make no adjustment to rebates. If the experience contains a mix of 2023 and 2024 experience, we will pro-rate the adjustment factor.

### 6.6. Payment Reform Initiatives

Blue Cross VT is committed to continuing its effort in payment reform through its Community Provider Value-Based programs such as Vermont Blue Integrated Care and Enhanced Community Primary Care programs. We estimate the monthly PMPM needed for our payment reform efforts as $\$ 2.50$ PMPM.

### 6.7. Contribution to Reserve

As directed by Blue Cross VT management, the filed rates include a 3.0 percent contribution to reserves (CTR). A contribution to member reserves is necessary to maintain an adequate level of surplus. Surplus, or member reserves, is a critical consumer protection that the Vermont Department of Financial Regulation requires. In the event of unforeseen adverse events that may otherwise impact Blue Cross VT's ability to pay claims, surplus allows subscribers to receive needed care and providers to continue to receive payments.

Attachment A provides a memo from Blue Cross VT senior management regarding the requested level of CTR. We reviewed the recommendations provided in Attachment A have and consider them to yield a reasonable contingency margin.

### 6.8. State Mandates and Assessments

## Vermont Vaccine Purchasing Program Payments

The Vermont Vaccine Purchasing Program ${ }^{24}$ offers health care providers state-supplied vaccines at no charge by collecting payments from Health plans, insurers, and other payers. This assessment is a PMPM charge applied to members residing in Vermont who are ages 0 to 64 . On May 5, 2023, the Vermont Vaccine Purchasing Program released a memo that included the rates for April 1, 2023 - March 31, 2024. We will use the approved state fiscal year 2025 rate once it is approved.

## New Hampshire Purchasing Program Payments

The New Hampshire Purchasing Program ${ }^{25}$ offers health care providers state-supplied vaccines at no charge by collecting payments from health plans, insurers, and other payers. The rate for calendar year 2024 and the current best estimate of the 2025 rate is $\$ 12.50$ per assessable life per month. We will use the new rate once it is approved.

## New York State Health Care Reform Act

Blue Cross VT pays the New York GME Covered Lives Assessment. ${ }^{26}$ for all members who are New York residents as part of the New York State Health Care Reform Act. The assessment varies based on the county of residence. We will use the new rates once they are approved.

## Maine Guaranteed Access Reinsurance Association

Blue Cross VT pays the Maine Guaranteed Access Reinsurance Association Assessment ${ }^{27}$. The 2019 assessment is $\$ 4.00$ per member per month for each member that is a Maine resident. We will use any new rates once they are approved.

## Health Care Claims Tax

The Health Care Claims Tax of 0.999 percent applies to all claims or capitations incurred by members with Vermont zip codes. We use the percentage of current members with Vermont ZIP codes to estimate the percentage of rating period claims expected to be incurred by Vermont members.

## Blueprint

Blue Cross VT participates in the Vermont Blueprint for Health program. The current assessments for this program, applied to members who are attributed to a Blueprint provider as of the month the renewal is produced, are $\$ 2.77$ PMPM for the Community Health Team and $\$ 3.00$ PMPM for the Patient Centered Medical Homes (PCMH). PCMH are eligible for up to $\$ 0.50$ for performance. We project that our total PMPM for PCMH will be $\$ 3.24$. We base the projected performance payment on the average payment for large groups in the year ended October 2023. We will incorporate any updates made to the Blueprint Manual ${ }^{28}$ in renewals.

[^13]
# Blue Cross and Blue Shield of Vermont <br> 2025 Large Group Rating Program Filing <br> Actuarial Memorandum 

## Green Mountain Care Board Billback

The Green Mountain Care Board assesses Blue Cross VT a billback. We apply billback amounts from the administrative charges experience period described in section 6.3 to projected member months to develop the charge of \$2.08 PMPM.

## Other Assessments

We include other state mandates and assessments in the calculation as applicable.

### 6.9. Federal Assessments

## Patient-Centered Outcomes Research Institute Fee:

This fee is part of the Affordable Care Act and applies to all plan years ended after September 30, 2012, and before October 1, 2029. We provide the estimated fees in the table below. We will update this estimate if we receive additional information.

| PCORI |  |
| :--- | :---: |
| Plan Year Ending Between | Fee Amount |
| October 2023 - September 2024 | \$3.22 PMPY |
| October 2024 - September 2025 | \$3.47 PMPY |
| October 2025 - September 2026 | \$3.74 PMPY |

## Other Assessments

We include other federal mandates and assessments in the calculation as applicable.

### 6.10. Hearing Aids

In 2024, hearing aids became an essential health benefit for fully insured large groups. Since we do not have credible experience for hearing aid costs, we will continue to use the approved estimate of $\$ 1.50$ PMPM from the 2024 Large Group Rating Program Filing in the rates.

## 7. Medical Loss Ratio Projection

We use the factors and formula in this filing to project a Medical Loss Ratio (MLR) for 2025. Using the manual rate as a proxy for projected claims, we project a 2025 MLR of 89.8 percent. The credibilityadjusted MLR for Large Group was 89.5 percent in 2021 and 92.5 percent in 2022. Exhibit 4C provides the development of the projected MLR. The calculations represent estimates assuming that all pricing assumptions hold true, and assuming no change from 2022 values for various quantities (e.g., HCQ, commissions).

## 8. Act 193 Information

This information is included in the template filed in SERFF with this filing (VT Rx Data Template - BCBSVT - 2025 Large Group.xlsx).

The data in the template is based on actual and projected experience for the groups included in the manual rate.

## 9. Actuarial Opinion

I, Martine Lemieux, Chief Actuary, am an employee of Blue Cross Blue Shield of Vermont. I have experience in the area of insured health care programs.

Section 10 lists applicable limitations and disclosures.
It is my opinion that the rating formula and factors presented in this filing are reasonable and have been prepared in accordance with applicable Actuarial Standards of Practice. The formula and factors will produce premium rates that are reasonable in relation to the benefits provided and will not be excessive inadequate or unfairly discriminatory. Attachment B provides evidence for the remainder of the statutory review criteria.

I am a Fellow of the Society of Actuaries and a Member of the American Academy of Actuaries, and I meet the Academy's Qualification Standards to render this opinion.


February 7, 2024

## 10. Disclosures

Information Date: The analysis provided in the report is based on information as known on January 31, 2024.

Scope: The purpose of this filing is to establish the formula, manual rate, and accompanying factors that will be used for renewals of Blue Cross and Blue Shield of Vermont large group plans. This filing is not intended to be used for other purposes.

Intended Users: This material has been prepared for the GMCB. Blue Cross VT understands that a redacted version of this memorandum and accompanying exhibits will be posted publicly.

Uncertainty or Risk: Future events may affect the results presented in the memorandum.
Reliance on Other Sources for Data and Other Information: This analysis relies upon data from the Blue Cross VT data warehouse. I have reviewed the data for reasonableness, but no audit was performed. This analysis relies upon several sources of information that are cited as footnotes at their respective references. If any of the sources we have relied upon are incorrect or inaccurate, it may affect the accuracy of the results presented in the report.

Subsequent Events: Subsequent events may affect the projected MLR presented herein. The degree to which future events may materially change the MLR is unknown.

## TABLE OF CONTENTS

Exhibit 1 Example Calculations
1A Example Calculation of Projected Single Claims Rate
1B Example Calculation of Projected Single Claims Rate with Multiple Experience Periods
1C Example Calculation of Required Premium by Product and Tier

Exhibit 2 Trend
2A Medical Unit Cost Trend Calculation
2B Medical Utilization Trend Calculation
2C Medical Utilization Trend Calculation
2D Pharmacy Trend Development; Generic, Brand and Non-Specialty Utilization
2E Pharmacy Trend Development; Specialty Trend Calculations
2F Pharmacy Trend Development; Summary
2G Monthly Trend Factors
2H AMP Cap Factor Development

## Exhibit 3 Benefit Factors

3A Generic Drug Utilization Adjustments - CONFIDENTIAL
3B Benefit Plan Relative Value Factors; Vermont Freedom Plan (VFP) and Comprehensive (COMP)
3C Benefit Plan Relative Value Factors; Vermont Health Partnership (VHP) Medical Plans
3D Benefit Plan Relative Value Factors; Prescription Drug Cards
3E Benefit Plan Relative Value Factors; Comprehensive Consumer Driven Health Plans (CDHPs)
3F Benefit Plan Relative Value Factors; Medicare Secondary Vermont Freedom Plan (VFP) and Indemnity J-Plan (JPLAN)
3G Benefit Plan Relative Value Factors; Medicare Secondary Consumer Driven Health Plans (CDHPs)
3H Benefit Plan Relative Value Factors; Medicare Secondary Prescription Drug Cards
31 Benefit Leverage Factors; Vermont Freedom Plan (VFP) and Comprehensive (COMP)
3J Benefit Leverage Factors; Prescription Drug Cards
3K Pharmacy Contract Adjustment Factors - CONFIDENTIAL
3L Tier Factors

Exhibit 4 Manual Rate
4A Example of Manual Rate Adjustment
4B Industry Factors
4C Projected MLR Calculation

Exhibit 5 Administrative Charges
5A Administrative Charges PUPM

Exhibit 6 Other Factors
6A Credibility Table
6B Pooling Point By Membership
6C COVID-19 Diagnosis and Procedure Codes

Example Calculation of Projected Single Claims Rate for Active Members

Benefit-Adjusted Projected Single Claims Rate:

|  | Medical | Pharmacy | Total |  |
| :---: | :---: | :---: | :---: | :---: |
| Experience Period Paid Claims | \$1,600,000 | \$320,000 |  | A |
| Experience Period Claims Amount above \$100,000 Pooling Limit | \$182,000 | \$36,400 |  | B |
| COVID-19 Related Claims | N/A | N/A |  | C |
| Capped Claims | \$1,418,000 | \$283,600 |  | $D=A-B-C$ |
| Completion Factor | 1.005 | 1.001 |  | E |
| Completed Capped Claims | \$1,430,000 | \$283,884 |  | $F=D \times E$ |
| Expected Claims above \$100,000 Pooling Limit | \$240,000 | \$48,000 |  | G |
| Experience Adjustment Factor ${ }^{1}$ | 1.000 | 1.000 |  | H |
| Adjusted Experience Period Claims | \$1,670,000 | \$331,884 |  | $\mathrm{I}=(\mathrm{F}+\mathrm{G}) \times \mathrm{H}$ |
| Experience Period Member Months | 4,000 | 4,000 |  | J |
| Adjusted Experience Period Claims PMPM | \$417.50 | \$82.97 |  | $K=1 \div J$ |
| Average Experience Period Seasonally Adjusted Benefit Relativity Factor | 0.768 | 0.768 |  | L |
| Demographic Normalization | 1.000 | 1.000 |  | M |
| Benefit-Adjusted Experience Period Single Claims Rate | \$543.40 | \$107.99 |  | $N=K * M \div L$ |
| Trend | 1.086 | 1.112 |  | 0 |
| Trend Months | 18 | 18 |  | P |
| Trend Factor | 1.132 | 1.172 |  | $\mathrm{Q}=\mathrm{O}^{\wedge}(\mathrm{P} / 12)$ |
| Projected Single Contract Rate | \$614.86 | \$126.56 | \$741.42 | $\mathrm{R}=\mathrm{N} \times \mathrm{Q}$ |
| Adjusted Manual Rate |  |  | \$976.02 | S |
| Credibility factor |  |  | 48\% | T |
| Benefit-Adjusted Projected Single Claims Rate |  |  | \$862.41 | $U=(R \times T)+\{S \times(1-T)\}$ |
| Credibility Calculation |  |  |  |  |
| Active Member Months |  |  | 4,000 | a |
| Member Months for Full Credibility at \$100,000 Pooling Limit |  |  | 17,055 | b |
| Credibility |  |  | 48\% | $\mathrm{c}=(\mathrm{a} / \mathrm{b})^{\wedge} 0.5$ |

(1) Adjustment for estimated cost sharing on COVID-19 claims.

## Example Calculation of Projected Single Claims Rate for Medicare Primary Members

## Benefit-Adjusted Projected Single Claims Rate:

|  | Medical | Pharmacy | Total |  |
| :---: | :---: | :---: | :---: | :---: |
| Experience Period Paid Claims | \$16,000 | \$24,000 |  | A |
| Experience Period Claims Amount above \$100,000 Pooling Limit | N/A | N/A |  | B |
| COVID-19 Related Claims | N/A | N/A |  | C |
| Capped Claims | \$16,000 | \$24,000 |  | $D=A-B-C$ |
| Completion Factor | 1.011 | 1.001 |  | E |
| Completed Capped Claims | \$16,200 | \$24,024 |  | $F=\mathrm{DxE}$ |
| Expected Claims above \$100,000 Pooling Limit | N/A | N/A |  | G |
| Experience Adjustment Factor | 1.000 | 1.000 |  | H |
| Adjusted Experience Period Claims | \$16,200 | \$24,024 |  | $\mathrm{I}=(\mathrm{F}+\mathrm{G}) \times \mathrm{H}$ |
| Experience Period Member Months | 96 | 96 |  | J |
| Adjusted Experience Period Claims PMPM | \$168.75 | \$250.25 |  | $\mathrm{K}=1 \div \mathrm{J}$ |
| Average Experience Period Seasonal Adjusted Benefit Relativity Factor | 0.900 | 0.900 |  | L |
| Demographic Normalization | 1.000 | 1.000 |  | M |
| Benefit-Adjusted Experience Period Single Claims Rate | \$187.50 | \$278.06 |  | $N=K * M \div L$ |
| Trend | 1.066 | 1.112 |  | 0 |
| Trend Months | 18 | 18 |  | P |
| Trend Factor | 1.100 | 1.172 |  | $Q=0^{\wedge}(P / 12)$ |
| Projected Single Contract Rate | \$206.29 | \$325.88 | \$532.17 | $\mathrm{R}=\mathrm{N} \times \mathrm{Q}$ |
| Adjusted Manual Rate |  |  | \$577.86 | S |
| Credibility factor |  |  | 11\% | T |
| Benefit-Adjusted Projected Single Claims Rate |  |  | \$572.96 | $U=(R \times T)+\{S \times(1-T)\}$ |

Credibility Calculation
Medicare Primary Member Months $\quad 96$
Member Months for Full Credibility 8,325

[^14]Example Calculation of Projected Single Claims Rate for Active Members with Multiple Experience Periods

| Benefit-Adjusted Projected Single Claims Rate: |  |  |  |  |  |  | Manual |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Period | A |  | B |  | C |  |  |  |
| Category | Medical | Pharmacy | Medical | Pharmacy | Medical | Pharmacy |  |  |
| Experience Period Start | 7/1/2023 | 7/1/2023 | 7/1/2022 | 7/1/2022 | 7/1/2021 | 7/1/2021 |  |  |
| Experience Period End | 6/30/2024 | 6/30/2024 | 6/30/2023 | 6/30/2023 | 6/30/2022 | 6/30/2022 |  |  |
| Paid Claims in Experience Period | \$1,600,000 | \$320,000 | \$1,500,000 | \$300,000 | \$1,360,000 | \$272,000 |  | A |
| Claims over \$100,000 Pooling Limit | \$182,000 | \$36,400 | \$321,000 | \$64,200 | \$80,000 | \$16,000 |  | B |
| COVID-19 Related Claims | N/A | N/A | N/A | N/A | N/A | N/A |  | C |
| Capped Claims | \$1,418,000 | \$283,600 | \$1,179,000 | \$235,800 | \$1,280,000 | \$256,000 |  | $D=A-B-C$ |
| Completion Factor | 1.005 | 1.001 | 1.001 | 1.000 | 1.000 | 1.000 |  | E |
| Completed Capped Claims | \$1,430,000 | \$283,884 | \$1,180,000 | \$235,800 | \$1,280,000 | \$256,000 |  | $F=D \times E$ |
| Expected Claims above \$100,000 Pooling Limit | \$240,000 | \$48,000 | \$212,000 | \$42,400 | \$180,000 | \$36,000 |  | G |
| Experience Adjustment Factor ${ }^{1}$ | 1.000 | 1.000 | 0.995 | 0.995 | 0.998 | 0.998 |  | H |
| Adjusted Experience Period Claims | \$1,670,000 | \$331,884 | \$1,384,951 | \$276,791 | \$1,457,131 | \$291,426 |  | $\mathrm{I}=(\mathrm{F}+\mathrm{G}) \times \mathrm{H}$ |
| Experience Period Member Months | 4,000 | 4,000 | 4,100 | 4,100 | 3,900 | 3,900 |  | J |
| Adjusted Experience Period Claims PMPM | \$417.50 | \$82.97 | \$337.79 | \$67.51 | \$373.62 | \$74.72 |  | $K=1 \div J$ |
| Average Experience Period Med/Rx Total Seasonally Adjusted |  |  |  |  |  |  |  |  |
| Benefit Relativity Factor | 0.768 | 0.768 | 0.750 | 0.750 | 0.760 | 0.760 |  | L |
| Demographic Normalization | 1.000 | 1.000 | 1.002 | 1.002 | 0.998 | 0.998 |  | M |
| Benefit-Adjusted Experience Period Single Claims Rate | \$543.40 | \$107.99 | \$451.29 | \$90.19 | \$490.63 | \$98.13 |  | $N=K * M \div L$ |
| Trend to Period A |  |  | 1.075 | 1.126 | 1.227 | 1.237 |  | 0 |
| Trend | 1.086 | 1.112 | 1.086 | 1.112 | 1.086 | 1.112 |  | P |
| Trend Months | 18 | 18 | 18 | 18 | 18 | 18 |  | Q |
| Trend Factor | 1.132 | 1.172 | 1.217 | 1.320 | 1.389 | 1.450 |  | $\mathrm{R}=\mathrm{O} \times \mathrm{P}^{\wedge}(\mathrm{Q} / 12)$ |
| Projected Single Contract Rate | \$614.86 | \$126.56 | \$549.09 | \$119.03 | \$681.25 | \$142.26 | \$976.02 | $\mathrm{S}=\mathrm{N} \times \mathrm{R}$ |
| Credibility Calculation | A |  |  |  | C |  | Manual |  |
| Starting Residual | 100 |  |  |  | 26.3 |  | 13.7\% | $T=1-\Sigma \mathrm{X}$ |
| Active Member Months | 4,0 |  | 4,100 | 4,100 | 3,900 | 3,900 |  | U |
| Member Months for Full Credibility at \$100,000 Pooling Limit | 17,0 |  |  |  | 17,0 |  |  | V |
| Credibility | 48. |  |  |  | 47.8 |  |  | $\mathrm{W}=(\mathrm{U} / \mathrm{V})^{\wedge} 0.5$ |
| Rating Credibility | 48. |  |  |  | 12.6 |  |  | $\mathbf{X}=\Sigma \mathrm{T} \times \mathrm{W}$ |
| Benefit-Adjusted Projected Single Claims Rate | \$297.77 | \$61.29 | \$138.84 | \$30.10 | \$85.63 | \$17.88 | \$133.87 | $\mathrm{Y}=\mathrm{X} \times \mathrm{S}$ |
| $\Sigma$ Benefit-Adjusted Projected Single Claims Rate | \$765.38 |  |  |  |  |  |  | $Z=\Sigma Y$ |

## Example Calculation of Required Premium by Product and Tier Illustrative Only

From Exhibit 1A : Active Benefit-Adjusted Projected Single Claims Rate (S)
\$862.41
Medicare Primary Benefit-Adjusted Projected Single Claims Rate (S)
\$572.96


| Plan B |  |  | Single | 2-Person |  Medicare <br> Secondary <br> Family  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Members per contract |  |  | 1.000 | 2.000 | 3.938 | 1.000 |
| BRV: | A |  | 1.023 | 2.046 | 2.846 | 1.046 |
| Projected Claims: | $\mathrm{B} 1=\mathrm{A} \times \mathrm{S}$ |  | \$882.24 | \$1,764.48 | \$2,454.19 | \$599.31 |
| Payment Reform Initiatives | B2 |  | \$2.50 | \$5.00 | \$9.85 |  |
| Projected Rx Rebate: | B3 |  | -\$40.00 | -\$80.00 | -\$157.60 | -\$40.00 |
| Net Cost of Reinsurance: | B4 |  | \$3.08 | \$6.16 | \$12.14 |  |
| Hearing Aids | B5 |  | \$1.50 | \$3.00 | \$5.91 | \$1.50 |
| Mandates and Assessments |  |  |  |  |  |  |
| Vaccines for Vemonters | C1 |  | \$2.50 | \$5.00 | \$9.85 | \$2.50 |
| Blueprint for Health | C2 |  | \$5.98 | \$11.96 | \$23.56 |  |
| Health Care Claims Tax | C3 $=0.000 \%$ * B1 |  | \$8.83 | \$17.66 | \$24.58 | \$6.00 |
| GMCB Billback | C4 |  | \$2.08 | \$4.16 | \$8.20 | \$2.08 |
| NH Vaccines | C5 |  | \$0.01 | \$0.02 | \$0.04 |  |
| NY GME | C6 |  | \$0.02 | \$0.04 | \$0.08 |  |
| MGARA | C7 |  | \$0.03 | \$0.06 | \$0.12 | \$0.03 |
| PCORI | C8 |  | \$0.31 | \$0.62 | \$1.23 | \$0.31 |
| Administrative Charge | D |  | \$55.03 | \$110.07 | \$216.83 | \$55.03 |
| Commission (\% premium) | E | 3.00\% |  |  |  |  |
| Contribution to Reserve | F | 3.00\% |  |  |  |  |
| Required Premium: | $H=\left[\Sigma\left(B_{i}\right)+\sum\left(C_{i}\right)\right.$ | - E-F) | \$983.10 | \$1,966.20 | \$2,775.49 | \$666.78 |

MEDICAL TREND DEVELOPMENT
COST TREND

|  | VHP |  |  | IND |  |  | TVHP |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Inpatient | GMCB | Other | Total | GMCB | Other | Total | GMCB | Other | Total |
| YE 202309 | \$22,221,067 | \$15,771,876 | \$37,992,943 | \$22,221,067 | \$15,771,876 | \$37,992,943 | \$22,221,067 | \$15,771,876 | \$37,992,943 |
| CY 2024 | \$23,596,020 | \$17,030,904 | \$40,626,925 | \$23,446,459 | \$17,030,904 | \$40,477,363 | \$23,593,549 | \$17,030,904 | \$40,624,453 |
| CY 2025 | \$25,070,592 | \$18,083,014 | \$43,153,605 | \$24,758,976 | \$18,083,014 | \$42,841,990 | \$25,061,077 | \$18,083,014 | \$43,144,091 |
| Trend $\mathrm{Y} 1 / \mathrm{Y} \mathrm{O}$ | 4.9\% | 6.3\% | 5.5\% | 4.4\% | 6.3\% | 5.2\% | 4.9\% | 6.3\% | 5.5\% |
| Trend Y2/Y1 | 6.2\% | 6.2\% | 6.2\% | 5.6\% | 6.2\% | 5.8\% | 6.2\% | 6.2\% | 6.2\% |
| Annual Cost Trend | 5.5\% | 5.8\% | 5.8\% | 4.9\% | 6.3\% | 5.5\% | 5.5\% | 6.3\% | 5.8\% |
|  | VHP |  |  | IND |  |  | TVHP |  |  |
| Outpatient | GMCB | Other | Total | GMCB | Other | Total | GMCB | Other | Total |
| YE 202309 | \$70,639,396 | \$25,412,899 | \$96,052,295 | \$70,639,396 | \$25,412,899 | \$96,052,295 | \$70,639,396 | \$25,412,899 | \$96,052,295 |
| CY 2024 | \$76,083,422 | \$27,380,114 | \$103,463,537 | \$76,086,567 | \$27,380,114 | \$103,466,682 | \$76,071,077 | \$27,380,114 | \$103,451,192 |
| CY 2025 | \$81,289,641 | \$29,027,819 | \$110,317,461 | \$81,445,054 | \$29,027,819 | \$110,472,874 | \$81,250,226 | \$29,027,819 | \$110,278,046 |
| Trend $\mathrm{Y} 1 / \mathrm{YO}$ | 6.1\% | 6.1\% | 6.1\% | 6.1\% | 6.1\% | 6.1\% | 6.1\% | 6.1\% | 6.1\% |
| Trend Y2/Y1 | 6.8\% | 6.0\% | 6.6\% | 7.0\% | 6.0\% | 6.8\% | 6.8\% | 6.0\% | 6.6\% |
| Annual Cost Trend | 6.4\% | 6.1\% | 6.3\% | 6.5\% | 6.1\% | 6.4\% | 6.4\% | 6.1\% | 6.3\% |


|  | VHP |  |  | IND |  |  | TVHP |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Pharmaceuticals | GMCB | Other | Total | GMCB | Other | Total | GMCB | Other | Total |
| YE 202309 | \$7,451,818 | \$6,829,522 | \$14,281,340 | \$7,451,818 | \$6,829,522 | \$14,281,340 | \$7,451,818 | \$6,829,522 | \$14,281,340 |
| CY 2024 | \$7,981,371 | \$7,424,506 | \$15,405,877 | \$7,981,371 | \$7,424,506 | \$15,405,877 | \$7,980,455 | \$7,424,506 | \$15,404,961 |
| CY 2025 | \$8,557,878 | \$7,921,414 | \$16,479,292 | \$8,557,878 | \$7,921,414 | \$16,479,292 | \$8,529,068 | \$7,921,414 | \$16,450,482 |
| Trend Y1/Y0 | 5.6\% | 6.9\% | 6.2\% | 5.6\% | 6.9\% | 6.2\% | 5.6\% | 6.9\% | 6.2\% |
| Trend $\mathrm{Y} 2 / \mathrm{Y} 1$ | 7.2\% | 6.7\% | 7.0\% | 7.2\% | 6.7\% | 7.0\% | 6.9\% | 6.7\% | 6.8\% |
| Annual Cost Trend | 6.3\% | 6.8\% | 6.6\% | 6.3\% | 6.8\% | 6.6\% | 6.2\% | 6.8\% | 6.5\% |


|  | VHP |  |  | IND |  |  | TVHP |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Professional | GMCB | Other | Total | GMCB | Other | Total | GMCB | Other | Total |
| YE 202309 | \$18,238,914 | \$40,399,588 | \$58,638,501 | \$18,238,914 | \$40,399,588 | \$58,638,501 | \$18,238,914 | \$40,399,588 | \$58,638,501 |
| CY 2024 | \$18,898,878 | \$42,980,032 | \$61,878,910 | \$18,898,878 | \$42,980,032 | \$61,878,910 | \$18,898,878 | \$42,980,032 | \$61,878,910 |
| CY 2025 | \$19,818,911 | \$44,867,080 | \$64,685,991 | \$19,818,911 | \$44,867,080 | \$64,685,991 | \$19,818,911 | \$44,867,080 | \$64,685,991 |
| Trend $\mathrm{Y} 1 / \mathrm{YO}$ | 2.9\% | 5.1\% | 4.4\% | 2.9\% | 5.1\% | 4.4\% | 2.9\% | 5.1\% | 4.4\% |
| Trend $\mathrm{Y} 2 / \mathrm{Y} 1$ | 4.9\% | 4.4\% | 4.5\% | 4.9\% | 4.4\% | 4.5\% | 4.9\% | 4.4\% | 4.5\% |
| Annual Cost Trend | 3.8\% | 4.8\% | 4.5\% | 3.8\% | 4.8\% | 4.5\% | 3.8\% | 4.8\% | 4.5\% |


|  | VHP |  |  | IND |  |  | TVHP |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | GMCB | Other | Total | GMCB | Other | Total | GMCB | Other | Total |
| YE 202309 | \$118,551,194 | \$88,413,885 | \$206,965,079 | \$118,551,194 | \$88,413,885 | \$206,965,079 | \$118,551,194 | \$88,413,885 | \$206,965,079 |
| CY 2024 | \$126,559,691 | \$94,815,556 | \$221,375,248 | \$126,413,275 | \$94,815,556 | \$221,228,832 | \$126,543,959 | \$94,815,556 | \$221,359,515 |
| CY 2025 | \$134,737,022 | \$99,899,327 | \$234,636,349 | \$134,580,819 | \$99,899,327 | \$234,480,147 | \$134,659,282 | \$99,899,327 | \$234,558,609 |
| Trend $\mathrm{Y} 1 / \mathrm{YO}$ | 5.4\% | 5.7\% | 5.5\% | 5.3\% | 5.7\% | 5.5\% | 5.3\% | 5.7\% | 5.5\% |
| Trend Y2/Y1 | 6.5\% | 5.4\% | 6.0\% | 6.5\% | 5.4\% | 6.0\% | 6.4\% | 5.4\% | 6.0\% |
| Annual Cost Trend | 5.8\% | 5.6\% | 5.7\% | 5.8\% | 5.6\% | 5.7\% | 5.8\% | 5.6\% | 5.7\% |

MEDICAL UTILIZATION TREND CALCULATION

| Month | Membership | Original Allowed Claims (adjusted to the VHP and Lab network) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Inpatient | Outpatient | $\begin{aligned} & \text { Professional } \\ & \text { MHSUD } \end{aligned}$ | Professional NonMHSUD | Specialty Pharmacy | Total Allowed Claims | PMPM |
| Oct-19 | 22,259 | \$1,972,410 | \$4,921,229 | \$322,843 | \$2,947,562 | \$766,286 | \$10,930,330 | \$491.05 |
| Nov-19 | 22,483 | \$1,773,934 | \$4,192,374 | \$264,195 | \$2,586,880 | \$669,092 | \$9,486,476 | \$421.94 |
| Dec-19 | 22,416 | \$1,747,301 | \$4,521,186 | \$254,734 | \$2,741,197 | \$739,073 | \$10,003,490 | \$446.27 |
| Jan-20 | 22,029 | \$1,833,273 | \$4,193,948 | \$319,186 | \$2,676,743 | \$697,905 | \$9,721,055 | \$441.28 |
| Feb-20 | 21,916 | \$2,219,309 | \$4,182,447 | \$270,102 | \$2,493,388 | \$380,064 | \$9,545,310 | \$435.54 |
| Mar-20 | 21,897 | \$1,669,424 | \$2,992,773 | \$289,458 | \$2,032,590 | \$437,197 | \$7,421,441 | \$338.93 |
| Apr-20 | 21,841 | \$1,824,752 | \$1,936,050 | \$316,464 | \$1,240,865 | \$515,475 | \$5,833,605 | \$267.09 |
| May-20 | 21,746 | \$2,492,722 | \$2,755,998 | \$296,422 | \$1,806,913 | \$486,729 | \$7,838,784 | \$360.47 |
| Jun-20 | 21,688 | \$2,394,891 | \$4,249,838 | \$314,420 | \$2,494,804 | \$726,139 | \$10,180,093 | \$469.39 |
| Jul-20 | 21,579 | \$2,481,688 | \$4,429,478 | \$312,131 | \$2,495,632 | \$794,527 | \$10,513,455 | \$487.21 |
| Aug-20 | 21,514 | \$2,547,898 | \$4,234,978 | \$294,008 | \$2,416,584 | \$558,688 | \$10,052,156 | \$467.24 |
| Sep-20 | 21,553 | \$2,564,750 | \$3,947,353 | \$318,153 | \$2,687,832 | \$621,615 | \$10,139,703 | \$470.45 |
| Oct-20 | 21,561 | \$1,440,679 | \$4,432,921 | \$344,717 | \$2,585,896 | \$572,412 | \$9,376,625 | \$434.89 |
| Nov-20 | 21,626 | \$1,262,128 | \$3,741,737 | \$303,506 | \$2,278,748 | \$596,950 | \$8,183,068 | \$378.39 |
| Dec-20 | 21,615 | \$1,786,275 | \$4,436,956 | \$330,217 | \$2,593,228 | \$725,887 | \$9,872,562 | \$456.75 |
| Jan-21 | 22,145 | \$2,005,751 | \$4,558,420 | \$333,314 | \$2,513,470 | \$699,216 | \$10,110,171 | \$456.54 |
| Feb-21 | 22,043 | \$2,380,887 | \$4,428,627 | \$329,016 | \$2,536,441 | \$555,911 | \$10,230,882 | \$464.13 |
| Mar-21 | 21,999 | \$1,910,253 | \$5,489,094 | \$401,802 | \$3,085,296 | \$788,611 | \$11,675,057 | \$530.71 |
| Apr-21 | 22,006 | \$2,784,158 | \$4,916,817 | \$358,407 | \$2,910,925 | \$609,083 | \$11,579,389 | \$526.19 |
| May-21 | 22,027 | \$2,742,127 | \$5,187,035 | \$326,670 | \$2,961,039 | \$623,493 | \$11,840,364 | \$537.54 |
| Jun-21 | 22,092 | \$1,994,201 | \$4,927,604 | \$336,057 | \$2,880,512 | \$672,088 | \$10,810,462 | \$489.34 |
| Jul-21 | 22,080 | \$1,515,187 | \$4,656,670 | \$303,689 | \$2,655,974 | \$925,171 | \$10,056,692 | \$455.47 |
| Aug-21 | 22,031 | \$2,141,144 | \$4,693,977 | \$314,855 | \$2,842,288 | \$789,792 | \$10,782,057 | \$489.40 |
| Sep-21 | 22,022 | \$2,476,763 | \$4,734,292 | \$347,623 | \$3,032,574 | \$826,823 | \$11,418,075 | \$518.48 |
| Oct-21 | 21,960 | \$2,386,511 | \$4,663,176 | \$352,082 | \$3,073,418 | \$638,632 | \$11,113,819 | \$506.09 |
| Nov-21 | 21,832 | \$2,254,101 | \$5,464,242 | \$344,083 | \$3,134,325 | \$828,837 | \$12,025,589 | \$550.82 |
| Dec-21 | 21,938 | \$1,451,916 | \$4,873,390 | \$338,166 | \$2,821,005 | \$769,531 | \$10,254,010 | \$467.41 |
| Jan-22 | 25,937 | \$1,763,537 | \$5,256,174 | \$433,654 | \$3,076,258 | \$815,640 | \$11,345,263 | \$437.42 |
| Feb-22 | 26,010 | \$2,396,552 | \$5,246,497 | \$411,873 | \$3,021,173 | \$791,676 | \$11,867,771 | \$456.28 |
| Mar-22 | 26,089 | \$2,831,247 | \$6,622,311 | \$496,447 | \$4,012,572 | \$774,814 | \$14,737,392 | \$564.89 |
| Apr-22 | 26,124 | \$2,342,773 | \$6,026,237 | \$419,167 | \$3,438,012 | \$873,541 | \$13,099,731 | \$501.44 |
| May-22 | 26,146 | \$2,267,862 | \$6,013,846 | \$452,080 | \$3,658,641 | \$932,458 | \$13,324,887 | \$509.63 |
| Jun-22 | 26,231 | \$2,759,523 | \$6,283,092 | \$455,127 | \$3,465,774 | \$867,921 | \$13,831,436 | \$527.29 |
| Jul-22 | 26,245 | \$2,994,750 | \$5,965,420 | \$393,342 | \$3,210,943 | \$938,221 | \$13,502,676 | \$514.49 |
| Aug-22 | 26,214 | \$3,003,395 | \$6,525,730 | \$454,186 | \$3,605,084 | \$1,056,613 | \$14,645,008 | \$558.67 |
| Sep-22 | 26,128 | \$2,366,545 | \$6,546,156 | \$446,303 | \$3,719,102 | \$1,029,057 | \$14,107,162 | \$539.93 |
| Oct-22 | 26,174 | \$2,024,803 | \$6,604,308 | \$461,623 | \$3,630,688 | \$1,084,922 | \$13,806,343 | \$527.48 |
| Nov-22 | 26,242 | \$2,962,958 | \$6,837,934 | \$455,474 | \$3,773,906 | \$1,085,869 | \$15,116,141 | \$576.03 |
| Dec-22 | 26,221 | \$3,183,398 | \$6,721,298 | \$432,183 | \$3,782,310 | \$968,797 | \$15,087,986 | \$575.42 |
| Jan-23 | 31,237 | \$3,324,328 | \$7,791,187 | \$593,666 | \$4,379,498 | \$966,086 | \$17,054,765 | \$545.98 |
| Feb-23 | 31,281 | \$2,777,349 | \$7,924,923 | \$540,351 | \$4,230,528 | \$1,077,879 | \$16,551,029 | \$529.11 |
| Mar-23 | 31,341 | \$3,575,028 | \$9,245,055 | \$618,790 | \$5,037,269 | \$1,471,888 | \$19,948,030 | \$636.48 |
| Apr-23 | 31,308 | \$2,606,220 | \$8,617,130 | \$540,568 | \$4,311,416 | \$1,084,786 | \$17,160,119 | \$548.11 |
| May-23 | 31,363 | \$3,904,673 | \$8,958,755 | \$633,381 | \$4,698,919 | \$1,364,123 | \$19,559,850 | \$623.66 |
| Jun-23 | 31,559 | \$2,301,966 | \$8,917,648 | \$579,638 | \$4,935,998 | \$1,432,556 | \$18,167,805 | \$575.68 |
| Jul-23 | 31,810 | \$3,739,251 | \$7,925,310 | \$489,871 | \$4,150,850 | \$1,216,137 | \$17,521,418 | \$550.81 |
| Aug-23 | 31,921 | \$4,733,077 | \$8,499,207 | \$574,362 | \$4,808,624 | \$1,212,007 | \$19,827,276 | \$621.14 |
| Sep-23 | 32,094 | \$2,859,894 | \$8,009,541 | \$558,510 | \$4,420,081 | \$1,316,292 | \$17,164,317 | \$534.81 |

MEDICAL UTILIZATION TREND CALCULATION

| Month | Adjusted Claims - Normalized for Contract Changes |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Inpatient | Outpatient | Professional MHSUD | Professional NonMHSUD | Specialty Pharmacy | Total Allowed Claims | PMPM |
| Oct-19 | \$2,508,015 | \$6,351,872 | \$358,028 | \$3,411,539 | \$975,344 | \$13,604,798 | \$611.20 |
| Nov-19 | \$2,246,610 | \$5,435,794 | \$292,557 | \$2,981,114 | \$861,408 | \$11,817,483 | \$525.62 |
| Dec-19 | \$2,254,122 | \$5,845,725 | \$281,618 | \$3,163,951 | \$943,153 | \$12,488,569 | \$557.13 |
| Jan-20 | \$2,318,020 | \$5,359,658 | \$353,186 | \$3,083,683 | \$887,589 | \$12,002,137 | \$544.83 |
| Feb-20 | \$2,820,348 | \$5,299,432 | \$299,152 | \$2,880,154 | \$479,051 | \$11,778,136 | \$537.42 |
| Mar-20 | \$2,126,469 | \$3,806,366 | \$320,323 | \$2,347,478 | \$551,171 | \$9,151,807 | \$417.95 |
| Apr-20 | \$2,263,076 | \$2,450,962 | \$350,453 | \$1,439,800 | \$657,526 | \$7,161,818 | \$327.91 |
| May-20 | \$3,136,638 | \$3,486,905 | \$328,350 | \$2,098,870 | \$606,762 | \$9,657,526 | \$444.11 |
| Jun-20 | \$2,944,284 | \$5,358,885 | \$348,554 | \$2,889,627 | \$910,119 | \$12,451,468 | \$574.12 |
| Jul-20 | \$3,050,559 | \$5,546,430 | \$346,262 | \$2,877,008 | \$997,415 | \$12,817,674 | \$593.99 |
| Aug-20 | \$3,165,906 | \$5,345,630 | \$326,239 | \$2,784,509 | \$700,000 | \$12,322,283 | \$572.76 |
| Sep-20 | \$3,135,647 | \$4,963,266 | \$352,554 | \$3,106,360 | \$775,843 | \$12,333,670 | \$572.25 |
| Oct-20 | \$1,766,979 | \$5,440,757 | \$378,102 | \$2,952,937 | \$706,949 | \$11,245,725 | \$521.58 |
| Nov-20 | \$1,541,471 | \$4,532,521 | \$332,112 | \$2,580,937 | \$734,738 | \$9,721,779 | \$449.54 |
| Dec-20 | \$2,271,713 | \$5,450,631 | \$361,710 | \$2,971,038 | \$893,384 | \$11,948,475 | \$552.79 |
| Jan-21 | \$2,409,857 | \$5,460,965 | \$364,489 | \$2,840,327 | \$826,003 | \$11,901,641 | \$537.44 |
| Feb-21 | \$2,862,729 | \$5,268,910 | \$359,826 | \$2,874,674 | \$664,057 | \$12,030,196 | \$545.76 |
| Mar-21 | \$2,261,960 | \$6,536,476 | \$439,270 | \$3,482,716 | \$935,861 | \$13,656,282 | \$620.77 |
| Apr-21 | \$3,330,777 | \$5,877,091 | \$391,654 | \$3,300,692 | \$722,995 | \$13,623,209 | \$619.07 |
| May-21 | \$3,303,365 | \$6,187,464 | \$347,213 | \$3,318,768 | \$741,121 | \$13,897,931 | \$630.95 |
| Jun-21 | \$2,380,847 | \$5,875,293 | \$356,690 | \$3,211,250 | \$800,905 | \$12,624,986 | \$571.47 |
| Jul-21 | \$1,819,650 | \$5,531,297 | \$322,203 | \$2,935,114 | \$1,101,784 | \$11,710,048 | \$530.35 |
| Aug-21 | \$2,469,984 | \$5,548,132 | \$334,582 | \$3,129,030 | \$943,100 | \$12,424,828 | \$563.97 |
| Sep-21 | \$2,928,932 | \$5,614,977 | \$368,495 | \$3,353,116 | \$981,539 | \$13,247,059 | \$601.54 |
| Oct-21 | \$2,759,905 | \$5,464,074 | \$373,359 | \$3,395,876 | \$750,566 | \$12,743,780 | \$580.32 |
| Nov-21 | \$2,582,958 | \$6,363,617 | \$364,051 | \$3,451,877 | \$979,678 | \$13,742,182 | \$629.45 |
| Dec-21 | \$1,683,209 | \$5,641,412 | \$357,602 | \$3,096,046 | \$905,146 | \$11,683,414 | \$532.57 |
| Jan-22 | \$2,024,444 | \$6,011,116 | \$458,105 | \$3,350,883 | \$941,745 | \$12,786,294 | \$492.98 |
| Feb-22 | \$2,702,324 | \$5,975,744 | \$434,814 | \$3,277,427 | \$917,171 | \$13,307,479 | \$511.63 |
| Mar-22 | \$3,246,489 | \$7,568,156 | \$524,278 | \$4,365,275 | \$895,188 | \$16,599,385 | \$636.26 |
| Apr-22 | \$2,682,073 | \$6,858,762 | \$441,841 | \$3,731,692 | \$1,008,847 | \$14,723,216 | \$563.59 |
| May-22 | \$2,585,113 | \$6,869,443 | \$475,800 | \$3,967,146 | \$1,070,778 | \$14,968,280 | \$572.49 |
| Jun-22 | \$3,142,556 | \$7,086,482 | \$477,959 | \$3,735,111 | \$979,792 | \$15,421,900 | \$587.93 |
| Jul-22 | \$3,279,444 | \$6,637,459 | \$412,584 | \$3,417,850 | \$1,047,279 | \$14,794,615 | \$563.71 |
| Aug-22 | \$3,318,940 | \$7,268,211 | \$476,390 | \$3,835,806 | \$1,173,961 | \$16,073,307 | \$613.16 |
| Sep-22 | \$2,593,802 | \$7,279,459 | \$468,166 | \$3,952,980 | \$1,142,971 | \$15,437,378 | \$590.84 |
| Oct-22 | \$2,227,699 | \$7,080,381 | \$465,939 | \$3,808,291 | \$1,165,222 | \$14,747,532 | \$563.44 |
| Nov-22 | \$3,257,452 | \$7,283,648 | \$459,821 | \$3,952,469 | \$1,171,524 | \$16,124,916 | \$614.47 |
| Dec-22 | \$3,437,253 | \$7,127,498 | \$435,653 | \$3,958,877 | \$1,052,195 | \$16,011,475 | \$610.64 |
| Jan-23 | \$3,408,969 | \$7,904,844 | \$596,735 | \$4,451,919 | \$989,860 | \$17,352,326 | \$555.51 |
| Feb-23 | \$2,854,609 | \$8,019,861 | \$543,232 | \$4,300,618 | \$1,107,640 | \$16,825,960 | \$537.90 |
| Mar-23 | \$3,664,216 | \$9,369,411 | \$621,455 | \$5,117,073 | \$1,516,706 | \$20,288,862 | \$647.36 |
| Apr-23 | \$2,649,073 | \$8,740,882 | \$542,454 | \$4,377,270 | \$1,119,838 | \$17,429,518 | \$556.71 |
| May-23 | \$3,973,372 | \$9,067,969 | \$635,102 | \$4,763,480 | \$1,405,513 | \$19,845,436 | \$632.77 |
| Jun-23 | \$2,350,834 | \$9,034,309 | \$580,774 | \$4,999,474 | \$1,463,479 | \$18,428,871 | \$583.95 |
| Jul-23 | \$3,742,389 | \$7,932,854 | \$490,503 | \$4,156,754 | \$1,217,164 | \$17,539,663 | \$551.39 |
| Aug-23 | \$4,736,852 | \$8,503,102 | \$574,736 | \$4,812,372 | \$1,212,717 | \$19,839,779 | \$621.53 |
| Sep-23 | \$2,859,894 | \$8,009,541 | \$558,510 | \$4,420,081 | \$1,316,292 | \$17,164,317 | \$534.81 |

MEDICAL UTILIZATION TREND CALCULATION

|  |  | Monthly PMPM |  |  |  |  | Rolling 12 PMPM |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Month | Membership | Facility | Professional MHSUD | Professional Non-MHSUD | Specialty Rx | Total | Facility | Professional MHSUD | Professional Non-MHSUD | Specialt y Rx | Total |
| Oct-19 | 22,259 | \$398.04 | \$16.08 | \$153.27 | \$43.82 | \$611.20 |  |  |  |  |  |
| Nov-19 | 22,483 | \$341.70 | \$13.01 | \$132.59 | \$38.31 | \$525.62 |  |  |  |  |  |
| Dec-19 | 22,416 | \$361.34 | \$12.56 | \$141.15 | \$42.08 | \$557.13 |  |  |  |  |  |
| Jan-20 | 22,029 | \$348.53 | \$16.03 | \$139.98 | \$40.29 | \$544.83 |  |  |  |  |  |
| Feb-20 | 21,916 | \$370.50 | \$13.65 | \$131.42 | \$21.86 | \$537.42 |  |  |  |  |  |
| Mar-20 | 21,897 | \$270.94 | \$14.63 | \$107.21 | \$25.17 | \$417.95 |  |  |  |  |  |
| Apr-20 | 21,841 | \$215.83 | \$16.05 | \$65.92 | \$30.11 | \$327.91 |  |  |  |  |  |
| May-20 | 21,746 | \$304.59 | \$15.10 | \$96.52 | \$27.90 | \$444.11 |  |  |  |  |  |
| Jun-20 | 21,688 | \$382.85 | \$16.07 | \$133.24 | \$41.96 | \$574.12 |  |  |  |  |  |
| Jul-20 | 21,579 | \$398.40 | \$16.05 | \$133.32 | \$46.22 | \$593.99 |  |  |  |  |  |
| Aug-20 | 21,514 | \$395.63 | \$15.16 | \$129.43 | \$32.54 | \$572.76 |  |  |  |  |  |
| Sep-20 | 21,553 | \$375.77 | \$16.36 | \$144.13 | \$36.00 | \$572.25 | \$346.95 | \$15.05 | \$125.76 | \$35.54 | \$523.30 |
| Oct-20 | 21,561 | \$334.30 | \$17.54 | \$136.96 | \$32.79 | \$521.58 | \$341.57 | \$15.17 | \$124.34 | \$34.62 | \$515.70 |
| Nov-20 | 21,626 | \$280.87 | \$15.36 | \$119.34 | \$33.97 | \$449.54 | \$336.54 | \$15.37 | \$123.22 | \$34.24 | \$509.37 |
| Dec-20 | 21,615 | \$357.27 | \$16.73 | \$137.45 | \$41.33 | \$552.79 | \$336.13 | \$15.72 | \$122.86 | \$34.16 | \$508.87 |
| Jan-21 | 22,145 | \$355.42 | \$16.46 | \$128.26 | \$37.30 | \$537.44 | \$336.72 | \$15.76 | \$121.87 | \$33.91 | \$508.25 |
| Feb-21 | 22,043 | \$368.90 | \$16.32 | \$130.41 | \$30.13 | \$545.76 | \$336.60 | \$15.98 | \$121.79 | \$34.60 | \$508.97 |
| Mar-21 | 21,999 | \$399.95 | \$19.97 | \$158.31 | \$42.54 | \$620.77 | \$347.45 | \$16.43 | \$126.09 | \$36.06 | \$526.04 |
| Apr-21 | 22,006 | \$418.43 | \$17.80 | \$149.99 | \$32.85 | \$619.07 | \$364.44 | \$16.58 | \$133.14 | \$36.29 | \$550.45 |
| May-21 | 22,027 | \$430.87 | \$15.76 | \$150.67 | \$33.65 | \$630.95 | \$375.02 | \$16.64 | \$137.67 | \$36.76 | \$566.09 |
| Jun-21 | 22,092 | \$373.72 | \$16.15 | \$145.36 | \$36.25 | \$571.47 | \$374.26 | \$16.64 | \$138.68 | \$36.29 | \$565.88 |
| Jul-21 | 22,080 | \$332.92 | \$14.59 | \$132.93 | \$49.90 | \$530.35 | \$368.80 | \$16.52 | \$138.64 | \$36.62 | \$560.57 |
| Aug-21 | 22,031 | \$363.95 | \$15.19 | \$142.03 | \$42.81 | \$563.97 | \$366.19 | \$16.52 | \$139.68 | \$37.47 | \$559.86 |
| Sep-21 | 22,022 | \$387.97 | \$16.73 | \$152.26 | \$44.57 | \$601.54 | \$367.23 | \$16.55 | \$140.36 | \$38.19 | \$562.33 |
| Oct-21 | 21,960 | \$374.50 | \$17.00 | \$154.64 | \$34.18 | \$580.32 | \$370.53 | \$16.51 | \$141.83 | \$38.29 | \$567.16 |
| Nov-21 | 21,832 | \$409.79 | \$16.68 | \$158.11 | \$44.87 | \$629.45 | \$381.13 | \$16.61 | \$145.02 | \$39.19 | \$581.96 |
| Dec-21 | 21,938 | \$333.88 | \$16.30 | \$141.13 | \$41.26 | \$532.57 | \$379.16 | \$16.58 | \$145.32 | \$39.19 | \$580.24 |
| Jan-22 | 25,937 | \$309.81 | \$17.66 | \$129.19 | \$36.31 | \$492.98 | \$374.41 | \$16.69 | \$145.17 | \$39.07 | \$575.33 |
| Feb-22 | 26,010 | \$333.64 | \$16.72 | \$126.01 | \$35.26 | \$511.63 | \$370.95 | \$16.72 | \$144.53 | \$39.43 | \$571.64 |
| Mar-22 | 26,089 | \$414.53 | \$20.10 | \$167.32 | \$34.31 | \$636.26 | \$372.76 | \$16.78 | \$145.59 | \$38.70 | \$573.83 |
| Apr-22 | 26,124 | \$365.21 | \$16.91 | \$142.85 | \$38.62 | \$563.59 | \$368.47 | \$16.72 | \$144.98 | \$39.15 | \$569.32 |
| May-22 | 26,146 | \$361.61 | \$18.20 | \$151.73 | \$40.95 | \$572.49 | \$363.00 | \$16.93 | \$145.16 | \$39.74 | \$564.84 |
| Jun-22 | 26,231 | \$389.96 | \$18.22 | \$142.39 | \$37.35 | \$587.93 | \$364.64 | \$17.11 | \$144.90 | \$39.79 | \$566.43 |
| Jul-22 | 26,245 | \$377.86 | \$15.72 | \$130.23 | \$39.90 | \$563.71 | \$368.21 | \$17.17 | \$144.49 | \$39.04 | \$568.91 |
| Aug-22 | 26,214 | \$403.87 | \$18.17 | \$146.33 | \$44.78 | \$613.16 | \$371.68 | \$17.41 | \$144.83 | \$39.26 | \$573.18 |
| Sep-22 | 26,128 | \$377.88 | \$17.92 | \$151.29 | \$43.75 | \$590.84 | \$371.03 | \$17.50 | \$144.85 | \$39.27 | \$572.64 |
| Oct-22 | 26,174 | \$355.62 | \$17.80 | \$145.50 | \$44.52 | \$563.44 | \$369.46 | \$17.56 | \$144.20 | \$40.08 | \$571.30 |
| Nov-22 | 26,242 | \$401.69 | \$17.52 | \$150.62 | \$44.64 | \$614.47 | \$369.34 | \$17.62 | \$143.76 | \$40.13 | \$570.86 |
| Dec-22 | 26,221 | \$402.91 | \$16.61 | \$150.98 | \$40.13 | \$610.64 | \$374.63 | \$17.63 | \$144.55 | \$40.05 | \$576.86 |
| Jan-23 | 31,237 | \$362.19 | \$19.10 | \$142.52 | \$31.69 | \$555.51 | \$378.68 | \$17.77 | \$145.60 | \$39.54 | \$581.59 |
| Feb-23 | 31,281 | \$347.64 | \$17.37 | \$137.48 | \$35.41 | \$537.90 | \$379.30 | \$17.82 | \$146.39 | \$39.48 | \$582.98 |
| Mar-23 | 31,341 | \$415.87 | \$19.83 | \$163.27 | \$48.39 | \$647.36 | \$379.99 | \$17.83 | \$146.34 | \$40.74 | \$584.89 |
| Apr-23 | 31,308 | \$363.80 | \$17.33 | \$139.81 | \$35.77 | \$556.71 | \$379.63 | \$17.85 | \$146.00 | \$40.44 | \$583.92 |
| May-23 | 31,363 | \$415.82 | \$20.25 | \$151.88 | \$44.81 | \$632.77 | \$384.35 | \$18.05 | \$146.10 | \$40.80 | \$589.30 |
| Jun-23 | 31,559 | \$360.76 | \$18.40 | \$158.42 | \$46.37 | \$583.95 | \$381.77 | \$18.07 | \$147.51 | \$41.57 | \$588.92 |
| Jul-23 | 31,810 | \$367.03 | \$15.42 | \$130.67 | \$38.26 | \$551.39 | \$380.72 | \$18.00 | \$147.27 | \$41.40 | \$587.40 |
| Aug-23 | 31,921 | \$414.77 | \$18.00 | \$150.76 | \$37.99 | \$621.53 | \$382.07 | \$17.99 | \$147.66 | \$40.85 | \$588.56 |
| Sep-23 | 32,094 | \$338.67 | \$17.40 | \$137.72 | \$41.01 | \$534.81 | \$378.53 | \$17.94 | \$146.51 | \$40.65 | \$583.64 |
|  |  |  |  |  |  | Annual Tre | 2.0\% | 2.5\% | 1.2\% | 3.5\% | 1.9\% |


|  | Impact of FWA Program Reco <br> Month Starting |  |
| :---: | :---: | :---: |
| Oct-19 | FWA Program Recovery Percent |  |
| Jan-20 |  | $0.81 \%$ |
| Oct-20 |  | $0.88 \%$ |
| Jan-21 |  | $1.42 \%$ |
| Jan-22 |  | $2.47 \%$ |
| Jan-23 |  | $2.57 \%$ |

MEDICAL UTILIZATION TREND CALCULATION

|  | Normalized Monthly PMPM |  |  |  |  | Rolling 12 PMPM |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Facility | Professional MHSUD | Professional NonMHSUD | Specialt y Rx | Total | Facility | Professional MHSUD | Professional NonMHSUD | Specialt y Rx | Total |
| Oct-19 | \$371.54 | \$15.01 | \$143.06 | \$40.90 | \$570.52 |  |  |  |  |  |
| Nov-19 | \$369.92 | \$14.09 | \$143.55 | \$41.48 | \$569.04 |  |  |  |  |  |
| Dec-19 | \$353.18 | \$12.28 | \$137.96 | \$41.12 | \$544.54 |  |  |  |  |  |
| Jan-20 | \$327.47 | \$15.06 | \$131.52 | \$37.86 | \$511.91 |  |  |  |  |  |
| Feb-20 | \$382.75 | \$14.10 | \$135.76 | \$22.58 | \$555.20 |  |  |  |  |  |
| Mar-20 | \$253.82 | \$13.70 | \$100.43 | \$23.58 | \$391.54 |  |  |  |  |  |
| Apr-20 | \$202.44 | \$15.05 | \$61.83 | \$28.24 | \$307.55 |  |  |  |  |  |
| May-20 | \$312.79 | \$15.51 | \$99.12 | \$28.65 | \$456.07 |  |  |  |  |  |
| Jun-20 | \$357.77 | \$15.02 | \$124.51 | \$39.22 | \$536.51 |  |  |  |  |  |
| Jul-20 | \$371.70 | \$14.97 | \$124.39 | \$43.12 | \$554.19 |  |  |  |  |  |
| Aug-20 | \$386.11 | \$14.80 | \$126.31 | \$31.75 | \$558.98 |  |  |  |  |  |
| Sep-20 | \$366.88 | \$15.97 | \$140.72 | \$35.15 | \$558.71 | \$338.06 | \$14.62 | \$122.54 | \$34.50 | \$509.72 |
| Oct-20 | \$314.23 | \$16.48 | \$128.74 | \$30.82 | \$490.27 | \$333.25 | \$14.74 | \$121.30 | \$33.66 | \$502.96 |
| Nov-20 | \$305.75 | \$16.72 | \$129.92 | \$36.98 | \$489.37 | \$327.82 | \$14.96 | \$120.10 | \$33.26 | \$496.15 |
| Dec-20 | \$352.24 | \$16.50 | \$135.52 | \$40.75 | \$545.01 | \$327.67 | \$15.32 | \$119.84 | \$33.20 | \$496.04 |
| Jan-21 | \$392.12 | \$18.16 | \$141.50 | \$41.15 | \$592.94 | \$333.16 | \$15.58 | \$120.70 | \$33.49 | \$502.93 |
| Feb-21 | \$386.47 | \$17.10 | \$136.62 | \$31.56 | \$571.75 | \$333.50 | \$15.84 | \$120.78 | \$34.24 | \$504.35 |
| Mar-21 | \$363.86 | \$18.17 | \$144.03 | \$38.70 | \$564.76 | \$342.75 | \$16.21 | \$124.45 | \$35.51 | \$518.91 |
| Apr-21 | \$397.52 | \$16.91 | \$142.50 | \$31.21 | \$588.14 | \$359.10 | \$16.37 | \$131.21 | \$35.76 | \$542.43 |
| May-21 | \$449.87 | \$16.46 | \$157.31 | \$35.13 | \$658.76 | \$370.60 | \$16.45 | \$136.08 | \$36.30 | \$559.42 |
| Jun-21 | \$354.48 | \$15.31 | \$137.88 | \$34.39 | \$542.06 | \$370.31 | \$16.47 | \$137.19 | \$35.89 | \$559.85 |
| Jul-21 | \$330.48 | \$14.49 | \$131.96 | \$49.53 | \$526.46 | \$366.84 | \$16.43 | \$137.80 | \$36.45 | \$557.51 |
| Aug-21 | \$344.56 | \$14.38 | \$134.46 | \$40.53 | \$533.92 | \$363.39 | \$16.39 | \$138.46 | \$37.17 | \$555.41 |
| Sep-21 | \$384.69 | \$16.59 | \$150.98 | \$44.19 | \$596.46 | \$364.89 | \$16.44 | \$139.32 | \$37.93 | \$558.57 |
| Oct-21 | \$370.85 | \$16.84 | \$153.13 | \$33.85 | \$574.66 | \$369.53 | \$16.47 | \$141.34 | \$38.17 | \$565.50 |
| Nov-21 | \$426.24 | \$17.34 | \$164.46 | \$46.67 | \$654.71 | \$379.45 | \$16.52 | \$144.19 | \$38.97 | \$579.12 |
| Dec-21 | \$315.24 | \$15.39 | \$133.25 | \$38.96 | \$502.84 | \$376.34 | \$16.43 | \$143.99 | \$38.82 | \$575.58 |
| Jan-22 | \$309.77 | \$17.66 | \$129.17 | \$36.30 | \$492.90 | \$368.59 | \$16.40 | \$142.76 | \$38.38 | \$566.14 |
| Feb-22 | \$350.82 | \$17.58 | \$132.49 | \$37.08 | \$537.97 | \$365.45 | \$16.46 | \$142.27 | \$38.81 | \$562.99 |
| Mar-22 | \$378.46 | \$18.35 | \$152.76 | \$31.33 | \$580.89 | \$366.80 | \$16.50 | \$143.12 | \$38.11 | \$564.54 |
| Apr-22 | \$364.88 | \$16.90 | \$142.71 | \$38.58 | \$563.07 | \$364.21 | \$16.51 | \$143.14 | \$38.70 | \$562.55 |
| May-22 | \$360.56 | \$18.15 | \$151.29 | \$40.84 | \$570.83 | \$357.24 | \$16.66 | \$142.79 | \$39.17 | \$555.86 |
| Jun-22 | \$370.61 | \$17.32 | \$135.33 | \$35.50 | \$558.76 | \$358.66 | \$16.82 | \$142.49 | \$39.21 | \$557.18 |
| Jul-22 | \$414.71 | \$17.25 | \$142.93 | \$43.80 | \$618.69 | \$365.82 | \$17.04 | \$143.32 | \$38.84 | \$565.01 |
| Aug-22 | \$365.97 | \$16.47 | \$132.59 | \$40.58 | \$555.61 | \$367.41 | \$17.19 | \$143.03 | \$38.87 | \$566.49 |
| Sep-22 | \$375.16 | \$17.79 | \$150.20 | \$43.43 | \$586.58 | \$366.82 | \$17.28 | \$143.07 | \$38.87 | \$566.04 |
| Oct-22 | \$352.52 | \$17.65 | \$144.23 | \$44.13 | \$558.52 | \$365.30 | \$17.35 | \$142.45 | \$39.69 | \$564.78 |
| Nov-22 | \$418.38 | \$18.25 | \$156.88 | \$46.50 | \$640.00 | \$365.50 | \$17.42 | \$142.12 | \$39.77 | \$564.81 |
| Dec-22 | \$399.70 | \$16.48 | \$149.78 | \$39.81 | \$605.78 | \$371.88 | \$17.49 | \$143.38 | \$39.83 | \$572.57 |
| Jan-23 | \$348.59 | \$18.39 | \$137.17 | \$30.50 | \$534.65 | \$374.64 | \$17.56 | \$143.92 | \$39.20 | \$575.33 |
| Feb-23 | \$369.22 | \$18.44 | \$146.02 | \$37.61 | \$571.30 | \$376.03 | \$17.64 | \$145.04 | \$39.22 | \$577.94 |
| Mar-23 | \$383.87 | \$18.30 | \$150.71 | \$44.67 | \$597.56 | \$376.59 | \$17.65 | \$144.97 | \$40.36 | \$579.57 |
| Apr-23 | \$385.54 | \$18.36 | \$148.17 | \$37.91 | \$589.97 | \$378.34 | \$17.78 | \$145.45 | \$40.27 | \$581.83 |
| May-23 | \$400.32 | \$19.50 | \$146.22 | \$43.14 | \$609.18 | \$381.73 | \$17.91 | \$145.07 | \$40.49 | \$585.20 |
| Jun-23 | \$347.53 | \$17.73 | \$152.61 | \$44.67 | \$562.54 | \$379.45 | \$17.93 | \$146.50 | \$41.25 | \$585.14 |
| Jul-23 | \$388.72 | \$16.33 | \$138.40 | \$40.52 | \$583.97 | \$377.65 | \$17.84 | \$146.03 | \$41.00 | \$582.52 |
| Aug-23 | \$381.95 | \$16.58 | \$138.83 | \$34.98 | \$572.34 | \$378.90 | \$17.83 | \$146.37 | \$40.49 | \$583.59 |
| Sep-23 | \$358.43 | \$18.42 | \$145.76 | \$43.41 | \$566.01 | \$377.36 | \$17.88 | \$146.04 | \$40.54 | \$581.82 |
|  |  |  |  |  | Annual Tr | 2.9\% | 3.5\% | 2.1\% | 4.3\% | 2.8\% |




MEDICAL UTILIZATION TREND CALCULATION

| Month | Utilization Trend Calculation - Professional - Mental Health - 24 Month |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Normalized PMPM | Logistic Regression |  | Linear Regression |  | Holt-Winters' Multiplicative |  | Holt-Winters' Additive |  | Double Exp Smoothing |  |
|  | Membership |  | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM |
| Oct-21 | 21,960 | \$16.84 | \$17.07 |  | \$17.08 |  | \$16.77 |  | \$16.98 |  | \$17.80 |  |
| Nov-21 | 21,832 | \$17.34 | \$17.11 |  | \$17.13 |  | \$17.36 |  | \$17.53 |  | \$17.64 |  |
| Dec-21 | 21,938 | \$15.39 | \$17.15 |  | \$17.17 |  | \$15.52 |  | \$15.66 |  | \$17.62 |  |
| Jan-22 | 25,937 | \$17.66 | \$17.19 |  | \$17.21 |  | \$17.73 |  | \$17.73 |  | \$17.18 |  |
| Feb-22 | 26,010 | \$17.58 | \$17.23 |  | \$17.25 |  | \$17.70 |  | \$17.71 |  | \$17.29 |  |
| Mar-22 | 26,089 | \$18.35 | \$17.27 |  | \$17.29 |  | \$18.33 |  | \$18.02 |  | \$17.36 |  |
| Apr-22 | 26,124 | \$16.90 | \$17.31 |  | \$17.33 |  | \$17.15 |  | \$17.34 |  | \$17.59 |  |
| May-22 | 26,146 | \$18.15 | \$17.35 |  | \$17.37 |  | \$18.38 |  | \$18.51 |  | \$17.47 |  |
| Jun-22 | 26,231 | \$17.32 | \$17.39 |  | \$17.41 |  | \$17.43 |  | \$17.19 |  | \$17.64 |  |
| Jul-22 | 26,245 | \$17.25 | \$17.43 |  | \$17.46 |  | \$17.22 |  | \$16.47 |  | \$17.60 |  |
| Aug-22 | 26,214 | \$16.47 | \$17.48 |  | \$17.50 |  | \$16.56 |  | \$16.24 |  | \$17.55 |  |
| Sep-22 | 26,128 | \$17.79 | \$17.52 | \$17.30 | \$17.54 | \$17.32 | \$17.97 | \$17.37 | \$17.84 | \$17.29 | \$17.34 | \$17.50 |
| Oct-22 | 26,174 | \$17.65 | \$17.56 | \$17.34 | \$17.58 | \$17.36 | \$17.97 | \$17.47 | \$17.59 | \$17.34 | \$17.44 | \$17.47 |
| Nov-22 | 26,242 | \$18.25 | \$17.60 | \$17.38 | \$17.62 | \$17.40 | \$18.44 | \$17.56 | \$18.15 | \$17.39 | \$17.50 | \$17.46 |
| Dec-22 | 26,221 | \$16.48 | \$17.64 | \$17.42 | \$17.66 | \$17.44 | \$16.32 | \$17.60 | \$16.29 | \$17.42 | \$17.68 | \$17.47 |
| Jan-23 | 31,237 | \$18.39 | \$17.68 | \$17.46 | \$17.71 | \$17.48 | \$18.65 | \$17.69 | \$18.39 | \$17.49 | \$17.45 | \$17.49 |
| Feb-23 | 31,281 | \$18.44 | \$17.73 | \$17.50 | \$17.75 | \$17.53 | \$18.49 | \$17.77 | \$18.38 | \$17.56 | \$17.66 | \$17.53 |
| Mar-23 | 31,341 | \$18.30 | \$17.76 | \$17.55 | \$17.79 | \$17.57 | \$19.15 | \$17.85 | \$18.70 | \$17.63 | \$17.85 | \$17.57 |
| Apr-23 | 31,308 | \$18.36 | \$17.81 | \$17.59 | \$17.83 | \$17.61 | \$17.58 | \$17.88 | \$17.98 | \$17.69 | \$17.98 | \$17.61 |
| May-23 | 31,363 | \$19.50 | \$17.85 | \$17.63 | \$17.87 | \$17.65 | \$18.91 | \$17.94 | \$19.19 | \$17.76 | \$18.10 | \$17.66 |
| Jun-23 | 31,559 | \$17.73 | \$17.89 | \$17.67 | \$17.91 | \$17.70 | \$18.05 | \$17.99 | \$17.91 | \$17.82 | \$18.44 | \$17.73 |
| Jul-23 | 31,810 | \$16.33 | \$17.93 | \$17.71 | \$17.95 | \$17.74 | \$17.86 | \$18.04 | \$17.17 | \$17.86 | \$18.34 | \$17.80 |
| Aug-23 | 31,921 | \$16.58 | \$17.97 | \$17.76 | \$18.00 | \$17.78 | \$16.85 | \$18.04 | \$16.85 | \$17.89 | \$17.96 | \$17.83 |
| Sep-23 | 32,094 | \$18.42 | \$18.02 | \$17.80 | \$18.04 | \$17.82 | \$18.10 | \$18.05 | \$18.42 | \$17.94 | \$17.69 | \$17.85 |
| Oct-23 | 32,094 |  | \$18.06 | \$17.84 | \$18.08 | \$17.86 | \$17.98 | \$18.05 | \$18.17 | \$17.99 | \$17.86 | \$17.88 |
| Nov-23 | 32,094 |  | \$18.10 | \$17.87 | \$18.12 | \$17.90 | \$18.48 | \$18.06 | \$18.73 | \$18.04 | \$17.87 | \$17.91 |
| Dec-23 | 32,094 |  | \$18.14 | \$17.91 | \$18.16 | \$17.94 | \$16.49 | \$18.04 | \$16.87 | \$18.06 | \$17.89 | \$17.92 |
| Jan-24 | 32,094 |  | \$18.19 | \$17.96 | \$18.20 | \$17.98 | \$18.51 | \$18.03 | \$18.96 | \$18.11 | \$17.91 | \$17.96 |
| Feb-24 | 32,094 |  | \$18.23 | \$18.00 | \$18.25 | \$18.02 | \$18.42 | \$18.03 | \$18.94 | \$18.16 | \$17.93 | \$17.98 |
| Mar-24 | 32,094 |  | \$18.27 | \$18.04 | \$18.29 | \$18.06 | \$18.60 | \$17.99 | \$19.26 | \$18.20 | \$17.95 | \$17.99 |
| Apr-24 | 32,094 |  | \$18.32 | \$18.08 | \$18.33 | \$18.10 | \$17.94 | \$18.01 | \$18.56 | \$18.25 | \$17.96 | \$17.99 |
| May-24 | 32,094 |  | \$18.36 | \$18.12 | \$18.37 | \$18.14 | \$19.01 | \$18.02 | \$19.75 | \$18.30 | \$17.98 | \$17.98 |
| Jun-24 | 32,094 |  | \$18.40 | \$18.17 | \$18.41 | \$18.18 | \$17.55 | \$17.98 | \$18.46 | \$18.35 | \$18.00 | \$17.94 |
| Jul-24 | 32,094 |  | \$18.44 | \$18.21 | \$18.45 | \$18.22 | \$16.71 | \$17.89 | \$17.73 | \$18.39 | \$18.02 | \$17.92 |
| Aug-24 | 32,094 |  | \$18.49 | \$18.25 | \$18.49 | \$18.27 | \$16.51 | \$17.86 | \$17.46 | \$18.44 | \$18.04 | \$17.92 |
| Sep-24 | 32,094 |  | \$18.53 | \$18.30 | \$18.54 | \$18.31 | \$18.09 | \$17.86 | \$19.04 | \$18.49 | \$18.05 | \$17.95 |
| Oct-24 | 32,094 |  | \$18.58 | \$18.34 | \$18.58 | \$18.35 | \$17.78 | \$17.84 | \$18.79 | \$18.55 | \$18.07 | \$17.97 |
| Nov-24 | 32,094 |  | \$18.62 | \$18.38 | \$18.62 | \$18.39 | \$18.27 | \$17.82 | \$19.35 | \$18.60 | \$18.09 | \$17.99 |
| Dec-24 | 32,094 |  | \$18.66 | \$18.42 | \$18.66 | \$18.43 | \$16.30 | \$17.81 | \$17.49 | \$18.65 | \$18.11 | \$18.01 |
| Jan-25 | 32,094 |  | \$18.71 | \$18.47 | \$18.70 | \$18.47 | \$18.30 | \$17.79 | \$19.57 | \$18.70 | \$18.13 | \$18.03 |
| Feb-25 | 32,094 |  | \$18.75 | \$18.51 | \$18.75 | \$18.52 | \$18.21 | \$17.77 | \$19.56 | \$18.75 | \$18.14 | \$18.04 |
| Mar-25 | 32,094 |  | \$18.79 | \$18.56 | \$18.78 | \$18.56 | \$18.39 | \$17.76 | \$19.88 | \$18.80 | \$18.16 | \$18.06 |
| Apr-25 | 32,094 |  | \$18.84 | \$18.60 | \$18.83 | \$18.60 | \$17.74 | \$17.74 | \$19.18 | \$18.85 | \$18.18 | \$18.08 |
| May-25 | 32,094 |  | \$18.88 | \$18.64 | \$18.87 | \$18.64 | \$18.80 | \$17.72 | \$20.37 | \$18.91 | \$18.20 | \$18.10 |
| Jun-25 | 32,094 |  | \$18.93 | \$18.69 | \$18.91 | \$18.68 | \$17.35 | \$17.70 | \$19.07 | \$18.96 | \$18.22 | \$18.12 |
| Jul-25 | 32,094 |  | \$18.97 | \$18.73 | \$18.95 | \$18.72 | \$16.52 | \$17.69 | \$18.34 | \$19.01 | \$18.23 | \$18.13 |
| Aug-25 | 32,094 |  | \$19.02 | \$18.77 | \$18.99 | \$18.76 | \$16.32 | \$17.67 | \$18.08 | \$19.06 | \$18.25 | \$18.15 |
| Sep-25 | 32,094 |  | \$19.06 | \$18.82 | \$19.03 | \$18.81 | \$17.89 | \$17.66 | \$19.66 | \$19.11 | \$18.27 | \$18.17 |
| Oct-25 | 32,094 |  | \$19.11 | \$18.86 | \$19.08 | \$18.85 | \$17.58 | \$17.64 | \$19.41 | \$19.16 | \$18.29 | \$18.19 |
| Nov-25 | 32,094 |  | \$19.15 | \$18.91 | \$19.12 | \$18.89 | \$18.07 | \$17.62 | \$19.97 | \$19.21 | \$18.31 | \$18.21 |
| Dec-25 | 32,094 |  | \$19.20 | \$18.95 | \$19.16 | \$18.93 | \$16.12 | \$17.61 | \$18.11 | \$19.27 | \$18.32 | \$18.22 |
| Utilization Trend |  |  | 2.83\% |  | 2.72\% |  | -1.09\% |  | 3.22\% |  |  | 0.91\% |
| RMSE (root mean square error) |  |  | 0.85 |  | 0.85 |  | 0.44 |  | 0.32 |  | 0.97 |  |


| Month | Utilization Trend Calculation - Professional - All Other - 48 Month |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Normalized PMPM | Logistic Regression |  | Linear Regression |  | Holt-Winters' Multiplicative |  | Holt-Winters' Additive |  | Double Exp Smoothing |  |
|  | Members |  | Fitted PMPM | Rolling 12 <br> PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM |
| Oct-19 | 22,259 | \$143.06 | \$122.21 |  | \$124.56 |  | \$133.14 |  | \$143.06 |  | \$129.10 |  |
| Nov-19 | 22,483 | \$143.55 | \$122.79 |  | \$125.14 |  | \$136.01 |  | \$149.45 |  | \$132.87 |  |
| Dec-19 | 22,416 | \$137.96 | \$123.37 |  | \$125.69 |  | \$130.16 |  | \$133.95 |  | \$136.02 |  |
| Jan-20 | 22,029 | \$131.52 | \$123.96 |  | \$126.27 |  | \$128.16 |  | \$133.65 |  | \$137.03 |  |
| Feb-20 | 21,916 | \$135.76 | \$124.56 |  | \$126.84 |  | \$129.53 |  | \$134.39 |  | \$136.10 |  |
| Mar-20 | 21,897 | \$100.43 | \$125.12 |  | \$127.38 |  | \$117.30 |  | \$135.00 |  | \$136.45 |  |
| Apr-20 | 21,841 | \$61.83 | \$125.72 |  | \$127.95 |  | \$95.62 |  | \$87.23 |  | \$127.31 |  |
| May-20 | 21,746 | \$99.12 | \$126.30 |  | \$128.51 |  | \$120.15 |  | \$76.46 |  | \$109.70 |  |
| Jun-20 | 21,688 | \$124.51 | \$126.91 |  | \$129.08 |  | \$124.70 |  | \$98.13 |  | \$105.53 |  |
| Jul-20 | 21,579 | \$124.39 | \$127.50 |  | \$129.64 |  | \$124.12 |  | \$121.29 |  | \$109.02 |  |
| Aug-20 | 21,514 | \$126.31 | \$128.12 |  | \$130.21 |  | \$124.59 |  | \$122.99 |  | \$111.89 |  |
| Sep-20 | 21,553 | \$140.72 | \$128.73 | \$125.41 | \$130.79 | \$127.65 | \$139.95 | \$125.33 | \$140.15 | \$123.13 | \$114.78 | \$123.95 |
| Oct-20 | 21,561 | \$128.74 | \$129.33 | \$126.01 | \$131.35 | \$128.21 | \$143.57 | \$126.16 | \$143.62 | \$123.12 | \$120.99 | \$123.27 |
| Nov-20 | 21,626 | \$129.92 | \$129.96 | \$126.61 | \$131.92 | \$128.78 | \$145.79 | \$126.94 | \$135.12 | \$121.85 | \$122.82 | \$122.40 |
| Dec-20 | 21,615 | \$135.52 | \$130.56 | \$127.22 | \$132.48 | \$129.36 | \$139.59 | \$127.71 | \$120.30 | \$120.68 | \$124.61 | \$121.41 |
| Jan-21 | 22,145 | \$141.50 | \$131.19 | \$127.83 | \$133.05 | \$129.93 | \$136.10 | \$128.39 | \$131.19 | \$120.47 | \$127.54 | \$120.62 |
| Feb-21 | 22,043 | \$136.62 | \$131.82 | \$128.44 | \$133.63 | \$130.50 | \$138.33 | \$129.13 | \$144.36 | \$121.32 | \$131.48 | \$120.23 |
| Mar-21 | 21,999 | \$144.03 | \$132.39 | \$129.05 | \$134.14 | \$131.07 | \$118.58 | \$129.23 | \$135.86 | \$121.40 | \$133.32 | \$119.97 |
| Apr-21 | 22,006 | \$142.50 | \$133.03 | \$129.67 | \$134.72 | \$131.64 | \$90.79 | \$128.81 | \$130.82 | \$125.05 | \$136.72 | \$120.77 |
| May-21 | 22,027 | \$157.31 | \$133.65 | \$130.28 | \$135.27 | \$132.21 | \$120.59 | \$128.83 | \$157.16 | \$131.80 | \$139.01 | \$123.23 |
| Jun-21 | 22,092 | \$137.88 | \$134.29 | \$130.90 | \$135.85 | \$132.77 | \$131.64 | \$129.41 | \$156.40 | \$136.67 | \$144.73 | \$126.51 |
| Jul-21 | 22,080 | \$131.96 | \$134.92 | \$131.52 | \$136.41 | \$133.34 | \$131.18 | \$130.00 | \$134.71 | \$137.77 | \$144.08 | \$129.43 |
| Aug-21 | 22,031 | \$134.46 | \$135.57 | \$132.14 | \$136.98 | \$133.90 | \$132.09 | \$130.61 | \$130.56 | \$138.38 | \$141.92 | \$131.91 |
| Sep-21 | 22,022 | \$150.98 | \$136.22 | \$132.76 | \$137.55 | \$134.46 | \$148.03 | \$131.31 | \$148.30 | \$139.06 | \$140.78 | \$134.06 |
| Oct-21 | 21,960 | \$153.13 | \$136.85 | \$133.38 | \$138.11 | \$135.02 | \$147.26 | \$131.63 | \$153.87 | \$139.92 | \$144.20 | \$135.97 |
| Nov-21 | 21,832 | \$164.46 | \$137.51 | \$134.00 | \$138.69 | \$135.57 | \$149.34 | \$131.94 | \$159.52 | \$141.94 | \$147.46 | \$138.00 |
| Dec-21 | 21,938 | \$133.25 | \$138.15 | \$134.63 | \$139.24 | \$136.13 | \$146.33 | \$132.51 | \$154.86 | \$144.78 | \$153.02 | \$140.34 |
| Jan-22 | 25,937 | \$129.17 | \$138.82 | \$135.32 | \$139.82 | \$136.74 | \$145.43 | \$133.46 | \$128.95 | \$144.37 | \$149.12 | \$142.25 |
| Feb-22 | 26,010 | \$132.49 | \$139.49 | \$136.00 | \$140.39 | \$137.35 | \$145.65 | \$134.23 | \$132.02 | \$143.19 | \$144.82 | \$143.37 |
| Mar-22 | 26,089 | \$152.76 | \$140.09 | \$136.67 | \$140.91 | \$137.94 | \$132.77 | \$135.34 | \$131.71 | \$142.69 | \$142.19 | \$144.06 |
| Apr-22 | 26,124 | \$142.71 | \$140.77 | \$137.34 | \$141.48 | \$138.52 | \$111.13 | \$136.58 | \$139.54 | \$143.33 | \$145.43 | \$144.76 |
| May-22 | 26,146 | \$151.29 | \$141.42 | \$138.00 | \$142.04 | \$139.10 | \$138.11 | \$137.96 | \$157.38 | \$143.55 | \$145.32 | \$145.26 |
| Jun-22 | 26,231 | \$135.33 | \$142.10 | \$138.66 | \$142.62 | \$139.66 | \$140.72 | \$138.70 | \$150.37 | \$143.19 | \$147.48 | \$145.50 |
| Jul-22 | 26,245 | \$142.93 | \$142.76 | \$139.31 | \$143.17 | \$140.23 | \$138.58 | \$139.26 | \$132.14 | \$142.83 | \$144.92 | \$145.55 |
| Aug-22 | 26,214 | \$132.59 | \$143.45 | \$139.95 | \$143.75 | \$140.78 | \$140.00 | \$139.85 | \$141.53 | \$143.63 | \$144.85 | \$145.76 |
| Sep-22 | 26,128 | \$150.20 | \$144.14 | \$140.59 | \$144.32 | \$141.32 | \$156.94 | \$140.74 | \$146.43 | \$143.53 | \$142.02 | \$145.80 |
| Oct-22 | 26,174 | \$144.23 | \$144.81 | \$141.22 | \$144.88 | \$141.86 | \$156.94 | \$141.66 | \$153.09 | \$143.61 | \$144.40 | \$145.80 |
| Nov-22 | 26,242 | \$156.88 | \$145.51 | \$141.85 | \$145.45 | \$142.39 | \$161.79 | \$142.82 | \$150.61 | \$143.08 | \$144.71 | \$145.59 |
| Dec-22 | 26,221 | \$149.78 | \$146.19 | \$142.47 | \$146.01 | \$142.91 | \$150.26 | \$143.20 | \$147.26 | \$142.60 | \$148.29 | \$145.29 |
| Jan-23 | 31,237 | \$137.17 | \$146.89 | \$143.20 | \$146.58 | \$143.52 | \$148.37 | \$143.52 | \$145.46 | \$143.99 | \$149.25 | \$145.37 |
| Feb-23 | 31,281 | \$146.02 | \$147.60 | \$143.92 | \$147.16 | \$144.12 | \$149.49 | \$143.93 | \$140.02 | \$144.57 | \$146.63 | \$145.54 |
| Mar-23 | 31,341 | \$150.71 | \$148.24 | \$144.63 | \$147.68 | \$144.71 | \$145.67 | \$144.98 | \$145.24 | \$145.65 | \$146.84 | \$145.92 |
| Apr-23 | 31,308 | \$148.17 | \$148.95 | \$145.34 | \$148.25 | \$145.30 | \$126.23 | \$145.87 | \$137.50 | \$145.37 | \$148.24 | \$146.18 |
| May-23 | 31,363 | \$146.22 | \$149.65 | \$146.04 | \$148.81 | \$145.87 | \$149.16 | \$146.77 | \$162.82 | \$146.05 | \$148.65 | \$146.47 |
| Jun-23 | 31,559 | \$152.61 | \$150.37 | \$146.73 | \$149.38 | \$146.44 | \$146.39 | \$147.19 | \$145.30 | \$145.66 | \$148.44 | \$146.58 |
| Jul-23 | 31,810 | \$138.40 | \$151.07 | \$147.42 | \$149.94 | \$147.00 | \$146.99 | \$147.82 | \$149.41 | \$147.01 | \$149.94 | \$147.01 |
| Aug-23 | 31,921 | \$138.83 | \$151.79 | \$148.11 | \$150.51 | \$147.55 | \$144.97 | \$148.14 | \$137.00 | \$146.52 | \$147.33 | \$147.19 |
| Sep-23 | 32,094 | \$145.76 | \$152.52 | \$148.78 | \$151.09 | \$148.10 | \$162.93 | \$148.81 | \$152.66 | \$147.06 | \$145.33 | \$147.40 |
| Oct-23 | 32,094 |  | \$153.23 | \$149.45 | \$151.64 | \$148.64 | \$161.12 | \$149.31 | \$148.65 | \$146.77 | \$145.56 | \$147.45 |
| Nov-23 | 32,094 |  | \$153.97 | \$150.12 | \$152.22 | \$149.17 | \$168.49 | \$150.08 | \$155.01 | \$147.21 | \$145.67 | \$147.49 |
| Dec-23 | 32,094 |  | \$154.69 | \$150.77 | \$152.77 | \$149.69 | \$157.65 | \$150.70 | \$145.40 | \$147.06 | \$145.79 | \$147.30 |
| Jan-24 | 32,094 |  | \$155.43 | \$151.48 | \$153.35 | \$150.25 | \$152.49 | \$151.05 | \$141.07 | \$146.68 | \$145.91 | \$147.02 |
| Feb-24 | 32,094 |  | \$156.18 | \$152.20 | \$153.92 | \$150.81 | \$155.93 | \$151.58 | \$143.91 | \$146.99 | \$146.02 | \$146.97 |
| Mar-24 | 32,094 |  | \$156.88 | \$152.91 | \$154.46 | \$151.38 | \$154.39 | \$152.30 | \$143.13 | \$146.81 | \$146.14 | \$146.91 |
| Apr-24 | 32,094 |  | \$157.64 | \$153.63 | \$155.03 | \$151.94 | \$138.90 | \$153.31 | \$129.90 | \$146.16 | \$146.26 | \$146.75 |
| May-24 | 32,094 |  | \$158.37 | \$154.35 | \$155.59 | \$152.50 | \$155.59 | \$153.84 | \$144.54 | \$144.66 | \$146.38 | \$146.56 |
| Jun-24 | 32,094 |  | \$159.13 | \$155.08 | \$156.16 | \$153.06 | \$155.33 | \$154.57 | \$143.60 | \$144.52 | \$146.49 | \$146.40 |
| Jul-24 | 32,094 |  | \$159.88 | \$155.81 | \$156.72 | \$153.62 | \$151.58 | \$154.95 | \$140.39 | \$143.77 | \$146.61 | \$146.12 |
| Aug-24 | 32,094 |  | \$160.64 | \$156.55 | \$157.30 | \$154.19 | \$150.16 | \$155.38 | \$138.98 | \$143.94 | \$146.73 | \$146.07 |
| Sep-24 | 32,094 |  | \$161.42 | \$157.29 | \$157.87 | \$154.75 | \$165.74 | \$155.61 | \$152.80 | \$143.95 | \$146.84 | \$146.20 |
| Oct-24 | 32,094 |  | \$162.17 | \$158.03 | \$158.43 | \$155.32 | \$168.87 | \$156.26 | \$155.68 | \$144.54 | \$146.96 | \$146.32 |
| Nov-24 | 32,094 |  | \$162.95 | \$158.78 | \$159.00 | \$155.88 | \$176.56 | \$156.93 | \$162.05 | \$145.12 | \$147.08 | \$146.43 |
| Dec-24 | 32,094 |  | \$163.71 | \$159.53 | \$159.56 | \$156.45 | \$165.17 | \$157.56 | \$152.44 | \$145.71 | \$147.20 | \$146.55 |
| Jan-25 | 32,094 |  | \$164.50 | \$160.29 | \$160.13 | \$157.01 | \$159.74 | \$158.16 | \$148.11 | \$146.30 | \$147.31 | \$146.67 |
| Feb-25 | 32,094 |  | \$165.29 | \$161.05 | \$160.71 | \$157.58 | \$163.31 | \$158.78 | \$150.95 | \$146.88 | \$147.43 | \$146.79 |
| Mar-25 | 32,094 |  | \$166.01 | \$161.81 | \$161.23 | \$158.14 | \$161.66 | \$159.38 | \$150.17 | \$147.47 | \$147.55 | \$146.90 |
| Apr-25 | 32,094 |  | \$166.80 | \$162.57 | \$161.80 | \$158.71 | \$145.42 | \$159.93 | \$136.94 | \$148.05 | \$147.66 | \$147.02 |
| May-25 | 32,094 |  | \$167.58 | \$163.34 | \$162.36 | \$159.27 | \$162.86 | \$160.53 | \$151.58 | \$148.64 | \$147.78 | \$147.14 |
| Jun-25 | 32,094 |  | \$168.39 | \$164.11 | \$162.93 | \$159.83 | \$162.57 | \$161.14 | \$150.64 | \$149.23 | \$147.90 | \$147.25 |
| Jul-25 | 32,094 |  | \$169.17 | \$164.89 | \$163.49 | \$160.40 | \$158.61 | \$161.72 | \$147.43 | \$149.81 | \$148.02 | \$147.37 |
| Aug-25 | 32,094 |  | \$169.99 | \$165.66 | \$164.06 | \$160.96 | \$157.11 | \$162.30 | \$146.02 | \$150.40 | \$148.13 | \$147.49 |
| Sep-25 | 32,094 |  | \$170.80 | \$166.45 | \$164.64 | \$161.53 | \$173.38 | \$162.94 | \$159.84 | \$150.99 | \$148.25 | \$147.61 |
| Oct-25 | 32,094 |  | \$171.60 | \$167.23 | \$165.19 | \$162.09 | \$176.62 | \$163.58 | \$162.72 | \$151.57 | \$148.37 | \$147.72 |
| Nov-25 | 32,094 |  | \$172.43 | \$168.02 | \$165.77 | \$162.65 | \$184.63 | \$164.26 | \$169.09 | \$152.16 | \$148.48 | \$147.84 |
| Dec-25 | 32,094 |  | \$173.23 | \$168.82 | \$166.32 | \$163.22 | \$172.69 | \$164.88 | \$159.48 | \$152.75 | \$148.60 | \$147.96 |
|  | lization Trend |  |  | 5.77\% |  | 4.41\% |  | 4.66\% |  | 1.70\% |  | 0.17\% |
|  | SE (root me | square error) |  | 14.64 |  | 14.52 |  | 15.31 |  | 11.76 |  | 15.26 |

MEDICAL UTILIZATION TREND CALCULATION


MEDICAL UTILIZATION TREND CALCULATION

| Month |  | Normalized PMPM | Logistic Regression |  | Linear Regression |  | Holt-Winters' Multiplicative |  | Holt-Winters' Additive |  | Double Exp Smoothing |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Membership |  | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM | Fitted PMPM | Rolling 12 <br> PMPM | Fitted PMPM | Rolling 12 <br> PMPM | Fitted PMPM | Rolling 12 PMPM |
| Oct-21 | 21,960 | \$153.13 | \$143.81 |  | \$144.36 |  | \$149.92 |  | \$146.45 |  | \$146.48 |  |
| Nov-21 | 21,832 | \$164.46 | \$143.88 |  | \$144.40 |  | \$161.71 |  | \$158.69 |  | \$146.84 |  |
| Dec-21 | 21,938 | \$133.25 | \$143.94 |  | \$144.43 |  | \$135.85 |  | \$139.75 |  | \$147.74 |  |
| Jan-22 | 25,937 | \$129.17 | \$144.00 |  | \$144.47 |  | \$129.93 |  | \$131.16 |  | \$147.07 |  |
| Feb-22 | 26,010 | \$132.49 | \$144.07 |  | \$144.51 |  | \$134.02 |  | \$137.17 |  | \$146.23 |  |
| Mar-22 | 26,089 | \$152.76 | \$144.13 |  | \$144.55 |  | \$151.71 |  | \$149.48 |  | \$145.58 |  |
| Apr-22 | 26,124 | \$142.71 | \$144.19 |  | \$144.59 |  | \$142.73 |  | \$143.30 |  | \$145.95 |  |
| May-22 | 26,146 | \$151.29 | \$144.25 |  | \$144.62 |  | \$150.12 |  | \$146.59 |  | \$145.81 |  |
| Jun-22 | 26,231 | \$135.33 | \$144.32 |  | \$144.66 |  | \$136.21 |  | \$141.98 |  | \$146.10 |  |
| Jul-22 | 26,245 | \$142.93 | \$144.38 |  | \$144.70 |  | \$142.13 |  | \$138.43 |  | \$145.59 |  |
| Aug-22 | 26,214 | \$132.59 | \$144.44 |  | \$144.74 |  | \$132.40 |  | \$133.64 |  | \$145.47 |  |
| Sep-22 | 26,128 | \$150.20 | \$144.51 | \$144.17 | \$144.78 | \$144.57 | \$149.65 | \$142.77 | \$145.87 | \$142.48 | \$144.85 | \$146.10 |
| Oct-22 | 26,174 | \$144.23 | \$144.57 | \$144.23 | \$144.81 | \$144.61 | \$154.20 | \$143.24 | \$149.61 | \$142.80 | \$145.12 | \$145.99 |
| Nov-22 | 26,242 | \$156.88 | \$144.63 | \$144.29 | \$144.85 | \$144.65 | \$165.94 | \$143.86 | \$161.39 | \$143.26 | \$145.09 | \$145.86 |
| Dec-22 | 26,221 | \$149.78 | \$144.70 | \$144.35 | \$144.89 | \$144.68 | \$136.85 | \$143.84 | \$142.06 | \$143.40 | \$145.68 | \$145.71 |
| Jan-23 | 31,237 | \$137.17 | \$144.76 | \$144.42 | \$144.93 | \$144.72 | \$131.79 | \$143.79 | \$134.01 | \$143.48 | \$145.90 | \$145.62 |
| Feb-23 | 31,281 | \$146.02 | \$144.83 | \$144.49 | \$144.97 | \$144.76 | \$135.56 | \$143.78 | \$140.21 | \$143.67 | \$145.48 | \$145.56 |
| Mar-23 | 31,341 | \$150.71 | \$144.88 | \$144.55 | \$145.00 | \$144.80 | \$154.90 | \$144.21 | \$152.91 | \$144.09 | \$145.52 | \$145.55 |
| Apr-23 | 31,308 | \$148.17 | \$144.95 | \$144.62 | \$145.04 | \$144.84 | \$145.22 | \$144.42 | \$146.53 | \$144.38 | \$145.79 | \$145.54 |
| May-23 | 31,363 | \$146.22 | \$145.01 | \$144.68 | \$145.08 | \$144.88 | \$153.36 | \$144.80 | \$149.91 | \$144.72 | \$145.93 | \$145.56 |
| Jun-23 | 31,559 | \$152.61 | \$145.08 | \$144.75 | \$145.12 | \$144.92 | \$138.14 | \$144.85 | \$144.97 | \$144.95 | \$145.96 | \$145.55 |
| Jul-23 | 31,810 | \$138.40 | \$145.14 | \$144.81 | \$145.16 | \$144.96 | \$145.06 | \$145.07 | \$141.96 | \$145.16 | \$146.31 | \$145.62 |
| Aug-23 | 31,921 | \$138.83 | \$145.20 | \$144.87 | \$145.19 | \$144.99 | \$134.85 | \$145.09 | \$136.87 | \$145.27 | \$145.94 | \$145.66 |
| Sep-23 | 32,094 | \$145.76 | \$145.27 | \$144.93 | \$145.23 | \$145.03 | \$152.60 | \$145.42 | \$149.22 | \$145.57 | \$145.61 | \$145.71 |
| Oct-23 | 32,094 |  | \$145.33 | \$144.99 | \$145.27 | \$145.07 | \$151.83 | \$145.36 | \$152.65 | \$145.91 | \$145.63 | \$145.75 |
| Nov-23 | 32,094 |  | \$145.39 | \$145.05 | \$145.31 | \$145.10 | \$164.26 | \$145.53 | \$164.64 | \$146.43 | \$145.64 | \$145.78 |
| Dec-23 | 32,094 |  | \$145.46 | \$145.11 | \$145.35 | \$145.14 | \$145.99 | \$146.17 | \$145.49 | \$146.65 | \$145.65 | \$145.78 |
| Jan-24 | 32,094 |  | \$145.52 | \$145.17 | \$145.39 | \$145.18 | \$136.95 | \$146.57 | \$137.14 | \$146.88 | \$145.67 | \$145.76 |
| Feb-24 | 32,094 |  | \$145.59 | \$145.24 | \$145.42 | \$145.21 | \$143.40 | \$147.21 | \$143.23 | \$147.12 | \$145.68 | \$145.78 |
| Mar-24 | 32,094 |  | \$145.65 | \$145.30 | \$145.46 | \$145.25 | \$155.54 | \$147.28 | \$155.71 | \$147.37 | \$145.69 | \$145.79 |
| Apr-24 | 32,094 |  | \$145.71 | \$145.36 | \$145.50 | \$145.29 | \$149.35 | \$147.62 | \$149.41 | \$147.61 | \$145.71 | \$145.78 |
| May-24 | 32,094 |  | \$145.78 | \$145.43 | \$145.54 | \$145.33 | \$152.45 | \$147.55 | \$152.72 | \$147.85 | \$145.72 | \$145.77 |
| Jun-24 | 32,094 |  | \$145.84 | \$145.49 | \$145.58 | \$145.37 | \$148.07 | \$148.37 | \$147.94 | \$148.09 | \$145.73 | \$145.75 |
| Jul-24 | 32,094 |  | \$145.90 | \$145.55 | \$145.61 | \$145.40 | \$144.22 | \$148.30 | \$144.63 | \$148.31 | \$145.75 | \$145.70 |
| Aug-24 | 32,094 |  | \$145.97 | \$145.62 | \$145.65 | \$145.44 | \$139.30 | \$148.66 | \$139.68 | \$148.54 | \$145.76 | \$145.69 |
| Sep-24 | 32,094 |  | \$146.03 | \$145.68 | \$145.69 | \$145.48 | \$151.80 | \$148.60 | \$151.95 | \$148.77 | \$145.77 | \$145.70 |
| Oct-24 | 32,094 |  | \$146.10 | \$145.74 | \$145.73 | \$145.52 | \$154.53 | \$148.82 | \$155.51 | \$149.00 | \$145.79 | \$145.71 |
| Nov-24 | 32,094 |  | \$146.16 | \$145.81 | \$145.77 | \$145.56 | \$167.18 | \$149.06 | \$167.50 | \$149.24 | \$145.80 | \$145.73 |
| Dec-24 | 32,094 |  | \$146.22 | \$145.87 | \$145.80 | \$145.60 | \$148.58 | \$149.28 | \$148.35 | \$149.48 | \$145.81 | \$145.74 |
| Jan-25 | 32,094 |  | \$146.29 | \$145.94 | \$145.84 | \$145.63 | \$139.37 | \$149.48 | \$140.00 | \$149.72 | \$145.83 | \$145.75 |
| Feb-25 | 32,094 |  | \$146.35 | \$146.00 | \$145.88 | \$145.67 | \$145.93 | \$149.69 | \$146.09 | \$149.96 | \$145.84 | \$145.77 |
| Mar-25 | 32,094 |  | \$146.41 | \$146.06 | \$145.92 | \$145.71 | \$158.29 | \$149.92 | \$158.57 | \$150.20 | \$145.85 | \$145.78 |
| Apr-25 | 32,094 |  | \$146.48 | \$146.13 | \$145.96 | \$145.75 | \$151.99 | \$150.14 | \$152.27 | \$150.43 | \$145.87 | \$145.79 |
| May-25 | 32,094 |  | \$146.54 | \$146.19 | \$145.99 | \$145.79 | \$155.13 | \$150.37 | \$155.58 | \$150.67 | \$145.88 | \$145.81 |
| Jun-25 | 32,094 |  | \$146.61 | \$146.26 | \$146.03 | \$145.82 | \$150.68 | \$150.58 | \$150.80 | \$150.91 | \$145.89 | \$145.82 |
| Jul-25 | 32,094 |  | \$146.67 | \$146.32 | \$146.07 | \$145.86 | \$146.76 | \$150.79 | \$147.49 | \$151.15 | \$145.91 | \$145.83 |
| Aug-25 | 32,094 |  | \$146.74 | \$146.38 | \$146.11 | \$145.90 | \$141.75 | \$151.00 | \$142.54 | \$151.39 | \$145.92 | \$145.85 |
| Sep-25 | 32,094 |  | \$146.80 | \$146.45 | \$146.15 | \$145.94 | \$154.45 | \$151.22 | \$154.81 | \$151.63 | \$145.93 | \$145.86 |
| Oct-25 | 32,094 |  | \$146.86 | \$146.51 | \$146.18 | \$145.98 | \$157.23 | \$151.44 | \$158.37 | \$151.86 | \$145.95 | \$145.87 |
| Nov-25 | 32,094 |  | \$146.93 | \$146.58 | \$146.22 | \$146.01 | \$170.10 | \$151.69 | \$170.36 | \$152.10 | \$145.96 | \$145.89 |
| Dec-25 | 32,094 |  | \$146.99 | \$146.64 | \$146.26 | \$146.05 | \$151.17 | \$151.90 | \$151.21 | \$152.34 | \$145.97 | \$145.90 |
| Utilization TrendRMSE (root mean square error) |  |  |  | 0.52\% |  | 0.31\% |  | 1.95\% |  | 2.04\% |  | 0.06\% |
|  |  |  |  | 8.62 |  | 8.62 |  | 6.17 |  | 4.67 |  | 8.91 |



| Month | Membership $\begin{array}{c}\text { Normalized } \\ \text { PMPM }\end{array}$ <br> M  |  | Utilization Trend Calculation - Facility-36 Month |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Logistic Regression |  | Linear Regression |  | Holt-Winters' Multiplicative |  | Holt-Winters' Additive |  | Double Exp Smoothing |  |
|  |  |  | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM |
| Oct-20 | 21,561 | \$314.23 | \$356.02 |  | \$358.41 |  | \$328.48 |  | \$334.57 |  | \$371.49 |  |
| Nov-20 | 21,626 | \$305.75 | \$356.73 |  | \$359.08 |  | \$345.38 |  | \$371.30 |  | \$368.70 |  |
| Dec-20 | 21,615 | \$352.24 | \$357.42 |  | \$359.72 |  | \$335.42 |  | \$340.84 |  | \$365.57 |  |
| Jan-21 | 22,145 | \$392.12 | \$358.13 |  | \$360.39 |  | \$355.71 |  | \$335.73 |  | \$364.99 |  |
| Feb-21 | 22,043 | \$386.47 | \$358.85 |  | \$361.05 |  | \$366.90 |  | \$356.72 |  | \$366.51 |  |
| Mar-21 | 21,999 | \$363.86 | \$359.50 |  | \$361.66 |  | \$361.86 |  | \$364.50 |  | \$367.67 |  |
| Apr-21 | 22,006 | \$397.52 | \$360.22 |  | \$362.32 |  | \$379.76 |  | \$371.70 |  | \$367.61 |  |
| May-21 | 22,027 | \$449.87 | \$360.92 |  | \$362.97 |  | \$414.12 |  | \$393.69 |  | \$369.30 |  |
| Jun-21 | 22,092 | \$354.48 | \$361.64 |  | \$363.63 |  | \$353.91 |  | \$349.97 |  | \$373.65 |  |
| Jul-21 | 22,080 | \$330.48 | \$362.34 |  | \$364.28 |  | \$349.53 |  | \$370.57 |  | \$372.86 |  |
| Aug-21 | 22,031 | \$344.56 | \$363.06 |  | \$364.94 |  | \$343.83 |  | \$355.09 |  | \$370.85 |  |
| Sep-21 | 22,022 | \$384.69 | \$363.79 | \$359.90 | \$365.61 | \$362.02 | \$377.69 | \$359.49 | \$363.24 | \$359.03 | \$369.64 | \$369.07 |
| Oct-21 | 21,960 | \$370.85 | \$364.49 | \$360.60 | \$366.25 | \$362.67 | \$329.47 | \$359.52 | \$343.79 | \$359.77 | \$370.57 | \$369.00 |
| Nov-21 | 21,832 | \$426.24 | \$365.22 | \$361.30 | \$366.92 | \$363.31 | \$339.63 | \$359.04 | \$382.44 | \$360.70 | \$370.75 | \$369.17 |
| Dec-21 | 21,938 | \$315.24 | \$365.93 | \$362.00 | \$367.56 | \$363.96 | \$347.27 | \$359.99 | \$356.59 | \$361.98 | \$373.80 | \$369.85 |
| Jan-22 | 25,937 | \$309.77 | \$366.66 | \$362.77 | \$368.23 | \$364.67 | \$373.38 | \$361.64 | \$349.35 | \$362.93 | \$370.94 | \$370.35 |
| Feb-22 | 26,010 | \$350.82 | \$367.39 | \$363.53 | \$368.89 | \$365.36 | \$378.98 | \$362.87 | \$366.35 | \$363.76 | \$367.91 | \$370.43 |
| Mar-22 | 26,089 | \$378.46 | \$368.06 | \$364.28 | \$369.49 | \$366.05 | \$368.30 | \$363.47 | \$372.22 | \$364.50 | \$367.13 | \$370.34 |
| Apr-22 | 26,124 | \$364.88 | \$368.79 | \$365.02 | \$370.16 | \$366.73 | \$391.21 | \$364.77 | \$379.74 | \$365.35 | \$367.83 | \$370.32 |
| May-22 | 26,146 | \$360.56 | \$369.51 | \$365.75 | \$370.80 | \$367.39 | \$431.02 | \$367.04 | \$400.08 | \$366.35 | \$367.79 | \$370.17 |
| Jun-22 | 26,231 | \$370.61 | \$370.25 | \$366.48 | \$371.47 | \$368.05 | \$358.78 | \$367.30 | \$352.34 | \$366.33 | \$367.52 | \$369.66 |
| Jul-22 | 26,245 | \$414.71 | \$370.96 | \$367.19 | \$372.11 | \$368.70 | \$348.64 | \$366.97 | \$373.47 | \$366.65 | \$367.78 | \$369.25 |
| Aug-22 | 26,214 | \$365.97 | \$371.71 | \$367.90 | \$372.78 | \$369.34 | \$349.37 | \$367.13 | \$361.38 | \$367.04 | \$370.34 | \$369.23 |
| Sep-22 | 26,128 | \$375.16 | \$372.45 | \$368.59 | \$373.44 | \$369.97 | \$385.76 | \$367.97 | \$370.19 | \$367.60 | \$370.25 | \$369.29 |
| Oct-22 | 26,174 | \$352.52 | \$373.17 | \$369.28 | \$374.09 | \$370.59 | \$346.75 | \$368.92 | \$350.06 | \$367.80 | \$370.64 | \$369.31 |
| Nov-22 | 26,242 | \$418.38 | \$373.92 | \$369.96 | \$374.75 | \$371.20 | \$370.01 | \$371.08 | \$387.71 | \$368.46 | \$369.83 | \$369.25 |
| Dec-22 | 26,221 | \$399.70 | \$374.64 | \$370.63 | \$375.40 | \$371.81 | \$342.54 | \$370.36 | \$361.23 | \$368.69 | \$372.49 | \$369.20 |
| Jan-23 | 31,237 | \$348.59 | \$375.39 | \$371.42 | \$376.06 | \$372.52 | \$360.46 | \$369.15 | \$357.29 | \$369.14 | \$374.07 | \$369.54 |
| Feb-23 | 31,281 | \$369.22 | \$376.14 | \$372.20 | \$376.73 | \$373.21 | \$377.05 | \$369.12 | \$375.59 | \$369.99 | \$372.92 | \$370.00 |
| Mar-23 | 31,341 | \$383.87 | \$376.82 | \$372.97 | \$377.33 | \$373.90 | \$377.68 | \$370.00 | \$381.87 | \$370.94 | \$372.88 | \$370.50 |
| Apr-23 | 31,308 | \$385.54 | \$377.57 | \$373.72 | \$378.00 | \$374.57 | \$390.21 | \$370.24 | \$389.20 | \$371.96 | \$373.62 | \$371.00 |
| May-23 | 31,363 | \$400.32 | \$378.31 | \$374.47 | \$378.64 | \$375.24 | \$417.88 | \$369.96 | \$409.98 | \$373.31 | \$374.40 | \$371.56 |
| Jun-23 | 31,559 | \$347.53 | \$379.06 | \$375.21 | \$379.31 | \$375.90 | \$369.07 | \$370.73 | \$363.54 | \$374.01 | \$375.93 | \$372.26 |
| Jul-23 | 31,810 | \$388.72 | \$379.80 | \$375.94 | \$379.95 | \$376.55 | \$374.49 | \$372.72 | \$383.27 | \$374.89 | \$374.64 | \$372.81 |
| Aug-23 | 31,921 | \$381.95 | \$380.56 | \$376.67 | \$380.62 | \$377.19 | \$360.22 | \$373.32 | \$369.67 | \$375.41 | \$375.54 | \$373.24 |
| Sep-23 | 32,094 | \$358.43 | \$381.32 | \$377.38 | \$381.28 | \$377.82 | \$389.26 | \$373.83 | \$378.80 | \$376.09 | \$376.06 | \$373.71 |
| Oct-23 | 32,094 |  | \$382.06 | \$378.09 | \$381.93 | \$378.44 | \$354.27 | \$374.05 | \$357.62 | \$376.33 | \$375.33 | \$374.06 |
| Nov-23 | 32,094 |  | \$382.82 | \$378.79 | \$382.59 | \$379.06 | \$390.43 | \$375.74 | \$395.20 | \$377.15 | \$375.50 | \$374.48 |
| Dec-23 | 32,094 |  | \$383.56 | \$379.48 | \$383.24 | \$379.66 | \$364.68 | \$377.09 | \$367.46 | \$377.43 | \$375.67 | \$374.72 |
| Jan-24 | 32,094 |  | \$384.33 | \$380.22 | \$383.90 | \$380.32 | \$362.06 | \$377.19 | \$361.88 | \$377.77 | \$375.85 | \$374.87 |
| Feb-24 | 32,094 |  | \$385.10 | \$380.97 | \$384.57 | \$380.97 | \$380.16 | \$377.45 | \$380.54 | \$378.18 | \$376.02 | \$375.13 |
| Mar-24 | 32,094 |  | \$385.82 | \$381.71 | \$385.19 | \$381.62 | \$384.98 | \$378.07 | \$387.09 | \$378.63 | \$376.19 | \$375.40 |
| Apr-24 | 32,094 |  | \$386.59 | \$382.46 | \$385.86 | \$382.27 | \$394.42 | \$378.44 | \$394.33 | \$379.08 | \$376.37 | \$375.63 |
| May-24 | 32,094 |  | \$387.34 | \$383.20 | \$386.50 | \$382.92 | \$418.72 | \$378.59 | \$415.25 | \$379.58 | \$376.54 | \$375.80 |
| Jun-24 | 32,094 |  | \$388.11 | \$383.95 | \$387.17 | \$383.57 | \$368.15 | \$378.50 | \$369.20 | \$380.03 | \$376.72 | \$375.87 |
| Jul-24 | 32,094 |  | \$388.86 | \$384.71 | \$387.81 | \$384.22 | \$384.35 | \$379.32 | \$389.62 | \$380.56 | \$376.89 | \$376.06 |
| Aug-24 | 32,094 |  | \$389.64 | \$385.46 | \$388.48 | \$384.88 | \$371.95 | \$380.29 | \$375.79 | \$381.06 | \$377.06 | \$376.18 |
| Sep-24 | 32,094 |  | \$390.42 | \$386.22 | \$389.14 | \$385.53 | \$385.75 | \$380.00 | \$384.39 | \$381.53 | \$377.24 | \$376.28 |
| Oct-24 | 32,094 |  | \$391.18 | \$386.98 | \$389.79 | \$386.18 | \$359.56 | \$380.44 | \$364.07 | \$382.07 | \$377.41 | \$376.46 |
| Nov-24 | 32,094 |  | \$391.96 | \$387.74 | \$390.45 | \$386.84 | \$396.25 | \$380.92 | \$401.65 | \$382.61 | \$377.58 | \$376.63 |
| Dec-24 | 32,094 |  | \$392.72 | \$388.51 | \$391.10 | \$387.49 | \$370.12 | \$381.37 | \$373.91 | \$383.14 | \$377.76 | \$376.80 |
| Jan-25 | 32,094 |  | \$393.50 | \$389.27 | \$391.76 | \$388.15 | \$367.45 | \$381.82 | \$368.33 | \$383.68 | \$377.93 | \$376.98 |
| Feb-25 | 32,094 |  | \$394.29 | \$390.04 | \$392.43 | \$388.80 | \$385.81 | \$382.29 | \$386.99 | \$384.22 | \$378.11 | \$377.15 |
| Mar-25 | 32,094 |  | \$395.00 | \$390.80 | \$393.03 | \$389.46 | \$390.69 | \$382.77 | \$393.54 | \$384.76 | \$378.28 | \$377.32 |
| Apr-25 | 32,094 |  | \$395.79 | \$391.57 | \$393.69 | \$390.11 | \$400.26 | \$383.26 | \$400.78 | \$385.29 | \$378.45 | \$377.50 |
| May-25 | 32,094 |  | \$396.56 | \$392.34 | \$394.34 | \$390.76 | \$424.92 | \$383.77 | \$421.70 | \$385.83 | \$378.63 | \$377.67 |
| Jun-25 | 32,094 |  | \$397.35 | \$393.11 | \$395.00 | \$391.42 | \$373.60 | \$384.23 | \$375.65 | \$386.37 | \$378.80 | \$377.85 |
| Jul-25 | 32,094 |  | \$398.12 | \$393.88 | \$395.65 | \$392.07 | \$390.03 | \$384.70 | \$396.07 | \$386.91 | \$378.97 | \$378.02 |
| Aug-25 | 32,094 |  | \$398.92 | \$394.65 | \$396.31 | \$392.72 | \$377.44 | \$385.16 | \$382.25 | \$387.44 | \$379.15 | \$378.19 |
| Sep-25 | 32,094 |  | \$399.72 | \$395.43 | \$396.98 | \$393.38 | \$391.43 | \$385.63 | \$390.84 | \$387.98 | \$379.32 | \$378.37 |
| Oct-25 | 32,094 |  | \$400.49 | \$396.20 | \$397.62 | \$394.03 | \$364.85 | \$386.07 | \$370.52 | \$388.52 | \$379.50 | \$378.54 |
| Nov-25 | 32,094 |  | \$401.29 | \$396.98 | \$398.29 | \$394.68 | \$402.07 | \$386.56 | \$408.10 | \$389.06 | \$379.67 | \$378.71 |
| Dec-25 | 32,094 |  | \$402.07 | \$397.76 | \$398.93 | \$395.34 | \$375.55 | \$387.01 | \$380.36 | \$389.59 | \$379.84 | \$378.89 |
|  | Utilization Tren |  |  | 2.36\% |  | 2.03\% |  | 1.55\% |  | 1.58\% |  | 0.61\% |
|  | RMSE (root me | quare error) |  | 31.38 |  | 31.34 |  | 33.25 |  | 28.14 |  | 32.66 |

MEDICAL UTILIZATION TREND CALCULATION

| Month | Utilization Trend Calculation - Facility-24 Month |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Normalized PMPM | Logistic Regression |  | Linear Regression |  | Holt-Winters' Multiplicative |  | Holt-Winters' Additive |  | Double Exp Smoothing |  |
|  | Membership |  | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM | Fitted PMPM | Rolling 12 <br> PMPM |
| Oct-21 | 21,960 | \$370.85 | \$361.19 |  | \$363.20 |  | \$359.42 |  | \$352.64 |  | \$373.06 |  |
| Nov-21 | 21,832 | \$426.24 | \$362.08 |  | \$364.02 |  | \$417.00 |  | \$414.73 |  | \$373.18 |  |
| Dec-21 | 21,938 | \$315.24 | \$362.94 |  | \$364.81 |  | \$327.58 |  | \$350.82 |  | \$376.75 |  |
| Jan-22 | 25,937 | \$309.77 | \$363.83 |  | \$365.63 |  | \$312.25 |  | \$319.60 |  | \$373.20 |  |
| Feb-22 | 26,010 | \$350.82 | \$364.73 |  | \$366.44 |  | \$348.73 |  | \$349.62 |  | \$369.47 |  |
| Mar-22 | 26,089 | \$378.46 | \$365.54 |  | \$367.18 |  | \$373.95 |  | \$370.84 |  | \$368.49 |  |
| Apr-22 | 26,124 | \$364.88 | \$366.44 |  | \$368.00 |  | \$362.83 |  | \$365.48 |  | \$369.27 |  |
| May-22 | 26,146 | \$360.56 | \$367.32 |  | \$368.79 |  | \$360.73 |  | \$370.64 |  | \$369.17 |  |
| Jun-22 | 26,231 | \$370.61 | \$368.22 |  | \$369.61 |  | \$364.13 |  | \$348.43 |  | \$368.80 |  |
| Jul-22 | 26,245 | \$414.71 | \$369.10 |  | \$370.40 |  | \$408.19 |  | \$392.87 |  | \$369.07 |  |
| Aug-22 | 26,214 | \$365.97 | \$370.01 |  | \$371.21 |  | \$363.19 |  | \$366.88 |  | \$372.09 |  |
| Sep-22 | 26,128 | \$375.16 | \$370.92 | \$366.20 | \$372.03 | \$367.77 | \$370.98 | \$363.95 | \$359.62 | \$363.15 | \$371.92 | \$371.07 |
| Oct-22 | 26,174 | \$352.52 | \$371.80 | \$367.04 | \$372.82 | \$368.53 | \$375.13 | \$365.24 | \$366.72 | \$364.21 | \$372.32 | \$371.04 |
| Nov-22 | 26,242 | \$418.38 | \$372.72 | \$367.87 | \$373.64 | \$369.28 | \$432.59 | \$367.30 | \$426.16 | \$365.90 | \$371.28 | \$370.91 |
| Dec-22 | 26,221 | \$399.70 | \$373.61 | \$368.69 | \$374.43 | \$370.02 | \$329.28 | \$366.90 | \$360.63 | \$366.52 | \$374.41 | \$370.79 |
| Jan-23 | 31,237 | \$348.59 | \$374.53 | \$369.66 | \$375.24 | \$370.89 | \$319.74 | \$366.72 | \$335.53 | \$367.30 | \$376.23 | \$371.13 |
| Feb-23 | 31,281 | \$369.22 | \$375.45 | \$370.61 | \$376.06 | \$371.75 | \$360.12 | \$367.53 | \$367.44 | \$368.73 | \$374.75 | \$371.61 |
| Mar-23 | 31,341 | \$383.87 | \$376.28 | \$371.56 | \$376.80 | \$372.59 | \$387.47 | \$368.92 | \$388.72 | \$370.46 | \$374.63 | \$372.15 |
| Apr-23 | 31,308 | \$385.54 | \$377.21 | \$372.48 | \$377.62 | \$373.42 | \$374.65 | \$369.93 | \$382.34 | \$371.96 | \$375.44 | \$372.68 |
| May-23 | 31,363 | \$400.32 | \$378.11 | \$373.40 | \$378.41 | \$374.23 | \$371.45 | \$370.78 | \$387.81 | \$373.52 | \$376.30 | \$373.28 |
| Jun-23 | 31,559 | \$347.53 | \$379.04 | \$374.31 | \$379.22 | \$375.04 | \$378.87 | \$372.02 | \$367.48 | \$374.88 | \$378.04 | \$374.06 |
| Jul-23 | 31,810 | \$388.72 | \$379.95 | \$375.21 | \$380.01 | \$375.84 | \$423.81 | \$374.01 | \$408.48 | \$376.58 | \$376.40 | \$374.64 |
| Aug-23 | 31,921 | \$381.95 | \$380.88 | \$376.10 | \$380.83 | \$376.62 | \$375.04 | \$374.90 | \$379.08 | \$377.52 | \$377.41 | \$375.08 |
| Sep-23 | 32,094 | \$358.43 | \$381.82 | \$376.98 | \$381.65 | \$377.40 | \$383.85 | \$375.97 | \$372.15 | \$378.33 | \$377.94 | \$375.56 |
| Oct-23 | 32,094 |  | \$382.73 | \$377.85 | \$382.44 | \$378.16 | \$373.63 | \$375.83 | \$376.83 | \$379.03 | \$376.97 | \$375.91 |
| Nov-23 | 32,094 |  | \$383.67 | \$378.71 | \$383.26 | \$378.92 | \$437.45 | \$377.13 | \$437.44 | \$380.73 | \$377.20 | \$376.35 |
| Dec-23 | 32,094 |  | \$384.59 | \$379.56 | \$384.05 | \$379.66 | \$375.84 | \$380.32 | \$372.58 | \$381.43 | \$377.43 | \$376.57 |
| Jan-24 | 32,094 |  | \$385.53 | \$380.47 | \$384.86 | \$380.46 | \$343.27 | \$382.17 | \$344.27 | \$382.06 | \$377.66 | \$376.69 |
| Feb-24 | 32,094 |  | \$386.48 | \$381.39 | \$385.68 | \$381.26 | \$373.89 | \$383.28 | \$375.10 | \$382.67 | \$377.90 | \$376.95 |
| Mar-24 | 32,094 |  | \$387.37 | \$382.31 | \$386.44 | \$382.06 | \$395.10 | \$383.93 | \$396.22 | \$383.31 | \$378.13 | \$377.24 |
| Apr-24 | 32,094 |  | \$388.33 | \$383.23 | \$387.26 | \$382.86 | \$389.57 | \$385.16 | \$390.25 | \$383.97 | \$378.36 | \$377.48 |
| May-24 | 32,094 |  | \$389.25 | \$384.15 | \$388.05 | \$383.66 | \$395.53 | \$387.14 | \$395.46 | \$384.62 | \$378.59 | \$377.67 |
| Jun-24 | 32,094 |  | \$390.21 | \$385.07 | \$388.87 | \$384.45 | \$371.14 | \$386.49 | \$374.08 | \$385.15 | \$378.83 | \$377.74 |
| Jul-24 | 32,094 |  | \$391.14 | \$386.00 | \$389.66 | \$385.26 | \$415.52 | \$385.82 | \$416.70 | \$385.85 | \$379.06 | \$377.96 |
| Aug-24 | 32,094 |  | \$392.11 | \$386.94 | \$390.48 | \$386.06 | \$388.00 | \$386.90 | \$388.93 | \$386.67 | \$379.29 | \$378.11 |
| Sep-24 | 32,094 |  | \$393.07 | \$387.87 | \$391.29 | \$386.86 | \$379.93 | \$386.57 | \$381.75 | \$387.47 | \$379.52 | \$378.25 |
| Oct-24 | 32,094 |  | \$394.01 | \$388.81 | \$392.08 | \$387.66 | \$383.11 | \$387.36 | \$387.56 | \$388.36 | \$379.76 | \$378.48 |
| Nov-24 | 32,094 |  | \$394.98 | \$389.76 | \$392.90 | \$388.47 | \$448.52 | \$388.28 | \$448.17 | \$389.26 | \$379.99 | \$378.71 |
| Dec-24 | 32,094 |  | \$395.92 | \$390.70 | \$393.69 | \$389.27 | \$385.34 | \$389.08 | \$383.32 | \$390.15 | \$380.22 | \$378.94 |
| Jan-25 | 32,094 |  | \$396.90 | \$391.65 | \$394.51 | \$390.08 | \$351.92 | \$389.80 | \$355.01 | \$391.05 | \$380.45 | \$379.18 |
| Feb-25 | 32,094 |  | \$397.87 | \$392.60 | \$395.32 | \$390.88 | \$383.29 | \$390.58 | \$385.83 | \$391.94 | \$380.69 | \$379.41 |
| Mar-25 | 32,094 |  | \$398.76 | \$393.55 | \$396.06 | \$391.68 | \$405.01 | \$391.41 | \$406.96 | \$392.83 | \$380.92 | \$379.64 |
| Apr-25 | 32,094 |  | \$399.74 | \$394.50 | \$396.88 | \$392.48 | \$399.32 | \$392.22 | \$400.98 | \$393.73 | \$381.15 | \$379.87 |
| May-25 | 32,094 |  | \$400.69 | \$395.45 | \$397.67 | \$393.28 | \$405.41 | \$393.04 | \$406.19 | \$394.62 | \$381.38 | \$380.11 |
| Jun-25 | 32,094 |  | \$401.68 | \$396.41 | \$398.49 | \$394.09 | \$380.39 | \$393.81 | \$384.81 | \$395.52 | \$381.62 | \$380.34 |
| Jul-25 | 32,094 |  | \$402.64 | \$397.36 | \$399.28 | \$394.89 | \$425.86 | \$394.68 | \$427.44 | \$396.41 | \$381.85 | \$380.57 |
| Aug-25 | 32,094 |  | \$403.63 | \$398.32 | \$400.09 | \$395.69 | \$397.63 | \$395.48 | \$399.67 | \$397.31 | \$382.08 | \$380.80 |
| Sep-25 | 32,094 |  | \$404.62 | \$399.29 | \$400.91 | \$396.49 | \$389.35 | \$396.26 | \$392.48 | \$398.20 | \$382.31 | \$381.04 |
| Oct-25 | 32,094 |  | \$405.59 | \$400.25 | \$401.70 | \$397.29 | \$392.58 | \$397.05 | \$398.30 | \$399.10 | \$382.55 | \$381.27 |
| Nov-25 | 32,094 |  | \$406.59 | \$401.22 | \$402.52 | \$398.09 | \$459.59 | \$397.98 | \$458.91 | \$399.99 | \$382.78 | \$381.50 |
| Dec-25 | 32,094 |  | \$407.56 | \$402.19 | \$403.31 | \$398.89 | \$394.83 | \$398.77 | \$394.05 | \$400.89 | \$383.01 | \$381.73 |
|  | Utilization Tren |  |  | 2.91\% |  | 2.49\% |  | 2.65\% |  | 2.60\% |  | 0.73\% |
|  | RMSE (root me | quare error) |  | 27.41 |  | 27.37 |  | 21.38 |  | 16.25 |  | 28.57 |



MEDICAL UTILIZATION TREND CALCULATION

| Month | Utilization Trend Calculation - Medical Specialty Pharmacy - 36 Month |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Normalized PMPM | Logistic Regression |  | Linear Regression |  | Holt-Winters' Multiplicative |  | Holt-Winters' Additive |  | Double Exp Smoothing |  |
|  | Membership |  | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM |
| Oct-20 | 21,561 | \$30.82 | \$36.42 |  | \$36.74 |  | \$32.74 |  | \$35.44 |  | \$40.33 |  |
| Nov-20 | 21,626 | \$36.98 | \$36.55 |  | \$36.88 |  | \$40.41 |  | \$42.40 |  | \$39.09 |  |
| Dec-20 | 21,615 | \$40.75 | \$36.69 |  | \$37.02 |  | \$39.78 |  | \$38.66 |  | \$38.88 |  |
| Jan-21 | 22,145 | \$41.15 | \$36.82 |  | \$37.16 |  | \$38.57 |  | \$34.88 |  | \$39.26 |  |
| Feb-21 | 22,043 | \$31.56 | \$36.96 |  | \$37.30 |  | \$33.39 |  | \$34.53 |  | \$39.64 |  |
| Mar-21 | 21,999 | \$38.70 | \$37.09 |  | \$37.43 |  | \$36.58 |  | \$37.25 |  | \$38.56 |  |
| Apr-21 | 22,006 | \$31.21 | \$37.23 |  | \$37.57 |  | \$33.57 |  | \$34.97 |  | \$38.66 |  |
| May-21 | 22,027 | \$35.13 | \$37.37 |  | \$37.71 |  | \$36.99 |  | \$38.64 |  | \$37.63 |  |
| Jun-21 | 22,092 | \$34.39 | \$37.51 |  | \$37.85 |  | \$34.91 |  | \$37.00 |  | \$37.29 |  |
| Jul-21 | 22,080 | \$49.53 | \$37.64 |  | \$37.98 |  | \$47.33 |  | \$43.34 |  | \$36.88 |  |
| Aug-21 | 22,031 | \$40.53 | \$37.78 |  | \$38.12 |  | \$40.27 |  | \$37.64 |  | \$38.76 |  |
| Sep-21 | 22,022 | \$44.19 | \$37.93 | \$37.17 | \$38.26 | \$37.51 | \$43.80 | \$38.20 | \$42.72 | \$38.12 | \$39.09 | \$38.67 |
| Oct-21 | 21,960 | \$33.85 | \$38.07 | \$37.31 | \$38.40 | \$37.64 | \$33.00 | \$38.21 | \$36.73 | \$38.22 | \$39.93 | \$38.64 |
| Nov-21 | 21,832 | \$46.67 | \$38.21 | \$37.44 | \$38.54 | \$37.78 | \$40.25 | \$38.20 | \$43.75 | \$38.34 | \$39.14 | \$38.64 |
| Dec-21 | 21,938 | \$38.96 | \$38.35 | \$37.58 | \$38.68 | \$37.92 | \$41.62 | \$38.36 | \$40.31 | \$38.48 | \$40.33 | \$38.76 |
| Jan-22 | 25,937 | \$36.30 | \$38.49 | \$37.73 | \$38.82 | \$38.07 | \$41.09 | \$38.60 | \$36.42 | \$38.57 | \$40.24 | \$38.86 |
| Feb-22 | 26,010 | \$37.08 | \$38.64 | \$37.88 | \$38.96 | \$38.21 | \$33.70 | \$38.56 | \$35.84 | \$38.64 | \$39.77 | \$38.89 |
| Mar-22 | 26,089 | \$31.33 | \$38.77 | \$38.03 | \$39.08 | \$38.36 | \$38.81 | \$38.74 | \$38.70 | \$38.76 | \$39.46 | \$38.97 |
| Apr-22 | 26,124 | \$38.58 | \$38.92 | \$38.17 | \$39.23 | \$38.50 | \$33.64 | \$38.67 | \$36.11 | \$38.81 | \$38.33 | \$38.93 |
| May-22 | 26,146 | \$40.84 | \$39.06 | \$38.32 | \$39.36 | \$38.64 | \$37.41 | \$38.68 | \$40.00 | \$38.93 | \$38.40 | \$38.99 |
| Jun-22 | 26,231 | \$35.50 | \$39.20 | \$38.46 | \$39.50 | \$38.78 | \$35.87 | \$38.72 | \$38.51 | \$39.04 | \$38.79 | \$39.10 |
| Jul-22 | 26,245 | \$43.80 | \$39.35 | \$38.60 | \$39.64 | \$38.92 | \$49.95 | \$39.07 | \$44.85 | \$39.24 | \$38.35 | \$39.20 |
| Aug-22 | 26,214 | \$40.58 | \$39.50 | \$38.74 | \$39.78 | \$39.05 | \$41.75 | \$39.22 | \$38.89 | \$39.32 | \$39.18 | \$39.23 |
| Sep-22 | 26,128 | \$43.43 | \$39.65 | \$38.88 | \$39.92 | \$39.19 | \$45.46 | \$39.43 | \$43.93 | \$39.48 | \$39.44 | \$39.26 |
| Oct-22 | 26,174 | \$44.13 | \$39.79 | \$39.01 | \$40.06 | \$39.32 | \$34.50 | \$39.47 | \$37.86 | \$39.53 | \$40.10 | \$39.28 |
| Nov-22 | 26,242 | \$46.50 | \$39.94 | \$39.15 | \$40.20 | \$39.45 | \$44.55 | \$39.84 | \$45.21 | \$39.72 | \$40.78 | \$39.42 |
| Dec-22 | 26,221 | \$39.81 | \$40.09 | \$39.28 | \$40.33 | \$39.57 | \$41.80 | \$39.88 | \$41.71 | \$39.84 | \$41.73 | \$39.55 |
| Jan-23 | 31,237 | \$30.50 | \$40.24 | \$39.44 | \$40.47 | \$39.72 | \$40.28 | \$39.83 | \$37.80 | \$39.92 | \$41.58 | \$39.69 |
| Feb-23 | 31,281 | \$37.61 | \$40.39 | \$39.60 | \$40.61 | \$39.87 | \$36.37 | \$39.98 | \$36.97 | \$39.96 | \$40.08 | \$39.72 |
| Mar-23 | 31,341 | \$44.67 | \$40.53 | \$39.75 | \$40.74 | \$40.02 | \$36.68 | \$39.76 | \$39.80 | \$40.05 | \$39.78 | \$39.75 |
| Apr-23 | 31,308 | \$37.91 | \$40.68 | \$39.90 | \$40.88 | \$40.16 | \$37.02 | \$39.98 | \$37.65 | \$40.13 | \$40.56 | \$39.93 |
| May-23 | 31,363 | \$43.14 | \$40.83 | \$40.05 | \$41.02 | \$40.30 | \$40.22 | \$40.20 | \$41.46 | \$40.26 | \$40.24 | \$40.08 |
| Jun-23 | 31,559 | \$44.67 | \$40.98 | \$40.20 | \$41.16 | \$40.44 | \$36.89 | \$40.23 | \$40.00 | \$40.37 | \$40.74 | \$40.24 |
| Jul-23 | 31,810 | \$40.52 | \$41.13 | \$40.35 | \$41.29 | \$40.58 | \$48.81 | \$40.28 | \$46.61 | \$40.60 | \$41.40 | \$40.48 |
| Aug-23 | 31,921 | \$34.98 | \$41.29 | \$40.50 | \$41.43 | \$40.71 | \$42.60 | \$40.38 | \$40.47 | \$40.72 | \$41.38 | \$40.66 |
| Sep-23 | 32,094 | \$43.41 | \$41.44 | \$40.64 | \$41.58 | \$40.84 | \$46.03 | \$40.51 | \$45.26 | \$40.89 | \$40.53 | \$40.74 |
| Oct-23 | 32,094 |  | \$41.59 | \$40.78 | \$41.71 | \$40.98 | \$40.02 | \$40.90 | \$39.15 | \$40.95 | \$41.02 | \$40.81 |
| Nov-23 | 32,094 |  | \$41.75 | \$40.93 | \$41.85 | \$41.11 | \$46.88 | \$41.16 | \$46.28 | \$41.11 | \$41.10 | \$40.83 |
| Dec-23 | 32,094 |  | \$41.90 | \$41.07 | \$41.99 | \$41.23 | \$42.24 | \$41.20 | \$42.73 | \$41.21 | \$41.18 | \$40.80 |
| Jan-24 | 32,094 |  | \$42.06 | \$41.22 | \$42.13 | \$41.37 | \$37.12 | \$40.93 | \$38.88 | \$41.29 | \$41.26 | \$40.78 |
| Feb-24 | 32,094 |  | \$42.22 | \$41.37 | \$42.27 | \$41.51 | \$38.11 | \$41.07 | \$38.31 | \$41.39 | \$41.34 | \$40.88 |
| Mar-24 | 32,094 |  | \$42.37 | \$41.52 | \$42.40 | \$41.65 | \$41.51 | \$41.47 | \$41.13 | \$41.50 | \$41.42 | \$41.02 |
| Apr-24 | 32,094 |  | \$42.53 | \$41.68 | \$42.54 | \$41.78 | \$38.61 | \$41.59 | \$38.79 | \$41.59 | \$41.50 | \$41.09 |
| May-24 | 32,094 |  | \$42.68 | \$41.83 | \$42.68 | \$41.92 | \$42.83 | \$41.81 | \$42.60 | \$41.68 | \$41.58 | \$41.20 |
| Jun-24 | 32,094 |  | \$42.84 | \$41.98 | \$42.82 | \$42.06 | \$41.61 | \$42.19 | \$41.08 | \$41.77 | \$41.66 | \$41.28 |
| Jul-24 | 32,094 |  | \$43.00 | \$42.14 | \$42.95 | \$42.20 | \$46.57 | \$42.01 | \$47.52 | \$41.85 | \$41.74 | \$41.31 |
| Aug-24 | 32,094 |  | \$43.16 | \$42.29 | \$43.10 | \$42.33 | \$40.47 | \$41.83 | \$41.60 | \$41.94 | \$41.82 | \$41.35 |
| Sep-24 | 32,094 |  | \$43.32 | \$42.45 | \$43.24 | \$42.47 | \$46.29 | \$41.86 | \$46.58 | \$42.05 | \$41.90 | \$41.46 |
| Oct-24 | 32,094 |  | \$43.48 | \$42.61 | \$43.37 | \$42.61 | \$41.29 | \$41.96 | \$40.54 | \$42.17 | \$41.98 | \$41.54 |
| Nov-24 | 32,094 |  | \$43.65 | \$42.77 | \$43.51 | \$42.75 | \$48.36 | \$42.09 | \$47.66 | \$42.28 | \$42.06 | \$41.62 |
| Dec-24 | 32,094 |  | \$43.80 | \$42.93 | \$43.65 | \$42.89 | \$43.57 | \$42.20 | \$44.11 | \$42.40 | \$42.14 | \$41.70 |
| Jan-25 | 32,094 |  | \$43.97 | \$43.08 | \$43.79 | \$43.03 | \$38.28 | \$42.29 | \$40.26 | \$42.51 | \$42.22 | \$41.78 |
| Feb-25 | 32,094 |  | \$44.14 | \$43.24 | \$43.93 | \$43.16 | \$39.30 | \$42.39 | \$39.69 | \$42.63 | \$42.30 | \$41.86 |
| Mar-25 | 32,094 |  | \$44.29 | \$43.40 | \$44.06 | \$43.30 | \$42.81 | \$42.50 | \$42.51 | \$42.74 | \$42.38 | \$41.94 |
| Apr-25 | 32,094 |  | \$44.45 | \$43.57 | \$44.20 | \$43.44 | \$39.81 | \$42.60 | \$40.18 | \$42.86 | \$42.46 | \$42.02 |
| May-25 | 32,094 |  | \$44.61 | \$43.73 | \$44.33 | \$43.58 | \$44.16 | \$42.71 | \$43.98 | \$42.98 | \$42.54 | \$42.10 |
| Jun-25 | 32,094 |  | \$44.78 | \$43.89 | \$44.47 | \$43.72 | \$42.90 | \$42.82 | \$42.47 | \$43.09 | \$42.62 | \$42.18 |
| Jul-25 | 32,094 |  | \$44.95 | \$44.05 | \$44.61 | \$43.85 | \$48.00 | \$42.94 | \$48.90 | \$43.21 | \$42.70 | \$42.26 |
| Aug-25 | 32,094 |  | \$45.12 | \$44.21 | \$44.75 | \$43.99 | \$41.72 | \$43.04 | \$42.98 | \$43.32 | \$42.77 | \$42.34 |
| Sep-25 | 32,094 |  | \$45.29 | \$44.38 | \$44.89 | \$44.13 | \$47.71 | \$43.16 | \$47.96 | \$43.44 | \$42.85 | \$42.42 |
| Oct-25 | 32,094 |  | \$45.45 | \$44.54 | \$45.03 | \$44.27 | \$42.55 | \$43.27 | \$41.92 | \$43.55 | \$42.93 | \$42.50 |
| Nov-25 | 32,094 |  | \$45.62 | \$44.71 | \$45.17 | \$44.41 | \$49.84 | \$43.39 | \$49.04 | \$43.67 | \$43.01 | \$42.58 |
| Dec-25 | 32,094 |  | \$45.79 | \$44.87 | \$45.30 | \$44.54 | \$44.90 | \$43.50 | \$45.50 | \$43.78 | \$43.09 | \$42.66 |
|  | Utilization Trend |  |  | 4.49\% |  | 3.92\% |  | 3.21\% |  | 3.08\% |  | 2.06\% |
|  | RMSE (root mea | square error) |  | 4.70 |  | 4.69 |  | 4.50 |  | 3.72 |  | 5.17 |

MEDICAL UTILIZATION TREND CALCULATION

| Month | Utilization Trend Calculation - Medical Specialty Pharmacy - 24 Month |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Membership | Normalized PMPM | Logistic Regression |  | Linear Regression |  | Holt-Winters' Multiplicative |  | Holt-Winters' Additive |  | Double Exp Smoothing |  |
|  |  |  | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 PMPM | Fitted PMPM | Rolling 12 <br> PMPM |
| Oct-21 | 21,960 | \$33.85 | \$37.89 |  | \$38.16 |  | \$36.17 |  | \$38.63 |  | \$41.33 |  |
| Nov-21 | 21,832 | \$46.67 | \$38.03 |  | \$38.30 |  | \$46.52 |  | \$46.00 |  | \$40.21 |  |
| Dec-21 | 21,938 | \$38.96 | \$38.17 |  | \$38.44 |  | \$39.06 |  | \$38.83 |  | \$41.42 |  |
| Jan-22 | 25,937 | \$36.30 | \$38.31 |  | \$38.59 |  | \$35.20 |  | \$32.86 |  | \$41.15 |  |
| Feb-22 | 26,010 | \$37.08 | \$38.45 |  | \$38.73 |  | \$37.16 |  | \$36.97 |  | \$40.45 |  |
| Mar-22 | 26,089 | \$31.33 | \$38.58 |  | \$38.86 |  | \$33.32 |  | \$37.63 |  | \$39.97 |  |
| Apr-22 | 26,124 | \$38.58 | \$38.73 |  | \$39.00 |  | \$38.55 |  | \$37.57 |  | \$38.56 |  |
| May-22 | 26,146 | \$40.84 | \$38.87 |  | \$39.14 |  | \$41.18 |  | \$41.37 |  | \$38.57 |  |
| Jun-22 | 26,231 | \$35.50 | \$39.01 |  | \$39.29 |  | \$36.46 |  | \$39.44 |  | \$38.97 |  |
| Jul-22 | 26,245 | \$43.80 | \$39.16 |  | \$39.43 |  | \$43.72 |  | \$41.33 |  | \$38.40 |  |
| Aug-22 | 26,214 | \$40.58 | \$39.30 |  | \$39.57 |  | \$40.45 |  | \$37.07 |  | \$39.32 |  |
| Sep-22 | 26,128 | \$43.43 | \$39.45 | \$38.69 | \$39.71 | \$38.96 | \$43.66 | \$39.24 | \$42.87 | \$39.14 | \$39.57 | \$39.77 |
| Oct-22 | 26,174 | \$44.13 | \$39.59 | \$38.83 | \$39.85 | \$39.10 | \$36.42 | \$39.21 | \$40.21 | \$39.26 | \$40.28 | \$39.71 |
| Nov-22 | 26,242 | \$46.50 | \$39.74 | \$38.96 | \$40.00 | \$39.23 | \$48.64 | \$39.50 | \$48.00 | \$39.53 | \$41.02 | \$39.78 |
| Dec-22 | 26,221 | \$39.81 | \$39.89 | \$39.09 | \$40.14 | \$39.36 | \$40.70 | \$39.63 | \$40.73 | \$39.68 | \$42.06 | \$39.86 |
| Jan-23 | 31,237 | \$30.50 | \$40.04 | \$39.25 | \$40.28 | \$39.51 | \$37.36 | \$39.77 | \$34.71 | \$39.75 | \$41.82 | \$39.94 |
| Feb-23 | 31,281 | \$37.61 | \$40.19 | \$39.40 | \$40.42 | \$39.66 | \$38.71 | \$39.87 | \$38.45 | \$39.84 | \$40.01 | \$39.91 |
| Mar-23 | 31,341 | \$44.67 | \$40.32 | \$39.55 | \$40.55 | \$39.81 | \$33.61 | \$39.80 | \$39.06 | \$39.94 | \$39.64 | \$39.88 |
| Apr-23 | 31,308 | \$37.91 | \$40.47 | \$39.71 | \$40.70 | \$39.96 | \$40.23 | \$39.93 | \$39.58 | \$40.10 | \$40.53 | \$40.04 |
| May-23 | 31,363 | \$43.14 | \$40.62 | \$39.85 | \$40.84 | \$40.10 | \$42.75 | \$40.10 | \$43.24 | \$40.29 | \$40.15 | \$40.17 |
| Jun-23 | 31,559 | \$44.67 | \$40.77 | \$40.00 | \$40.98 | \$40.24 | \$37.47 | \$40.13 | \$41.33 | \$40.45 | \$40.70 | \$40.31 |
| Jul-23 | 31,810 | \$40.52 | \$40.92 | \$40.15 | \$41.12 | \$40.38 | \$45.63 | \$40.36 | \$43.57 | \$40.67 | \$41.45 | \$40.55 |
| Aug-23 | 31,921 | \$34.98 | \$41.07 | \$40.29 | \$41.26 | \$40.52 | \$42.24 | \$40.53 | \$39.05 | \$40.79 | \$41.39 | \$40.72 |
| Sep-23 | 32,094 | \$43.41 | \$41.23 | \$40.44 | \$41.41 | \$40.66 | \$45.37 | \$40.73 | \$44.49 | \$40.96 | \$40.38 | \$40.77 |
| Oct-23 | 32,094 |  | \$41.38 | \$40.58 | \$41.54 | \$40.79 | \$42.36 | \$41.18 | \$41.75 | \$41.09 | \$40.94 | \$40.82 |
| Nov-23 | 32,094 |  | \$41.53 | \$40.72 | \$41.69 | \$40.93 | \$49.44 | \$41.36 | \$49.35 | \$41.31 | \$41.01 | \$40.82 |
| Dec-23 | 32,094 |  | \$41.68 | \$40.86 | \$41.83 | \$41.06 | \$41.88 | \$41.45 | \$42.15 | \$41.42 | \$41.07 | \$40.76 |
| Jan-24 | 32,094 |  | \$41.84 | \$41.01 | \$41.97 | \$41.20 | \$34.98 | \$41.24 | \$36.17 | \$41.53 | \$41.13 | \$40.70 |
| Feb-24 | 32,094 |  | \$42.00 | \$41.16 | \$42.11 | \$41.34 | \$39.68 | \$41.32 | \$40.11 | \$41.66 | \$41.20 | \$40.80 |
| Mar-24 | 32,094 |  | \$42.14 | \$41.31 | \$42.25 | \$41.48 | \$41.32 | \$41.95 | \$40.77 | \$41.80 | \$41.26 | \$40.94 |
| Apr-24 | 32,094 |  | \$42.30 | \$41.46 | \$42.39 | \$41.62 | \$40.54 | \$41.97 | \$41.02 | \$41.92 | \$41.33 | \$41.00 |
| May-24 | 32,094 |  | \$42.46 | \$41.61 | \$42.53 | \$41.76 | \$44.72 | \$42.14 | \$44.76 | \$42.05 | \$41.39 | \$41.11 |
| Jun-24 | 32,094 |  | \$42.62 | \$41.77 | \$42.68 | \$41.90 | \$43.11 | \$42.60 | \$42.86 | \$42.17 | \$41.46 | \$41.17 |
| Jul-24 | 32,094 |  | \$42.77 | \$41.92 | \$42.81 | \$42.04 | \$44.55 | \$42.52 | \$44.93 | \$42.29 | \$41.52 | \$41.17 |
| Aug-24 | 32,094 |  | \$42.93 | \$42.07 | \$42.96 | \$42.18 | \$39.80 | \$42.31 | \$40.56 | \$42.41 | \$41.59 | \$41.19 |
| Sep-24 | 32,094 |  | \$43.09 | \$42.23 | \$43.10 | \$42.32 | \$46.08 | \$42.37 | \$46.19 | \$42.55 | \$41.65 | \$41.30 |
| Oct-24 | 32,094 |  | \$43.25 | \$42.38 | \$43.24 | \$42.46 | \$44.06 | \$42.51 | \$43.51 | \$42.70 | \$41.72 | \$41.36 |
| Nov-24 | 32,094 |  | \$43.41 | \$42.54 | \$43.39 | \$42.61 | \$51.42 | \$42.68 | \$51.11 | \$42.85 | \$41.78 | \$41.43 |
| Dec-24 | 32,094 |  | \$43.57 | \$42.70 | \$43.52 | \$42.75 | \$43.55 | \$42.82 | \$43.91 | \$42.99 | \$41.84 | \$41.49 |
| Jan-25 | 32,094 |  | \$43.73 | \$42.86 | \$43.67 | \$42.89 | \$36.38 | \$42.93 | \$37.93 | \$43.14 | \$41.91 | \$41.55 |
| Feb-25 | 32,094 |  | \$43.90 | \$43.01 | \$43.81 | \$43.03 | \$41.26 | \$43.07 | \$41.87 | \$43.28 | \$41.97 | \$41.62 |
| Mar-25 | 32,094 |  | \$44.04 | \$43.17 | \$43.94 | \$43.17 | \$42.95 | \$43.20 | \$42.53 | \$43.43 | \$42.04 | \$41.68 |
| Apr-25 | 32,094 |  | \$44.21 | \$43.33 | \$44.09 | \$43.31 | \$42.14 | \$43.34 | \$42.77 | \$43.58 | \$42.10 | \$41.75 |
| May-25 | 32,094 |  | \$44.37 | \$43.49 | \$44.22 | \$43.45 | \$46.47 | \$43.48 | \$46.52 | \$43.72 | \$42.17 | \$41.81 |
| Jun-25 | 32,094 |  | \$44.54 | \$43.65 | \$44.37 | \$43.59 | \$44.79 | \$43.62 | \$44.62 | \$43.87 | \$42.23 | \$41.88 |
| Jul-25 | 32,094 |  | \$44.70 | \$43.81 | \$44.51 | \$43.73 | \$46.29 | \$43.77 | \$46.69 | \$44.02 | \$42.30 | \$41.94 |
| Aug-25 | 32,094 |  | \$44.87 | \$43.97 | \$44.65 | \$43.88 | \$41.35 | \$43.90 | \$42.31 | \$44.16 | \$42.36 | \$42.01 |
| Sep-25 | 32,094 |  | \$45.03 | \$44.13 | \$44.79 | \$44.02 | \$47.86 | \$44.05 | \$47.95 | \$44.31 | \$42.43 | \$42.07 |
| Oct-25 | 32,094 |  | \$45.20 | \$44.30 | \$44.93 | \$44.16 | \$45.77 | \$44.19 | \$45.27 | \$44.45 | \$42.49 | \$42.14 |
| Nov-25 | 32,094 |  | \$45.37 | \$44.46 | \$45.08 | \$44.30 | \$53.41 | \$44.35 | \$52.87 | \$44.60 | \$42.55 | \$42.20 |
| Dec-25 | 32,094 |  | \$45.53 | \$44.62 | \$45.22 | \$44.44 | \$45.23 | \$44.49 | \$45.66 | \$44.75 | \$42.62 | \$42.26 |
| Utilization TrendRMSE (root mean square error) |  |  | 4.47\% |  |  | 4.03\% |  | 4.00\% |  | 4.00\% |  | 1.61\% |
|  |  |  | 4.37 |  |  | 4.36 |  | 4.02 |  | 3.03 |  | 4.86 |

MEDICAL UTILIZATION TREND CALCULATION

| Category | Months | Forecasting Model | Parameter Name | Value of Parameter Estimate |
| :---: | :---: | :---: | :---: | :---: |
| Facility | 48 | Double Exp Smoothing | WEIGHT | 0.049 |
| Facility | 48 | Holt Winters Multiplicative | Level | 0.007 |
| Facility | 48 | Holt Winters Multiplicative | trend | 0.028 |
| Facility | 48 | Holt Winters Multiplicative | SEASON | 0.233 |
| Facility | 48 | Holt Winters Additive | level | 0.034 |
| Facility | 48 | Holt Winters Additive | trend | 0.001 |
| Facility | 48 | Holt Winters Additive | SEASON | 0.001 |
| Facility | 36 | Double Exp Smoothing | WEIGHT | 0.026 |
| Facility | 36 | Holt Winters Multiplicative | level | 0.008 |
| Facility | 36 | Holt Winters Multiplicative | trend | 0.032 |
| Facility | 36 | Holt Winters Multiplicative | SEASON | 0.292 |
| Facility | 36 | Holt Winters Additive | Level | 0.041 |
| Facility | 36 | Holt Winters Additive | trend | 0.001 |
| Facility | 36 | Holt Winters Additive | SEASON | 0.001 |
| Facility | 24 | Double Exp Smoothing | WEIGHT | 0.031 |
| Facility | 24 | Holt Winters Multiplicative | Level | 0.012 |
| Facility | 24 | Holt Winters Multiplicative | trend | 0.034 |
| Facility | 24 | Holt Winters Multiplicative | SEASON | 0.519 |
| Facility | 24 | Holt Winters Additive | Level | 0.082 |
| Facility | 24 | Holt Winters Additive | trend | 0.001 |
| Facility | 24 | Holt Winters Additive | SEASON | 0.001 |
| Professional (Non-MH) | 48 | Double Exp Smoothing | WEIGHT | 0.133 |
| Professional (Non-MH) | 48 | Holt Winters Multiplicative | Level | 0.002 |
| Professional (Non-MH) | 48 | Holt Winters Multiplicative | trend | 0.121 |
| Professional (Non-MH) | 48 | Holt Winters Multiplicative | SEASON | 0.280 |
| Professional (Non-MH) | 48 | Holt Winters Additive | Level | 0.999 |
| Professional (Non-MH) | 48 | Holt Winters Additive | trend | 0.001 |
| Professional (Non-MH) | 48 | Holt Winters Additive | SEASON | 0.001 |
| Professional (Non-MH) | 36 | Double Exp Smoothing | WEIGHT | 0.057 |
| Professional (Non-MH) | 36 | Holt Winters Multiplicative | Level | 0.001 |
| Professional (Non-MH) | 36 | Holt Winters Multiplicative | trend | 0.001 |
| Professional (Non-MH) | 36 | Holt Winters Multiplicative | SEASON | 0.289 |
| Professional (Non-MH) | 36 | Holt Winters Additive | level | 0.029 |
| Professional (Non-MH) | 36 | Holt Winters Additive | trend | 0.001 |
| Professional ( $\mathrm{Non-MH)}$ | 36 | Holt Winters Additive | SEASON | 0.001 |
| Professional (Non-MH) | 24 | Double Exp Smoothing | WEIGHT | 0.025 |
| Professional (Non-MH) | 24 | Holt Winters Multiplicative | Level | 0.001 |
| Professional (Non-MH) | 24 | Holt Winters Multiplicative | trend | 0.795 |
| Professional (Non-MH) | 24 | Holt Winters Multiplicative | SEASON | 0.506 |
| Professional (Non-MH) | 24 | Holt Winters Additive | Level | 0.037 |
| Professional (Non-MH) | 24 | Holt Winters Additive | trend | 0.001 |
| Professional (Non-MH) | 24 | Holt Winters Additive | SEASON | 0.001 |
| Professional - Mental Health | 48 | Double Exp Smoothing | WEIGHT | 0.230 |
| Professional - Mental Health | 48 | Holt Winters Multiplicative | level | 0.726 |
| Professional - Mental Health | 48 | Holt Winters Multiplicative | trend | 0.001 |
| Professional - Mental Health | 48 | Holt Winters Multiplicative | SEASON | 0.713 |
| Professional - Mental Health | 48 | Holt Winters Additive | level | 0.702 |
| Professional - Mental Health | 48 | Holt Winters Additive | TREND | 0.001 |
| Professional - Mental Health | 48 | Holt Winters Additive | SEASON | 0.001 |
| Professional - Mental Health | 36 | Double Exp Smoothing | WEIGHT | 0.114 |
| Professional - Mental Health | 36 | Holt Winters Multiplicative | Level | 0.313 |
| Professional - Mental Health | 36 | Holt Winters Multiplicative | trend | 0.001 |
| Professional - Mental Health | 36 | Holt Winters Multiplicative | SEASON | 0.603 |
| Professional - Mental Health | 36 | Holt Winters Additive | level | 0.669 |
| Professional - Mental Health | 36 | Holt Winters Additive | TREND | 0.001 |
| Professional - Mental Health | 36 | Holt Winters Additive | SEASON | 0.001 |
| Professional - Mental Health | 24 | Double Exp Smoothing | WEIGHT | 0.107 |
| Professional - Mental Health | 24 | Holt Winters Multiplicative | level | 0.104 |
| Professional - Mental Health | 24 | Holt Winters Multiplicative | TREND | 0.463 |
| Professional - Mental Health | 24 | Holt Winters Multiplicative | SEASON | 0.579 |
| Professional - Mental Health | 24 | Holt Winters Additive | Level | 0.055 |
| Professional - Mental Health | 24 | Holt Winters Additive | TREND | 0.001 |
| Professional - Mental Health | 24 | Holt Winters Additive | SEASON | 0.001 |
| Medical Specialty Pharmacy | 48 | Double Exp Smoothing | WEIGHT | 0.075 |
| Medical Specialty Pharmacy | 48 | Holt Winters Multiplicative | Level | 0.001 |
| Medical Specialty Pharmacy | 48 | Holt Winters Multiplicative | trend | 0.001 |
| Medical Specialty Pharmacy | 48 | Holt Winters Multiplicative | SEASON | 0.320 |
| Medical Specialty Pharmacy | 48 | Holt Winters Additive | Level | 0.020 |
| Medical Specialty Pharmacy | 48 | Holt Winters Additive | TREND | 0.001 |
| Medical Specialty Pharmacy | 48 | Holt Winters Additive | SEASON | 0.001 |
| Medical Specialty Pharmacy | 36 | Double Exp Smoothing | WEIGHT | 0.074 |
| Medical Specialty Pharmacy | 36 | Holt Winters Multiplicative | level | 0.001 |
| Medical Specialty Pharmacy | 36 | Holt Winters Multiplicative | TREND | 0.001 |
| Medical Specialty Pharmacy | 36 | Holt Winters Multiplicative | SEASON | 0.442 |
| Medical Specialty Pharmacy | 36 | Holt Winters Additive | Level | 0.035 |
| Medical Specialty Pharmacy | 36 | Holt Winters Additive | trend | 0.001 |
| Medical Specialty Pharmacy | 36 | Holt Winters Additive | SEASON | 0.001 |
| Medical Specialty Pharmacy | 24 | Double Exp Smoothing | WEIGHT | 0.086 |
| Medical Specialty Pharmacy | 24 | Holt Winters Multiplicative | Level | 0.001 |
| Medical Specialty Pharmacy | 24 | Holt Winters Multiplicative | trend | 0.001 |
| Medical Specialty Pharmacy | 24 | Holt Winters Multiplicative | SEASON | 0.550 |
| Medical Specialty Pharmacy | 24 | Holt Winters Additive | level | 0.048 |
| Medical Specialty Pharmacy | 24 | Holt Winters Additive | trend | 0.001 |
| Medical Specialty Pharmacy | 24 | Holt Winters Additive | SEASON | 0.001 |

Generic Drugs - Cost Trend

| $\begin{aligned} & \text { Incurred } \\ & \text { Date } \end{aligned}$ | Monthly Data |  |  |  | Rolling 12 |  |  |  | Exponential Fit |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Supply | AWP Cost | Cost/Supply | Monthly Cost Trend | Supply | AWP Cost | Cost/Supply | Rolling 12 Cost Trend | Monthly Data | Rolling 12 Data |
| Oct-19 | 624,158 | \$2,492,382.3 | \$3.99 |  |  |  |  |  | \$3.86 | \$3.92 |
| Nov-19 | 574,288 | \$2,328,051.6 | \$4.05 |  |  |  |  |  | \$3.87 | \$3.93 |
| Dec-19 | 643,568 | \$2,634,508.0 | \$4.09 |  |  |  |  |  | \$3.88 | \$3.94 |
| Jan-20 | 606,380 | \$2,424,285.8 | \$4.00 |  |  |  |  |  | \$3.90 | \$3.95 |
| Feb-20 | 546,093 | \$2,268,486,6 | \$4.15 |  |  |  |  |  | \$3.91 | \$3.96 |
| Mar-20 | 692,395 | \$2,773,286.4 | \$4.01 |  |  |  |  |  | \$3.92 | \$3.97 |
| Apr-20 | 562,207 | \$2,251,437.0 | \$4.00 |  |  |  |  |  | \$3.93 | \$3.98 |
| May-20 | 540,153 | \$2,193,137.6 | \$4.06 |  |  |  |  |  | \$3.94 | \$3.98 |
| Jun-20 | 600,496 | \$2,371,344.4 | \$3.95 |  |  |  |  |  | \$3.95 | \$3.99 |
| Jul-20 | 602,328 | \$2,491,084,6 | \$4.14 |  |  |  |  |  | \$3.97 | \$4.00 |
| Aug-20 | 583,157 | \$2,381,017.7 | \$4.08 |  |  |  |  |  | \$3.98 | \$4.01 |
| Sep-20 | 589,165 | \$2,372,253.5 | \$4.03 |  | 7,164,388 | \$28,981,275 | \$4.05 |  | \$3.99 | \$4.02 |
| Oct-20 | 603,194 | \$2,484,634.4 | \$4.12 | 3.2\% | 7,143,424 | \$28,973,528 | \$4.06 |  | \$4.00 | \$4.03 |
| Nov-20 | 593,747 | \$2,455,066.7 | \$4.13 | 2.0\% | 7,162,883 | \$29,100,543 | \$4.06 |  | \$4.01 | \$4.04 |
| Dec-20 | 653,499 | \$2,737,907.2 | \$4.19 | 2.3\% | 7,172,814 | \$29,203,942 | \$4.07 |  | \$4.02 | \$4.05 |
| Jan-21 | 605,010 | \$2,515,262.4 | \$4.16 | 4.0\% | 7,171,444 | \$29,294,919 | \$4.08 |  | \$4.04 | \$4.05 |
| Feb-21 | 557,920 | \$2,292,274.5 | \$4.11 | -1.1\% | 7,183,271 | \$29,318,706 | \$4.08 |  | \$4.05 | \$4.06 |
| Mar-21 | 671,408 | \$2,743,550.4 | \$4.09 | 2.0\% | 7,162,284 | \$29,288,970 | \$4.09 |  | \$4.06 | \$4.07 |
| Apr-21 | 622,711 | \$2,607,669.8 | \$4.19 | 4.6\% | 7,222,788 | \$29,645,203 | \$4.10 |  | \$4.07 | \$4.08 |
| May-21 | 603,046 | \$2,51,981.7 | \$4.16 | 2.6\% | 7,285,681 | \$29,963,047 | \$4.11 |  | \$4.08 | \$4.09 |
| Jun-21 | 650,528 | \$2,772,676.4 | \$4.26 | 7.9\% | 7,335,713 | \$30,364,379 | \$4.14 |  | \$4.10 | \$4.10 |
| Jul-21 | 584,807 | \$2,437,927.0 | \$4.17 | 0.8\% | 7,318,192 | \$30,311,222 | \$4.14 |  | \$4.11 | \$4.11 |
| Aug-21 | 629,096 | \$2,654,033.4 | \$4.22 | 3.3\% | 7,364,131 | \$30,584,237 | \$4.15 |  | \$4.12 | \$4.12 |
| Sep-21 | 622,879 | \$2,572,906.2 | \$4.13 | 2.6\% | 7,397,845 | \$30,784,890 | \$4.16 | 2.9\% | \$4.13 | \$4.13 |
| Oct-21 | 629,550 | \$2,641,033.9 | \$4.20 | 1.8\% | 7,424,201 | \$30,941,290 | \$4.17 | 2.8\% | \$4.15 | \$4.13 |
| Nov-21 | 626,906 | \$2,685,814.3 | \$4.28 | 3.6\% | 7,457,360 | \$31,172,037 | \$4.18 | 2.9\% | \$4.16 | \$4.14 |
| Dec-21 | 669,839 | \$2,785,963.6 | \$4.16 | -0.7\% | 7,473,700 | \$31,220,094 | \$4.18 | 2.6\% | \$4.17 | \$4.15 |
| Jan-22 | 734,373 | \$3,012,828.8 | \$4.10 | -1.3\% | 7,603,063 | \$31,717,660 | \$4.17 | 2.1\% | \$4.18 | \$4.16 |
| Feb-22 | 683,111 | \$2,841,586.2 | \$4.16 | 1.2\% | 7,728,254 | \$32,266,972 | \$4.18 | 2.3\% | \$4.20 | \$4.17 |
| Mar-22 | 790,070 | \$3,224,483.4 | \$4.08 | -0.1\% | 7,846,916 | \$32,747,905 | \$4.17 | 2.1\% | \$4.21 | \$4.18 |
| Apr-22 | 748,840 | \$3,149,259.9 | \$4.21 | 0.4\% | 7,973,045 | \$33,289,495 | \$4.18 | 1.7\% | \$4.22 | \$4.19 |
| May-22 | 767,913 | \$3,224,996.6 | \$4.20 | 0.9\% | 8,137,912 | \$34,003,510 | \$4.18 | 1.6\% | \$4.23 | \$4.20 |
| Jun-22 | 776,093 | \$3,320,595.4 | \$4.28 | 0.4\% | 8,263,477 | \$34,551,429 | \$4.18 | 1.0\% | \$4.24 | \$4.21 |
| Jul-22 | 748,203 | \$3,242,184.2 | \$4.33 | 3.9\% | 8,426,873 | \$35,355,686 | \$4.20 | 1.3\% | \$4.26 | \$4.22 |
| Aug-22 | 811,289 | \$3,427,095.3 | \$4.22 | 0.1\% | 8,609,066 | \$36,128,748 | \$4.20 | 1.0\% | \$4.27 | \$4.23 |
| Sep-22 | 759,016 | \$3,281,012.4 | \$4.32 | 4.6\% | 8,745,203 | \$36,836,854 | \$4.21 | 1.2\% | \$4.28 | \$4.23 |
| Oct-22 | 787,505 | \$3,407,552.9 | \$4.33 | 3.1\% | 8,903,158 | \$37,603,373 | \$4.22 | 1.3\% | \$4.29 | \$4.24 |
| Nov-22 | 777,830 | \$3,372,441.9 | \$4.34 | 1.2\% | 9,054,082 | \$38,290,001 | \$4.23 | 1.2\% | \$4.31 | \$4.25 |
| Dec-22 | 809,198 | \$3,545,756.5 | \$4.38 | 5.4\% | 9,193,441 | \$39,049,794 | \$4.25 | 1.7\% | \$4.32 | \$4.26 |
| Jan-23 | 922,167 | \$3,970,380.8 | \$4.31 | 4.9\% | 9,381,235 | \$40,007,346 | \$4.26 | 2.2\% | \$4.33 | \$4.27 |
| Feb-23 | 845,604 | \$3,618,348.4 | \$4.28 | 2.9\% | 9,543,728 | \$40,784,108 | \$4.27 | 2.4\% | \$4.35 | \$4.28 |
| Mar-23 | 960,036 | \$4,175,022.6 | \$4.35 | 6.6\% | 9,713,694 | \$41,734,647 | \$4.30 | 3.0\% | \$4.36 | \$4.29 |
| Apr-23 | 870,203 | \$3,776,451.8 | \$4.34 | 3.2\% | 9,835,057 | \$42,361,839 | \$4.31 | 3.2\% | \$4.37 | \$4.30 |
| May-23 | 972,588 | \$4,241,327.0 | \$4.36 | 3.8\% | 10,039,732 | \$43,378,169 | \$4.32 | 3.4\% | \$4.38 | \$4.31 |
| Jun-23 | 953,498 | \$4,158,426.3 | \$4.36 | 1.9\% | 10,217,137 | \$44,216,000 | \$4.33 | 3.5\% | \$4.40 | \$4.32 |
| Jul-23 | 939,629 | \$4,169,724.4 | \$4.44 | 2.4\% | 10,408,563 | \$45,143,540 | \$4.34 | 3.4\% | \$4.41 | \$4.33 |
| Aug-23 | 991,388 | \$4,477,908.8 | \$4.52 | 6.9\% | 10,588,662 | \$46,194,354 | \$4.36 | 4.0\% | \$4.42 | \$4.34 |
| Sep-23 | 944,890 | \$4,174,118.8 | \$4.42 | 2.2\% | 10,774,536 | \$47,087,460 | \$4.37 | 3.8\% | \$4.44 | \$4.35 |


| $3.3 \%$ | $3.6 \%$ | $2.6 \%$ |
| :--- | :--- | :--- |


pharmacy trend development

Brand Drugs - Cost Trend

| $\begin{aligned} & \text { Incurred } \\ & \text { Date } \\ & \hline \end{aligned}$ | Monthly Data |  |  |  | Rolling 12 |  |  |  | Exponential fit |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Supply | AWP Cost | Cost/Supply | $\begin{gathered} \text { Monthly Cost } \\ \text { Trend } \end{gathered}$ | Supply | AWP Cost | Cost/Supply | Rolling 12 Cost Trend | Monthly Data | Rolling 12 Data |
| Oct-19 | 36,655 | \$616,147.2 | \$16.81 |  |  |  |  |  | \$20.36 | \$18.86 |
| Nov-19 | 36,815 | \$630,556.5 | \$17.13 |  |  |  |  |  | \$20.39 | \$18.93 |
| Dec-19 | 42,597 | \$791,279.9 | \$18.58 |  |  |  |  |  | \$20.43 | \$19.00 |
| Jan-20 | 31,844 | \$555,203.6 | \$17.44 |  |  |  |  |  | \$20.47 | \$19.06 |
| Feb-20 | 33,020 | \$618,976.3 | \$18.75 |  |  |  |  |  | \$20.50 | \$19.13 |
| Mar-20 | 42,599 | \$793,396.3 | \$18.62 |  |  |  |  |  | \$20.54 | \$19.20 |
| Apr-20 | 31,118 | \$574,407.4 | \$18.46 |  |  |  |  |  | \$20.57 | \$19.27 |
| May-20 | 34,068 | \$641,243.7 | \$18.82 |  |  |  |  |  | \$20.61 | \$19.33 |
| Jun-20 | 35,055 | \$649,688.7 | \$18.53 |  |  |  |  |  | \$20.65 | \$19.40 |
| Jul-20 | 34,446 | \$645,231.9 | \$18.73 |  |  |  |  |  | \$20.68 | \$19.47 |
| Aug-20 | 36,188 | \$685,806.3 | \$18.95 |  |  |  |  |  | \$20.72 | \$19.54 |
| Sep-20 | 32,999 | \$619,598.6 | \$18.78 |  | 427,404 | \$7,821,536 | \$18.30 |  | \$20.76 | \$19.61 |
| Oct-20 | 36,648 | \$670,280.7 | \$18.29 | 8.8\% | 427,397 | \$7,875,670 | \$18.43 |  | \$20.79 | \$19.68 |
| Nov-20 | 36,048 | \$671,033.7 | \$18.62 | 8.7\% | 426,630 | \$7,916,147 | \$18.56 |  | \$20.83 | \$19.75 |
| Dec-20 | 41,129 | \$758,826.2 | \$18.45 | -0.7\% | 425,162 | \$7,883,694 | \$18.54 |  | \$20.87 | \$19.82 |
| Jan-21 | 33,757 | \$627,654.4 | \$18.59 | 6.6\% | 427,075 | \$7,956,144 | \$18.63 |  | \$20.91 | \$19.89 |
| Feb-21 | 31,799 | \$636,062.0 | \$20.00 | 6.7\% | 425,854 | \$7,973,230 | \$18.72 |  | \$20.94 | \$19.96 |
| Mar-21 | 38,772 | \$830,114.7 | \$21.41 | 15.0\% | 422,027 | \$8,009,948 | \$18.98 |  | \$20.98 | \$20.02 |
| Apr-21 | 37,456 | \$744,649.1 | \$19.88 | 7.7\% | 428,365 | \$8,180,190 | \$19.10 |  | \$21.02 | \$20.10 |
| May-21 | 35,836 | \$753,536.9 | \$21.03 | 11.7\% | 430,133 | \$8,292,483 | \$19.28 |  | \$21.05 | \$20.16 |
| Jun-21 | 42,544 | \$872,336.1 | \$20.50 | 10.6\% | 437,622 | \$8,515,131 | \$19.46 |  | \$21.09 | \$20.24 |
| Jul-21 | 31,673 | \$616,027.9 | \$19.45 | 3.8\% | 434,849 | \$8,485,927 | \$19.51 |  | \$21.13 | \$20.31 |
| Aug-21 | 34,714 | \$742,074.8 | \$21.38 | 12.8\% | 433,375 | \$8,542,195 | \$19.71 |  | \$21.17 | \$20.38 |
| Sep-21 | 35,626 | \$747,211.0 | \$20.97 | 11.7\% | 436,002 | \$8,669,807 | \$19.88 | 8.7\% | \$21.20 | \$20.45 |
| Oct-21 | 35,057 | \$694,125.4 | \$19.80 | 8.3\% | 434,411 | \$8,693,652 | \$20.01 | 8.6\% | \$21.24 | \$20.52 |
| Nov-21 | 37,778 | \$812,282.4 | \$21.50 | 15.5\% | 436,141 | \$8,834,901 | \$20.26 | 9.2\% | \$21.28 | \$20.60 |
| Dec-21 | 38,972 | \$788,209.8 | \$20.23 | 9.6\% | 433,984 | \$8,864,284 | \$20.43 | 10.2\% | \$21.32 | \$20.67 |
| Jan-22 | 43,805 | \$912,596.4 | \$20.83 | 12.0\% | 444,032 | \$9,149,226 | \$20.60 | 10.6\% | \$21.36 | \$20.74 |
| Feb-22 | 39,702 | \$901,283.2 | \$22.70 | 13.5\% | 451,935 | \$9,414,448 | \$20.83 | 11.3\% | \$21.39 | \$20.82 |
| Mar-22 | 45,685 | \$993,773.2 | \$21.75 | 1.6\% | 458,848 | \$9,578,106 | \$20.87 | 10.0\% | \$21.43 | \$20.89 |
| Apr-22 | 46,248 | \$965,289.6 | \$20.87 | 5.0\% | 467,640 | \$9,798,747 | \$20.95 | 9.7\% | \$21.47 | \$20.96 |
| May-22 | 42,951 | \$1,014,925.4 | \$23.63 | 12.4\% | 474,755 | \$10,060,135 | \$21.19 | 9.9\% | \$21.51 | \$21.03 |
| Jun-22 | 46,893 | \$1,041,836.1 | \$22.22 | 8.4\% | 479,104 | \$10,229,635 | \$21.35 | 9.7\% | \$21.54 | \$21.11 |
| Jul-22 | 43,910 | \$948,073.8 | \$21.59 | 11.0\% | 491,341 | \$10,561,681 | \$21.50 | 10.2\% | \$21.58 | \$21.18 |
| Aug-22 | 51,934 | \$1,134,936.3 | \$21.85 | 2.2\% | 508,561 | \$10,954,543 | \$21.54 | 9.3\% | \$21.62 | \$21.26 |
| Sep-22 | 47,861 | \$1,033,322.2 | \$21.59 | 2.9\% | 520,796 | \$11,240,654 | \$21.58 | 8.5\% | \$21.66 | \$21.33 |
| Oct-22 | 46,445 | \$1,019,456.5 | \$21.95 | 10.9\% | 532,184 | \$11,565,985 | \$21.73 | 8.6\% | \$21.70 | \$21.41 |
| Nov-22 | 47,959 | \$1,066,510.9 | \$22.24 | 3.4\% | 542,365 | \$11,820,214 | \$21.79 | 7.6\% | \$21.74 | \$21.49 |
| Dec-22 | 52,348 | \$1,112,415.2 | \$21.25 | 5.1\% | 555,741 | \$12,144,419 | \$21.85 | 7.0\% | \$21.77 | \$21.56 |
| Jan-23 | 50,797 | \$1,098,303.5 | \$21.62 | 3.8\% | 562,733 | \$12,330,126 | \$21.91 | 6.3\% | \$21.81 | \$21.64 |
| Feb-23 | 47,386 | \$1,062,234.2 | \$22.42 | -1.3\% | 570,417 | \$12,491,077 | \$21.90 | 5.1\% | \$21.85 | \$21.72 |
| Mar-23 | 53,349 | \$1,158,077.9 | \$21.71 | -0.2\% | 578,081 | \$12,655,382 | \$21.89 | 4.9\% | \$21.89 | \$21.79 |
| Apr-23 | 52,979 | \$1,145,674.5 | \$21.63 | 3.6\% | 584,812 | \$12,835,767 | \$21.95 | 4.7\% | \$21.93 | \$21.86 |
| May-23 | 56,485 | \$1,216,186.5 | \$21.53 | -8.9\% | 598,346 | \$13,037,028 | \$21.79 | 2.8\% | \$21.97 | \$21.94 |
| Jun-23 | 56,974 | \$1,268,503.4 | \$22.26 | 0.2\% | 608,427 | \$13,263,695 | \$21.80 | 2.1\% | \$22.01 | \$22.02 |
| Jul-23 | 58,577 | \$1,242,760.9 | \$21.22 | -1.7\% | 623,094 | \$13,558,382 | \$21.76 | 1.2\% | \$22.05 | \$22.09 |
| Aug-23 | 54,880 | \$1,205,529.4 | \$21.97 | 0.5\% | 626,040 | \$13,628,975 | \$21.77 | 1.1\% | \$22.09 | \$22.17 |
| Sep-23 | 54,709 | \$1,217,816.2 | \$22.26 | 3.1\% | 632,888 | \$13,813,469 | \$21.83 | 1.1\% | \$22.13 | \$22.25 |


| $1.1 \%$ | $2.1 \%$ | $4.3 \%$ |
| :--- | :--- | :--- |



| 24 Months on Monthly |  |
| :--- | :---: |
| 1.000 | 1.595 |
| 0.000 | 1.529 |
| 0.117 | 0.035 |
| 2.912 | 22.000 |


| 24 Months on Annual |  |
| :---: | :---: |
| 1.000 | 0.120 |
| 0.000 | 0.570 |
| 0.789 | 0.013 |
| 82.422 | 22.000 |

Non-Specialty Drugs - Utilization Trend

| Incurred Date | Monthly Data |  |  | Rolling 12 |  |  | Normalization for Pharmacy Days |  |  | Smoothed |  |  |  | Exponential Fit -24 months |  | Exponential Fit - 36 months |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Membership | Supply | Supply per Member | Membership | Supply | Supply per Member | Pharmacy Days | Normalization for Pharmacy Days | Supply Adjusted for Pharmacy Days | Smoothing Factor | Smoothed Monthly Supply | Smoothed Rolling Supply | Rolling 12 Utilization Trend | Monthly Data | Rolling 12 Data | Monthly Data | Rolling 12 Data |
| Oct-19 | 22,259 | 699,649 | 31.43 |  |  |  | 29.5 | 0.97 | 32.43 |  | 32.43 |  |  | 30.04 | 29.09 | 29.94 | 29.35 |
| Nov-19 | 22,483 | 646,987 | 28.78 |  |  |  | 31.7 | 1.04 | 27.62 |  | 27.62 |  |  | 30.11 | 29.17 | 30.01 | 29.43 |
| Dec-19 | 22,416 | 728,104 | 32.48 |  |  |  | 29.7 | 0.97 | 33.33 |  | 33.33 |  |  | 30.18 | 29.25 | 30.08 | 29.51 |
| Jan-20 | 22,029 | 669,098 | 30.37 |  |  |  | 30.0 | 0.99 | 30.82 |  | 30.82 |  |  | 30.25 | 29.34 | 30.16 | 29.58 |
| Feb-20 | 21,916 | 609,651 | 27.82 |  |  |  | 30.5 | 1.00 | 27.80 |  | 27.80 |  |  | 30.32 | 29.42 | 30.23 | 29.66 |
| Mar-20 | 21,897 | 773,052 | 35.30 |  |  |  | 27.9 | 0.92 | 38.52 | 1.0630 | 29.69 |  |  | 30.38 | 29.50 | 30.30 | 29.73 |
| Apr-20 | 21,841 | 620,415 | 28.41 |  |  |  | 30.6 | 1.00 | 28.28 | 0.9745 | 29.83 |  |  | 30.46 | 29.58 | 30.37 | 29.81 |
| May-20 | 21,746 | 601,752 | 27.67 |  |  |  | 31.1 | 1.02 | 27.12 | 0.9625 | 29.92 |  |  | 30.52 | 29.67 | 30.44 | 29.89 |
| Jun-20 | 21,688 | 663,221 | 30.58 |  |  |  | 31.2 | 1.03 | 29.81 | 0.9499 | 29.71 |  |  | 30.60 | 29.75 | 30.51 | 29.97 |
| Jul-20 | 21,579 | 664,707 | 30.80 |  |  |  | 29.5 | 0.97 | 31.78 | 1.0775 | 31.85 |  |  | 30.66 | 29.84 | 30.58 | 30.04 |
| Aug-20 | 21,514 | 647,164 | 30.08 |  |  |  | 31.4 | 1.03 | 29.16 | 0.9726 | 30.59 |  |  | 30.74 | 29.92 | 30.65 | 30.12 |
| Sep-20 | 21,553 | 649,700 | 30.14 | 262,921 | 7,973,500 | 30.33 | 31.2 | 1.02 | 29.45 |  | 29.45 | 30.26 |  | 30.81 | 30.01 | 30.73 | 30.20 |
| Oct-20 | 21,561 | 669,316 | 31.04 | 262,223 | 7,943,167 | 30.29 | 29.9 | 0.98 | 31.65 |  | 31.65 | 30.19 |  | 30.88 | 30.09 | 30.80 | 30.28 |
| Nov-20 | 21,626 | 656,166 | 30.34 | 261,366 | 7,952,346 | 30.43 | 31.4 | 1.03 | 29.42 |  | 29.42 | 30.34 |  | 30.95 | 30.18 | 30.87 | 30.36 |
| Dec-20 | 21,615 | 726,388 | 33.61 | 260,565 | 7,950,630 | 30.51 | 28.8 | 0.94 | 35.59 |  | 35.59 | 30.52 |  | 31.02 | 30.26 | 30.94 | 30.44 |
| Jan-21 | 22,145 | 664,534 | 30.01 | 260,681 | 7,946,066 | 30.48 | 30.7 | 1.01 | 29.72 |  | 29.72 | 30.43 |  | 31.09 | 30.35 | 31.02 | 30.52 |
| Feb-21 | 22,043 | 611,737 | 27.75 | 260,808 | 7,948,152 | 30.48 | 30.4 | 1.00 | 27.81 |  | 27.81 | 30.43 |  | 31.17 | 30.44 | 31.09 | 30.60 |
| Mar-21 | 21,999 | 740,012 | 33.64 | 260,910 | 7,915,112 | 30.34 | 28.5 | 0.94 | 35.95 |  | 35.95 | 30.96 |  | 31.23 | 30.52 | 31.16 | 30.67 |
| Apr-21 | 22,006 | 687,049 | 31.22 | 261,075 | 7,981,746 | 30.57 | 31.6 | 1.04 | 30.09 |  | 30.09 | 30.98 |  | 31.30 | 30.60 | 31.23 | 30.75 |
| May-21 | 22,027 | 665,505 | 30.21 | 261,356 | 8,045,499 | 30.78 | 30.7 | 1.01 | 30.00 |  | 30.00 | 30.98 |  | 31.38 | 30.69 | 31.31 | 30.83 |
| Jun-21 | 22,092 | 720,360 | 32.61 | 261,760 | 8,102,638 | 30.95 | 30.1 | 0.99 | 33.00 | 0.9499 | 28.95 | 30.92 |  | 31.45 | 30.78 | 31.38 | 30.91 |
| Jul-21 | 22,080 | 636,620 | 28.83 | 262,261 | 8,074,551 | 30.79 | 31.1 | 1.02 | 28.26 | 1.0775 | 33.91 | 31.09 |  | 31.52 | 30.86 | 31.45 | 30.99 |
| Aug-21 | 22,031 | 684,916 | 31.09 | 262,778 | 8,112,303 | 30.87 | 31.3 | 1.03 | 30.23 | 0.9726 | 30.85 | 31.11 |  | 31.59 | 30.95 | 31.53 | 31.07 |
| Sep-21 | 22,022 | 684,130 | 31.07 | 263,247 | 8,146,733 | 30.95 | 30.9 | 1.02 | 30.57 |  | 30.57 | 31.20 | 3.1\% | 31.67 | 31.04 | 31.60 | 31.15 |
| Oct-21 | 21,960 | 688,647 | 31.36 | 263,646 | 8,166,064 | 30.97 | 30.8 | 1.01 | 31.01 |  | 31.01 | 31.15 | 3.2\% | 31.74 | 31.13 | 31.68 | 31.23 |
| Nov-21 | 21,832 | 689,078 | 31.56 | 263,852 | 8,198,976 | 31.07 | 30.7 | 1.01 | 31.34 |  | 31.34 | 31.31 | 3.2\% | 31.81 | 31.22 | 31.75 | 31.32 |
| Dec-21 | 21,938 | 738,392 | 33.66 | 264,175 | 8,210,980 | 31.08 | 29.3 | 0.96 | 34.94 |  | 34.94 | 31.26 | 2.4\% | 31.89 | 31.30 | 31.83 | 31.40 |
| Jan-22 | 25,937 | 807,126 | 31.12 | 267,967 | 8,353,572 | 31.17 | 31.1 | 1.02 | 30.44 |  | 30.44 | 31.31 | 2.9\% | 31.96 | 31.39 | 31.90 | 31.48 |
| Feb-22 | 26,010 | 750,870 | 28.87 | 271,934 | 8,492,705 | 31.23 | 29.3 | 0.96 | 29.98 |  | 29.98 | 31.46 | 3.4\% | 32.03 | 31.48 | 31.98 | 31.56 |
| Mar-22 | 26,089 | 869,805 | 33.34 | 276,024 | 8,622,498 | 31.24 | 27.9 | 0.92 | 36.37 |  | 36.37 | 31.57 | 2.0\% | 32.10 | 31.57 | 32.05 | 31.64 |
| Apr-22 | 26,124 | 827,661 | 31.68 | 280,142 | 8,763,110 | 31.28 | 32.2 | 1.06 | 29.94 |  | 29.94 | 31.53 | 1.8\% | 32.18 | 31.66 | 32.12 | 31.72 |
| May-22 | 26,146 | 843,959 | 32.28 | 284,261 | 8,941,564 | 31.46 | 30.6 | 1.00 | 32.14 |  | 32.14 | 31.71 | 2.3\% | 32.25 | 31.74 | 32.20 | 31.80 |
| Jun-22 | 26,231 | 857,154 | 32.68 | 288,400 | 9,078,358 | 31.48 | 30.4 | 1.00 | 32.68 |  | 32.68 | 32.01 | 3.5\% | 32.33 | 31.84 | 32.28 | 31.89 |
| Jul-22 | 26,245 | 826,155 | 31.48 | 292,565 | 9,267,893 | 31.68 | 30.8 | 1.01 | 31.12 |  | 31.12 | 31.79 | 2.2\% | 32.40 | 31.92 | 32.35 | 31.97 |
| Aug-22 | 26,214 | 899,826 | 34.33 | 296,748 | 9,482,803 | 31.96 | 30.4 | 1.00 | 34.34 |  | 34.34 | 32.08 | 3.1\% | 32.47 | 32.02 | 32.43 | 32.05 |
| Sep-22 | 26,128 | 842,344 | 32.24 | 300,854 | 9,641,017 | 32.05 | 31.6 | 1.04 | 31.07 |  | 31.07 | 32.10 | 2.9\% | 32.55 | 32.11 | 32.51 | 32.14 |
| Oct-22 | 26,174 | 870,512 | 33.26 | 305,068 | 9,822,882 | 32.20 | 30.7 | 1.01 | 33.02 |  | 33.02 | 32.26 | 3.6\% | 32.62 | 32.20 | 32.58 | 32.22 |
| Nov-22 | 26,242 | 864,524 | 32.94 | 309,478 | 9,998,328 | 32.31 | 30.1 | 0.99 | 33.34 |  | 33.34 | 32.42 | 3.5\% | 32.70 | 32.29 | 32.66 | 32.30 |
| Dec-22 | 26,221 | 900,637 | 34.35 | 313,761 | 10,160,573 | 32.38 | 30.1 | 0.99 | 34.76 |  | 34.76 | 32.44 | 3.8\% | 32.77 | 32.38 | 32.73 | 32.39 |
| Jan-23 | 31,237 | 1,015,168 | 32.50 | 319,061 | 10,368,615 | 32.50 | 31.2 | 1.02 | 31.74 |  | 31.74 | 32.53 | 3.9\% | 32.85 | 32.47 | 32.81 | 32.47 |
| Feb-23 | 31,281 | 937,957 | 29.98 | 324,332 | 10,555,702 | 32.55 | 30.2 | 0.99 | 30.27 |  | 30.27 | 32.52 | 3.4\% | 32.93 | 32.57 | 32.89 | 32.56 |
| Mar-23 | 31,341 | 1,066,247 | 34.02 | 329,584 | 10,752,144 | 32.62 | 27.9 | 0.92 | 37.12 |  | 37.12 | 32.65 | 3.4\% | 33.00 | 32.65 | 32.96 | 32.63 |
| Apr-23 | 31,308 | 971,559 | 31.03 | 334,768 | 10,896,042 | 32.55 | 31.9 | 1.05 | 29.62 |  | 29.62 | 32.58 | 3.3\% | 33.08 | 32.75 | 33.04 | 32.72 |
| May-23 | 31,363 | 1,085,474 | 34.61 | 339,985 | 11,137,557 | 32.76 | 30.1 | 0.99 | 35.06 |  | 35.06 | 32.84 | 3.6\% | 33.15 | 32.84 | 33.12 | 32.80 |
| Jun-23 | 31,559 | 1,068,172 | 33.85 | 345,313 | 11,348,575 | 32.86 | 31.1 | 1.02 | 33.14 |  | 33.14 | 32.88 | 2.7\% | 33.23 | 32.93 | 33.20 | 32.89 |
| Jul-23 | 31,810 | 1,056,379 | 33.21 | 350,878 | 11,578,799 | 33.00 | 30.6 | 1.00 | 33.08 |  | 33.08 | 33.03 | 3.9\% | 33.30 | 33.02 | 33.27 | 32.97 |
| Aug-23 | 31,921 | 1,113,310 | 34.88 | 356,585 | 11,792,283 | 33.07 | 29.5 | 0.97 | 36.05 |  | 36.05 | 33.20 | 3.5\% | 33.38 | 33.12 | 33.35 | 33.06 |
| Sep-23 | 32,094 | 1,059,216 | 33.00 | 362,551 | 12,009,155 | 33.12 | 32.2 | 1.06 | 31.19 |  | 31.19 | 33.18 | 3.4\% | 33.46 | 33.21 | 33.43 | 33.15 |


|  |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Annual Trend |  |  |  |  |  |
|  | $3.4 \%$ | $2.8 \%$ | $3.4 \%$ | $2.9 \%$ | $3.2 \%$ |
|  |  |  |  |  |  |



Regressions

| 24 Months on Monthly |  |
| :---: | :---: |
| 1.000 | 1.112 |
| 0.000 | 2.874 |
| 0.059 | 0.066 |
| 1.382 | 22.000 |


| 24 Months on Annual |  | 36 Months on Mon |  | 36 Months on An |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| .000 | 0.504 | 1.000 | 1.030 | 1.000 | 0.71 |
| 0.000 | 0.114 | 0.000 | 1.668 | 0.000 | 0.087 |
| 0.984 | 0.003 | 0.111 | 0.071 | 0.982 | 0.004 |
| 1321.572 | 22.000 | 4.252 | 34.000 | 1903.373 | 34.000 |

PHARMACY TREND DEVELOPMENT - SPECIALTY TREND CALCULATION



| 24 Months on Monthly |  |
| :---: | :---: |
| 1.000 | 0.000 |
| 0.000 | 3.331 |
| 0.543 | 0.077 |
| 26.113 | 22.000 |


| 24 Months on Rolling 12 |  |
| :---: | :---: |
| 1.000 | 0.000 |
| 0.000 | 0.256 |
| 0.995 | 0.006 |
| 4119.629 | 22.000 |


|  |  | Generic | New Senerics | ${ }_{\text {Brands Soing Seneric }}$ | Brand | G1P. 1 | Vaccines | Over the counter | Devie | compouns | covio 19 | Non.Specalaty Total | Specialy | Total Pharmar |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Experience ereiod Member Monts | m |  |  |  |  |  |  |  |  |  |  |  |  | ${ }^{362,551}$ |
| Esperience Peeriod Days Supply | a | 10,664,688 | 109,888 | ${ }^{91,461}$ | ${ }^{880,762}$ | 188,10 | 5.646 | ${ }^{13,168}$ | 178,775 | 1,219 | ${ }^{22,805}$ | 12,26, 381 | ${ }^{141,01}$ | 12,407,382 |
| Experience Peiode Alowed Chare per Suply | ${ }^{\text {b }}$ | - |  |  |  |  |  |  | E |  | E |  | ${ }_{5225.78}$ |  |
| Experience erioid PMPM | d=c/m |  |  |  |  |  |  |  |  |  |  | ${ }_{5} 5757$ | S88781 | S16328 |
| Uuliaraio Teend | - |  |  |  |  |  |  |  |  |  |  | 3.1\% |  |  |
| Cost Trend | f | 3.3\% | 3,3\% | 0.0\% | 4.5\% | 4.5\% | 4.5\% | 0.0\% | 4.5\% | 0.0\% | 4.5\% |  | - |  |
| Impato on Costof frands ging Seneric |  |  |  |  |  |  |  | - |  |  | T |  |  |  |
|  | $h=b \times\left((1+e) \times(1+\mathrm{f})^{\wedge}(27 / 12)\right) \times g$ $j=i \times a \times\left((1+e)^{\wedge}(27 / 12)\right)$ |  |  |  |  |  |  |  |  |  | - |  | $\underline{1}$ |  |
| Proection Period PMPM | $k=1 / \mathrm{m}$, |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anuua Trend before Contract Changes | $1=(k / 4)(121 / 27]-1$ |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Reducition of Priected Caims due to Contrat Changes |  |  |  |  |  |  |  |  |  |  | - |  | $\square$ |  |
| Projeceed Tootal Alwed Chares ater Contrat Changes | $0=n \times j$ |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Impatit Contrat (hanges on Propected Phammar PMPM |  |  |  |  |  |  |  |  |  |  |  |  | 14.0\% |  |


|  |  | Monthiy Unit Cost Normalized Adjusted Allowed Claims PMPM |  |  |  |  | Rolling 12 Unit Cost Normalized Adjusted Allowed Claims PMPM |  |  |  |  | Smoothed Unit C | Ost Normalized | Adjusted Allowe | Calm PMPM | Utilization Factor | Unit cost |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Month | Members | Faciliy | Professional | Mental Heath | MedRx | Total | Faciliy | Professional | Mental Health | Medxx | Total | Facility | Professional | Mental Heath | MedRx |  | vHP | IND | TVHP |
| Oct-19 | 22,259 | \$371.54 | ${ }^{5143.06}$ | \$15.01 | ${ }^{540.90}$ | ${ }_{5}^{5570.52}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Nov-19 | 22,483 | $\underset{\$ 369.92}{ }$ | ${ }_{\$ 1137.55}$ | $\$ 14.09$ $\$ 128$ | \$41.48 | S569.04 S54.54 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Dec-19 | 22,416 | ${ }_{\text {\$3533.18 }}$ | ${ }^{5137.96}$ | \$12.28 | ${ }_{5} 541.12$ | \$544.54 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Jan-20 feb-20 | 22,029 21,916 | \$327.47 $\$ 382.75$ | ${ }_{\substack{\text { S }}}^{\$ 131.52}$ | \$15.06 $\$ 14.10$ | \$37.86 <br> $\$ 22.58$ | \$511.91 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mar-20 | ${ }_{21,897}$ | ${ }_{\text {S }}$ | ${ }_{\text {S100.43 }}$ | \$13.70 | ${ }_{\text {\$23.58 }}$ | ${ }_{\text {S391.54 }}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Apr-20 | 21,841 | \$202.44 | \$61.83 | \$15.05 | \$28.24 | \$307.55 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| May-20 | ${ }^{21,746}$ | ${ }_{5}^{5312.79}$ | \$99.12 | \$15.51 | \$28.65 | 5456.07 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Jun-20 | 21,688 | ${ }_{\text {S }} \mathbf{5 3 5 7 . 7 7}$ | ${ }^{5124.51}$ | \$15.02 | \$39.22 | \$536.51 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Jul-20 Aug-20 | 21,579 | \$371.70 $\$ 386.11$ | ${ }_{\text {S }} \mathbf{5 1 2 4 . 3 9}$ | $\$ 14.97$ $\$ 14.80$ | ${ }_{\text {S }}^{5431.12}$ | \$554.19 <br> 558.98 |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sep-20 | 21,553 | \$366.88 | \$140.72 | \$15.97 | \$35.15 | \$558.71 | \$338.06 | \$122.54 | \$14.62 | \$34.50 | \$509.72 |  |  |  |  | 1.00 | 1.0000 | 1.0000 | 1.0000 |
| Oct-20 | 21,561 | \$314.23 | \$128.74 | \$16.48 | \$30.82 | \$490.27 | \$333.25 | \$121.30 | \$14.74 | \$33.66 | \$502.96 |  |  |  |  | 0.88 | 1.0143 | 1.0144 | 1.0144 |
| Nov-20 | 21,626 | \$305.75 | \$129.92 | \$16.72 | \$36.98 | 5489.37 | \$327.82 | \$120.10 | \$14.96 | \$33.26 | \$496.15 |  |  |  |  | 0.88 | 1.0151 | 1.0152 | 1.0151 |
| Dec-20 | 21,615 | \$352.24 | \$135.52 | \$16.50 | \$40.75 | \$545.01 | \$327.67 | \$119.84 | \$15.32 | 53.20 | 5496.04 |  |  |  |  | 0.98 | 1.0158 | 1.0159 | 1.0159 |
| Jan-21 | 22,145 | \$392.12 | \$141.50 | \$18.16 | \$41.15 | 5592.94 | \$333.16 | \$120.70 | \$15.58 | 53.49 | \$502.93 |  |  |  |  | 1.06 | 1.0367 | 1.0381 | 1.0368 |
| ${ }^{\text {Feb-21 }}$ | 22,043 | ${ }^{5386.47}$ | \$136.62 | ${ }_{517.10}$ | \$ 51.56 | \$571.75 | \$333.50 | \$120.78 | \$15.84 | \$34.24 | \$504.35 |  |  |  |  | 1.02 | 1.0374 | ${ }_{1}^{1.0387}$ | 1.0374 |
| Mar-21 | $\stackrel{21,999}{ }$ | ${ }_{5}^{5363.86}$ | ${ }_{\text {S }}$ \$14.03 | \$18.17 | \$38.70 | \$564.76 | \$342.75 | \$124.45 | ${ }_{\$ 16.21}$ | ${ }_{53551}$ | \$518.913 |  |  |  |  | ${ }_{1}^{1.01}$ | ${ }^{1.0380}$ | 1.0394 | ${ }^{1.0380}$ |
| Apr-21 | 22,006 | 5397.52 | \$142.50 | \$16.91 | \$31.21 | 5588.14 | \$359.10 | \$131.21 | \$16.37 | \$35.76 | \$542.43 |  |  |  |  | 1.05 | 1.0386 | 1.0400 | 1.0387 |
| May-21 | 22,027 | 5449.87 | \$157.31 | \$16.46 | \$35.13 | \$658.76 | \$370.60 | \$136.08 | \$16.45 | \$36.30 | \$559.42 |  |  |  |  | 1.18 | 1.0446 | 1.0460 | 1.0446 |
| Jun-21 | 22,092 | \$354.48 | \$137.88 | \$15.31 | \$34.39 | \$542.06 | \$370.31 | \$137.19 | \$16.47 | \$35.89 | \$559.85 |  |  |  |  | 0.97 | 1.0452 | 1.0466 | 1.0453 |
| Jul-21 | 22,080 | \$330.48 | \$131.96 | \$14.49 | 549.53 | \$526.46 | \$366.84 | \$137.80 | \$16.43 | \$36.45 | \$557.51 |  |  |  |  | 0.94 | 1.0507 | 1.0543 | 1.0530 |
| Aug 21 | 22,031 | \$344.56 | S134.46 $\$ 15098$ | \$14.38 | \$40.53 |  | \$ $\$ 363.39$ | \$138.46 $\$ 13932$ | \$16.39 |  | \$555.41 $\$ 558.57$ |  |  |  |  | 0.96 1.07 | 1.0513 10519 | 1.0550 1.0556 | 1.0536 1.0543 1 |
| Sep-21 Oct-21 | 22,022 21,960 | ${ }_{\text {\$ }}^{\$ 3840.69}$ | \$150.98 $\$ 153.13$ | $\$ 16.59$ $\$ 16.84$ | $\$ 44.19$ $\$ 3.85$ | \$596.46 | ${ }_{\text {\$364.83 }}$ | $\underset{\substack{\text { S13932 } \\ \text { S14, }}}{\text { S }}$ | $\underset{\$ 16.44}{\$ 16.47}$ | ${ }_{538.17}^{\$ 37.93}$ | \$558.57 |  |  |  |  | 1.07 1.03 | 1.0519 1.0597 | 1.0556 1.0634 | 1.0543 1.0621 1 |
| Nov-21 | 21,832 | \$426.24 | \$164.46 | \$17.34 | 54.67 | \$654.71 | \$379.45 | \$144.19 | \$16.52 | \$38.97 | \$579.12 |  |  |  |  | 1.17 | 1.0604 | 1.0641 | ${ }^{1.0627}$ |
| Dec. 21 | 21,938 | \$315.24 | \$133.25 | \$15.39 | \$38.96 | \$502.84 | \$376.34 | \$143.99 | \$16.43 | \$33.82 | \$575.58 |  |  |  |  | 0.90 | 1.0610 | 1.0647 | 1.0633 |
| Jan-22 | 25,937 | \$309.77 | \$129.17 | \$17.66 | \$36.30 | \$492.90 | \$368.59 | \$142.76 | \$16.40 | \$38.38 | \$566.14 |  |  |  |  | 0.88 | 1.0809 | 1.0858 | 1.0833 |
| Feb-22 | 26,010 | \$350.82 | \$132.49 | \$17.58 | \$37.08 | \$537.97 | \$365.45 | \$142.27 | \$16.46 | \$38.81 | \$562.99 |  |  |  |  | 0.96 | 1.0818 | 1.0867 | 1.0842 |
| Mar-22 | 26,089 | \$378.46 | \$152.76 | \$18.35 | ${ }^{511.33}$ | \$580.89 | \$366.80 | \$143.12 | \$16.50 | \$38.11 | \$564.54 |  |  |  |  | 1.04 | 1.0822 | 1.0872 | 1.0846 |
| Apr-22 | 26,124 | \$364.88 | \$142.71 | \$16.90 | \$38.58 | \$563.07 | \$364.21 | \$143.14 | \$16.51 | \$38.70 | \$562.55 |  |  |  |  | 1.01 | 1.0832 | ${ }^{1.0881}$ | 1.0856 |
| May-22 | 26,146 26,231 2621 | \$360.56 | \$151.29 | \$18.15 | \$40.84 | 5570.83 $\$ 55876$ | \$357.24 | \$142.79 $\$ 14249$ | \$16.66 | ${ }_{\text {\% }}^{539.17}$ | $\$ 555.86$ $\$ 55718$ |  |  |  |  | 1.02 1.00 | 1.0837 10959 | 1.0886 1.1009 | 1.0860 <br> 1.0938 <br> 1 |
| Jun-22 Jul-22 | 26,231 | $\underset{\text { S414.71 }}{\$ 37.61}$ | \$135.33 \$142.93 | $\$ 17.32$ $\$ 17.25$ | \$35.50 54.30 | ${ }_{\text {S }}^{5588.769}$ | ${ }_{\text {S }}^{5358.66}$ | \$142.49 $\$ 143.32$ | $\$ 16.82$ $\$ 17.04$ |  | ${ }_{\text {S }}^{5557.18}$ |  |  |  |  | 1.00 1.11 | 1.0959 1.1109 | 1.1009 1.1160 | 1.0983 1.1133 |
| Aug-22 | 26,214 | \$365.97 | \$132.59 | \$16.47 | 54.58 | \$555.61 | \$367.41 | \$143.03 | \$17.19 | \$38.87 | \$566.49 |  |  |  |  | 0.99 | 1.1113 | 1.1164 | 1.1138 |
| Sep-22 | 26,128 | \$375.16 | \$150.20 | \$17.79 | 543.43 | 5586.58 | \$366.82 | \$143.07 | \$17.28 | \$38.87 | \$566.04 |  |  |  |  | 1.05 | 1.1118 | 1.1169 | 1.1143 |
| Oct-22 | 26,174 | \$532.52 | ${ }_{\text {S }}$ \$144.23 | ${ }_{517.65}$ | ${ }_{5} 54.13$ | \$558.52 | \$365.30 | \$142.45 | \$17.35 | ${ }_{539.69}$ | \$564.78 | ${ }_{\$ 372.48}$ | \$144.67 | \$17.60 | \$39.76 | 1.00 | ${ }^{1.1417}$ | 1.1469 | ${ }^{1.1442}$ |
| Nov-22 | 26,242 | \$418.38 | \$156.88 | \$18.25 | \$46.50 | S540.00 <br> S5058 | \$365.50 | \$142.12 | \$17.42 | \$39.77 | \$564.81 $\$ 572.57$ | $\$ 373.36$ |  | $\$ 17.65$ |  | 1.15 | 1.1427 <br> 11435 <br> 1 | ${ }^{1.1479}$ | 1.1452 <br> 1.1460 <br> 1 |
| ${ }^{\text {Dec-22 }}$ Jan-23 | 26,221 <br> 31,237 | \$399.70 $\$ 348.59$ | \$149.78 | \$16.48 $\$ 18.39$ | ${ }_{\text {\$ }}^{\$ 39.81}$ | ${ }_{\substack{\text { S605.78 } \\ \$ 534.55}}^{\text {S }}$ |  | \$143.38 $\$ 143.92$ | \$17.49 $\$ 17.56$ | \$39.83 $\$ 39.20$ | ${ }_{\text {S }}^{55775.53}$ | ${ }_{\$ 3775.12}^{\$ 124}$ | \$145.17 \$145.42 | ${ }_{\text {S }}^{517.70}$ | 540.04 540.18 | 1.08 0.96 | ${ }_{1}^{1.11935}$ | 1.1.187 1.2029 | 1.1460 1.2001 |
| Feb-23 | 31,281 | \$369.22 | \$146.02 | \$18.44 | \$37.61 | \$571.30 | \$376.03 | \$145.04 | \$17.64 | \$39.22 | \$577.94 | \$37.01 | \$145.66 | \$17.81 | \$40.32 | 1.02 | 1.1983 | 1.2037 | 1.2009 |
| Mar-23 | 31,341 | \$383.87 | \$150.71 | \$18.30 | 544.67 | 5597.56 | \$376.59 | \$144.97 | \$17.65 | 540.36 | \$579.57 | \$376.90 | \$145.91 | \$17.86 | \$40.46 | 1.07 | 1.1990 | 1.2044 | 1.2016 |
| Apr.23 | 31,308 | \$385.54 | \$148.17 | \$18.36 | \$37.91 | \$589.97 | \$378.34 | \$145.45 | \$17.78 | \$40.27 | 5581.83 | \$377.79 | \$146.16 | \$17.91 | \$40.61 | 1.06 | 1.1996 | 1.2050 | 1.2022 |
| May-23 | ${ }^{31,363}$ | \$400.32 | \$146.22 | \$19.50 | \$43.14 | \$609.18 | \$381.73 | \$145.07 | \$17.91 | \$40.49 | \$585.20 | \$378.68 | \$146.42 | \$17.96 | \$40.75 | 1.09 | 1.2003 | 1.2057 | 1.2029 |
| Jun-23 | 31,559 | \$347.53 | \$152.61 | \$17.73 | 54.67 | \$562.54 | \$379.45 | \$146.50 | \$17.93 | \$41.25 | \$585.14 | \$379.58 | \$146.67 | \$18.01 | 540.89 | 1.01 | 1.2010 | 1.2064 | 1.2036 |
| Jul-23 | 31,810 | \$388.72 | \$138.40 | \$16.33 | \$40.52 | \$583.97 | \$377.65 | \$146.03 | \$17.84 | \$41.00 | \$582.52 | \$380.47 | \$146.92 | \$18.06 | 541.03 | 1.05 | 1.2168 | 1.2223 | 1.2194 |
| Aug. 23 <br> Spl 23 | 31,921 <br> 31209 | ${ }_{5}^{5881.95}$ |  | \$16.58 $\$ 1842$ | \$34.98 | S572.34 S6601 | 5378.90 $\$ 37736$ | $\$ 146.37$ | $\$ 17.83$ | $540.49$ | $\$ 583.59$ | \$381.37 | $\$ 147.17$ | $\$ 18.11$ | $\begin{array}{r}541.18 \\ \hline 4.182 \\ \hline\end{array}$ | 1.02 | ${ }^{1.2175}$ | 1.2230 1 12237 | ${ }_{1}^{1.2201}$ |
| Sep-23 <br> Oct-23 | 32,094 30,213 | \$358.43 $\$ 377.63$ | S145.76 $\$ 146.84$ | \$18.42 | ${ }_{\text {S43.41 }}$ | S566.01 <br> 583.62 | 5377.36 $\$ 377.92$ | S146.04 \$14.26 | \$17.88 $\$ 17.93$ | S40.54 540.67 | 5581.82 5582.77 | 5382.27 $\$ 37.63$ | \$147.42 $\$ 146.84$ | S18.16 <br> $\$ 18.04$ | $\begin{array}{r}\text { S41.32 } \\ \\ \hline 44.11\end{array}$ | 1.01 1.04 | 1.2182 1.2367 | 1.2237 <br> 1.2424 <br> 1223 | 1.2208 <br> 1.2395 |
| Nov-23 | 30,213 | \$380.85 | \$147.76 | \$18.23 | \$41.64 | \$588.48 | \$378.48 | \$146.48 | \$17.97 | \$40.80 | 5583.73 | \$380.85 | \$147.76 | \$18.23 | \$41.64 | 1.05 | 1.2373 | 1.2431 | 1.2402 |
| Dec.23 | 30,213 | \$381.78 | \$148.04 | \$18.29 | 54.80 | \$589.91 | \$379.04 | \$146.69 | \$18.02 | \$40.94 | \$584.69 | \$381.78 | \$148.04 | \$18.29 | 54.80 | 1.06 | 1.2380 | 1.2438 | 1.2409 |
| Jan-24 | 30,213 | \$381.96 | \$148.07 | \$18.30 | \$41.81 | \$590.14 | \$379.61 | \$146.91 | \$18.06 | \$41.07 | \$585.65 | \$381.96 | \$148.07 | \$18.30 | 54.81 | 1.06 | 1.2556 | 1.2605 | 1.2583 |
| Feb-24 | 30,213 | \$382.84 | \$148.32 | \$18.35 | \$41.95 | \$591.46 | \$380.17 | \$147.13 | \$18.10 | \$41.21 | \$586.61 | \$382.84 | \$148.32 | \$18.35 | \$41.95 | 1.06 | 1.2562 | 1.2611 | 1.2589 |
| Mar-24 | 30,213 | \$383.73 | ${ }_{5148.56}$ | \$18.40 | \$42.09 | \$592.78 | \$380.74 | \$147.35 | \$18.15 | \$41.34 | \$587.58 | ${ }_{\$ 383.73}$ | \$148.56 | \$18.40 | 542.09 | 1.06 | ${ }^{1.2571}$ | ${ }^{1.2620}$ | 1.2598 |
| Apr-24 | ${ }^{30,213}$ | ${ }^{5384.62}$ | \$148.81 | \$18.45 | \$42.24 | \$599.12 | \$381.30 | ${ }_{5147.57}$ | \$18.19 | ${ }_{541.48}$ | \$588.54 | \$384.62 | \$148.81 | \$18.45 | 542.24 | 1.06 | ${ }^{1.2576}$ | ${ }^{1.2626}$ | 1.2603 |
| May 24 | 30,213 | \$385.51 $\$ 38639$ | \$149.05 | 518.50 $\$ 1855$ | \$42.38 | S595.44 <br> 5969 | \$381.87 <br> $\$ 3824$ | \$147.79 | \$18.24 | 541.61 $\$ 4175$ |  | ${ }_{\$ 385651}$ |  | 518.50 <br> $\$ 1855$ | 542.38 <br> 4252 | 1.07 | 1.2581 <br> 1.2586 <br> 1.258 | ${ }^{1.2631}$ | 1.2609 1.2654 1 |
| Jun-24 Jul-24 | 30,213 30,213 | \$386.39 $\$ 387.26$ | \$149.29 \$199.53 | \$18.55 $\$ 18.60$ | ${ }_{5442.55}^{54.52}$ | ( $\begin{gathered}\text { \$596.74 } \\ 5598.04\end{gathered}$ | ${ }_{\text {S }} \mathbf{\$ 8 8 2 . 4 4}$ | ${ }_{\text {S1488.01 }}^{\text {S14, }}$ | $\$ 18.28$ $\$ 18.33$ | \$41.75 $\$ 41.88$ | \$590.48 5591.45 | ${ }_{\$}^{\$ 3868.39}$ | \$149.29 5149.53 | $\$ 18.55$ $\$ 18.60$ | 542.52 <br> $\$ 42.65$ | 1.07 1.07 | ${ }^{1.2586}$ | 1.2636 1.2802 | 1.2614 1.2780 |
| Aug-24 | 30,213 | \$388.15 | \$149.77 | \$18.65 | \$42.79 | \$599.36 | \$383.58 | \$148.45 | ${ }_{\$ 18.37}$ | ${ }_{\text {S42.02 }}$ | \$592.42 | \$388.15 | \$149.77 | \$18.65 | ${ }_{542,79}$ | 1.07 | ${ }_{1}^{1.2757}$ | ${ }_{1}^{1.2887}$ | ${ }_{1}^{1.2785}$ |
| Sep-24 | 30,213 | \$389.04 | \$150.01 | 518.70 | 542.93 | 5600.67 | \$384.15 | \$148.67 | \$18.42 | \$42.16 | \$593.40 | \$389.04 | \$150.01 | 518.70 | 542.93 | 1.08 | 1.2773 | 1.2813 | 1.2790 |
| Oct-24 | 30,213 | \$384.49 | \$199.49 | \$18.59 | 542.77 | 5595.34 | \$384.72 | \$148.89 | \$18.46 | 542.30 | \$594.37 | \$384.49 | \$149.49 | 518.59 | \$42.77 | 1.07 | 1.2993 | 1.3041 | 1.3018 |
| Nov-24 | 30,213 | \$387.72 | \$150.42 | \$18.78 | 543.30 | \$600.22 | \$385.29 | \$199.11 | \$18.51 | \$42.44 | \$595.35 | \$387.72 | \$150.42 | 518.78 | \$43.30 | 1.07 | 1.2998 | 1.3046 | 1.3023 |
| Dec-24 | 30,213 | \$388.66 | \$150.70 | \$18.84 | \$43.47 | \$601.66 | \$385.86 | \$199.34 | \$18.56 | \$42.57 | \$596.33 | \$38.66 | \$150.70 | \$18.84 | \$43.47 | 1.08 | 1.3003 | ${ }^{1.3051}$ | 1.3028 |
| Jan-25 | 30,213 | \$388.85 | \$150.74 | \$18.84 | 543.49 | \$601.92 | \$386.44 | \$199.56 | \$18.60 | 542.71 | \$597.31 | \$388.85 | \$150.74 | \$18.84 | \$43.49 | 1.08 | 1.3308 | 1.3360 | 1.3333 |
| Feb-25 | 30,213 | \$389.74 | \$150.99 | \$18.90 | 543.63 | \$603.26 | \$387.01 | \$199.78 | \$18.65 | \$42.85 | \$598.29 | \$389.74 | \$150.99 | 518.90 | 543.63 | 1.08 | 1.3314 | ${ }^{1.3367}$ | 1.3340 |
| Mar-25 | ${ }^{30,213}$ | \$390.64 | ${ }_{\text {S } 151.23}$ | \$18.95 | 543,78 | \$5604.50 | \$387.59 | \$150.00 | \$18.69 | \$42.99 | \$599.28 | \$390.64 | ${ }_{\text {S151.23 }}$ | \$18.95 | 543,78 | 1.08 | ${ }^{1.3319}$ | ${ }^{1.3372}$ | 1.3345 |
| Apr-25 | 30,213 | 5391.54 | \$151.49 | \$19.00 | 543.93 | \$605.96 | \$388.17 | \$150.23 | \$18.74 | \$43.13 | 5600.27 | \$391.54 | \$151.49 | \$19.00 | 543.93 | 1.08 | ${ }^{1.3324}$ | 1.3377 | ${ }^{1.3350}$ |
| May-25 | 30,213 | \$392.44 | \$151.74 | \$19.05 | \$44.07 | 5567.30 5608.63 |  | \$150.45 $\$ 150.67$ |  |  |  |  |  |  |  | 1.09 | 1.3330 13355 | 1.3383 13388 |  |
| Jun-25 Jul-25 | 30,213 30,213 | ${ }_{\text {\$ }}^{\text {\$3939.33 }}$ | \$151.98 \$152.22 | \$19.10 $\$ 19.15$ | \$44.22 $\$ 4.36$ | \$608.63 5609.94 | \$389.32 $\$ 389.90$ | \$150.67 $\$ 150.90$ | $\$ 18.83$ $\$ 18.88$ | \$43.42 $\$ 43.56$ | 5602.25 <br> 5603.24 | $\underset{\$ 394.21}{\$ 3933}$ | \$151.98 $\$ 152.22$ | $\$ 19.10$ $\$ 19.15$ | 544.22 $\$ 4.36$ | 1.09 1.09 | 1.3335 1.3517 | 1.3388 1.3571 | 1.3361 1.3544 |
| Aug.25 | 30,213 | \$395.11 | \$152.46 | \$19.20 | \$44.50 | \$611.28 | \$390.48 | \$151.12 | \$18.93 | ${ }_{\text {S43.70 }}$ | \$604.23 | \$395.11 | \$152.46 | \$19.20 | \$44.50 | 1.09 1.09 | ${ }_{1}^{1.5523}$ | ${ }_{1.3577}$ | ${ }_{1}^{1.3549}$ |
| Sep-25 | 30,213 | \$396.01 | \$152.71 | \$19.26 | \$44.65 | \$612.62 | \$391.06 | \$151.35 | \$18.97 | \$43.85 | \$605.23 | \$396.01 | \$152.71 | \$19.26 | 54.65 | 1.10 | 1.3528 | 1.3582 | 1.3554 |
| Ott-25 | 30,213 | \$391.47 | \$152.20 | \$19.15 | 544.49 | \$607.30 | \$391.64 | \$151.57 | \$19.02 | \$43.99 | 5606.22 | \$391.47 | \$152.20 | \$19.15 | \$44.49 | 1.09 | ${ }^{1.3773}$ | 1.3828 | 1.3799 |
| Noo-25 | ${ }^{30,213}$ | \$394.71 | \$153.13 | \$19.34 | 545.03 | ${ }_{\text {S } 51212.21}$ | \$392.23 | \$151.80 $\$ 152028$ |  | 544.13 | 5607.22 $\$ 608.22$ |  |  | \$19.34 |  |  | 1.3778 <br> 1783 | 1.3833 1.8388 1 |  |
| Dec-25 Jan-26 | 30,213 | \$395.66 $\$ 395.86$ | \$153.41 \$153.45 | \$19.40 | 545.20 $\$ 45.22$ | ${ }_{\text {S613135 }}{ }_{\text {S6137 }}$ | \$39281 $\$ 3939$ | \$152.02 $\$ 152.25$ | \$19.11 | \$44.28 $\$ 44.42$ | 5608.22 5609.23 | \$395.66 $\$ 395.86$ | ${ }_{\text {\$153.41 }}$ | $\$ 19.40$ $\$ 19.41$ | \$45.20 S45.22 | 1.10 1.10 | 1.3783 1.4107 | 1.3838 1.4168 | 1.3810 1.4135 |
| Feb-26 | 30,213 | \$396.77 | \$153.70 | \$19.46 | \$45.38 | \$615.31 | \$393.98 | \$152.48 | \$19.21 | 544.57 | \$610.23 | \$396.77 | \$153.70 | \$19.46 | \$45.38 | 1.10 | ${ }_{1.4113}$ | ${ }_{1.4173}$ | ${ }_{1.4140}^{1.418}$ |
| Mar-26 | 30,213 | \$397.67 | \$153.96 | \$19.52 | 545.53 | \$616.67 | \$394.57 | \$152.70 | \$19.25 | \$44.71 | \$611.24 | \$397.67 | \$153.96 | \$19.52 | 545.53 | 1.10 | ${ }^{1.4118}$ | 1.4179 | 1.4146 |
| Apr-26 | 30,213 | \$398.59 | \$154.21 | \$19.57 | 545.68 | \$618.05 | \$395.15 | \$152.93 | \$19.30 | \$44.86 | \$612.25 | \$398.59 | \$154.21 | \$19.57 | 545.68 | 1.11 | ${ }^{1.4123}$ | 1.4184 | ${ }^{1.4151}$ |
| May-26 | ${ }^{30,213}$ | \$399.50 | \$154.47 | \$19.62 | 545.84 | 5619.42 | \$395.74 | \$153.16 | \$19.35 | \$45.01 | ${ }_{5}^{5613.25}$ | \$399.50 | \$154.47 | \$19.62 | 545.84 | 1.11 | 1.4129 | ${ }^{1.4190}$ |  |
| Jun-26 <br> Jul-26 | 30,213 30,213 | \$400.39 $\$ 401.29$ | \$154.71 \$154.96 | \$19.68 S19.73 | $\begin{aligned} & \$ 45.98 \\ & 546.13 \end{aligned}$ | 5620.77 5622.11 | \$396.33 $\$ 396.92$ | \$153.39 $\$ 153.61$ | \$19.40 | ( ${ }_{545.15}$ | $5614.27$ | \$400.39 5401.29 | \$154.71 | S19.68 ¢19.73 | 545.98 546.13 | 1.11 1.11 | 1.1434 | ${ }_{1.4395}^{1.495}$ | 1.1462 |
|  | 30,213 | \$401.29 | \$154.96 | \$19.73 | 546.13 |  | 5396.92 |  |  |  |  | \$401.29 |  | \$19.73 |  | 1.11 | 1.4333 | 1.4395 | 1.4361 |
|  |  |  |  |  | Trend |  |  |  |  |  |  | Smoothing Statistics <br> The monthly PMPMs were fit to average to the rolling 12 PMPM and be sloped with the YE 202309 monthly trend |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  | 1.80\% | 1.80\% | 3.00\% | 4.00\% |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | 1.0024 | 1.0017 | 1.0029 | 1.0428 <- YE 202309 Trend <br> 1.0035 <- Monthly Trend |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | 1.0024 | 1.0017 | 1.0029 | 1.0035 <- Smth Monthly Trend <br> 0.0000 <- Recon |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | ${ }^{0.0000}$ | 0.0000 | ${ }^{0.0000}$ |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | ${ }_{\text {\% }} \$ 377.36$ | ${ }^{5146.04}$ | 517.88 $\$ 1788$ | \$40.54 <- YE 202309 PMPM <br> \$40.54 <- Avg Smth PMPM |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  | \$377.36 0.0000 | S146.04 0.0000 | \$17.88 0.0000 |  |  |  |  |  |

MONTHLYTREND FACTOR Development

| Month | $\begin{array}{\|c\|c\|c\|c\|c\|c\|:\|l\|l\|} \hline \text { Mass } \begin{array}{c} \text { Cross } \\ \text { Managed } \end{array} \\ \hline \end{array}$ | $\begin{gathered} \hline \text { Medical - Blue } \\ \text { Cross VT Non- } \\ \text { Managed } \end{gathered}$ | Medical - TVHP | Pharmacy | Medicare Primary Medica |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| September 2020 October 2020 | 1.0000 0.8901 | 1.0000 | 1.0000 | ${ }^{1.0000}$ | 1.0000 1.0063 |
| October 2020 November 2020 | ${ }^{0.8901}$ |  | ${ }_{0.8891}$ | 1.01771.0171 | ${ }_{1.0127}^{1.0063}$ |
| December 2020 | 0.9909 | ${ }_{0}^{0.8992}$ | 0.8891 0.9910 |  | 1.0127 <br> 1.0191 |
|  | 1.1002 | ${ }_{1.1017}^{0.9910}$ | 0.9910 1.1003 | ${ }_{1.0207}^{1.071}$ | 1.0291 1.0257 |
| February 2021 | ${ }_{1}^{1.0616}$ | ${ }^{1.0630}$ | ${ }^{1.0616}$ | 1.0207 1.0269 | $1.0324$ |
| March 2021 | 1.04921.0933 |  |  | 1.0344 |  |
| April 2021 |  | 1.0506 1.0948 | 1.0493 1.0934 1.0 | 1.0589 | $\begin{aligned} & 1.0392 \\ & 1.0460 \end{aligned}$ |
| May 2021 | ${ }_{1.2316}^{1.093}$ | ${ }_{1}^{1.20938}$ | ${ }_{1}^{1.0934}$ | ${ }^{1.0792}$ | $\begin{aligned} & 1.0460 \\ & { }_{1.0528} \end{aligned}$ |
| June 2021 | 1.0140 | 1.0154 | 1.0141 | $\begin{aligned} & 1.1019 \\ & 1.0958 \end{aligned}$ |  |
| July 2021 | 1.0490 0.9900 | ${ }_{0}^{1.09935}$ | 0.9922 |  | $\begin{aligned} & 1.0596 \\ & 1.0666 \end{aligned}$ |
| Augus 2021 | $\begin{aligned} & 1.0047 \\ & 1.1230 \end{aligned}$ | 1.08821.1269 | 1.00691.1255 | ${ }_{1}^{1.1077}$ | 1.0666 1.0735 |
| September 2021 |  |  |  | 1.12001.1200 | $\begin{aligned} & 1.0 .085 \\ & 1.0876 \end{aligned}$ |
| October 2021 | 1.0900 | ${ }^{1.1 .9938}$ | ${ }_{1} 1.0924$ |  |  |
| November 2021 | 1.22460.9549 | 1.2469 | 1.2453 | ${ }_{1}^{1.11243}$ | $\begin{aligned} & 1.0876 \\ & 1.0947 \end{aligned}$ |
| December 2021 |  |  | 0.95700.9557 | 1.14601.1492 | $\begin{aligned} & 1.097 \\ & 1.1028 \end{aligned}$ |
| January 2022 | ${ }_{0}^{1.9549}$ | 0.9582 0.9579 |  |  | $\begin{aligned} & 1.1 .1900 \\ & 1.16160 \end{aligned}$ |
| February 2022 | $\begin{aligned} & 1.0416 \\ & { }_{1.1252} \end{aligned}$ | 1.04641.1303 | 1.04391.1277 | 1.1525 |  |
| March 2022 |  |  |  | 1.1 .15641.1512 | ${ }_{1}^{1.11262}$ |
| April 2022 | ${ }_{1.0916}^{1.1526}$ | ${ }_{1.0966}^{1.1503}$ | 1.0941 |  | 1.1308 |
| May 2022 | $\begin{aligned} & 1.1 .072 \\ & 1.0960 \end{aligned}$ | 1.11221.120 | 1.1096 | 1.1557 | 1.11382 <br> 1.1487 <br> 1.145 |
| June 2022 |  |  | 1.0984 | 1.1585 |  |
| July 2022 | ${ }_{1}^{1.2301}$ | 1.1010 <br> 1.2358 <br> 1 |  | 1.1717 | 1.1531 |
|  | $\begin{aligned} & 1.1052 \\ & { }_{11.672} \end{aligned}$ | 1.1102 | 1.1076 | ${ }_{1}^{1.1 .2027}$ | $\begin{aligned} & 1.1606 \\ & { }_{1.1682} \end{aligned}$ |
| September 2022 |  | $\begin{aligned} & 1.1 .126 \\ & { }_{1.1465} \end{aligned}$ | $\begin{aligned} & 1.1698 \\ & 1.1438 \end{aligned}$ |  |  |
| October 2022 | ${ }_{1.1413}^{1.17272}$ |  |  | 1.2238 | ${ }^{1.17588}$ |
| (exember 20222 | ${ }^{1.1 .1423}$ | 1.1465 1.3149 | 1.14388 1.3118 | 1.23231.2405 | $1.1835$ |
|  | $\begin{aligned} & 1.2398 \\ & { }_{1.1459} \end{aligned}$ | $1.2454$ | $1.2425$ |  |  |
| January 2023 |  |  |  | 1.2539 | $\begin{aligned} & 1.1912 \\ & { }_{1.1976} \end{aligned}$ |
| February 2023 March 2023 | 1.22533 | $\begin{aligned} & 1.1 .151 \\ & 1.2308 \end{aligned}$ | $\begin{aligned} & 1.1484 \\ & 1.2279 \end{aligned}$ | 1.26241.2778 | $\begin{aligned} & 1.2039 \\ & { }_{1.2103} \end{aligned}$ |
|  |  | 1.2388 1.2881 | ${ }_{1}^{1.28751}$ |  |  |
| April 2023 | ${ }_{1.2667}^{1.283}$ | ${ }_{1.2725}^{1.281}$ | ${ }_{1.2695}$ | 1.2903 | ${ }_{1.21288}^{1.203}$ |
| $\begin{array}{\|l\|l} \text { May } 2023 \\ \text { June } 2023 \end{array}$ | $\begin{aligned} & 1.3087 \\ & 1.2092 \end{aligned}$ | $\begin{aligned} & 1.3146 \\ & 1.2147 \end{aligned}$ | $\begin{aligned} & 1.3115 \\ & 1.218 \end{aligned}$ | 1.3135 |  |
|  |  |  |  |  |  |
| July 2023 | ${ }_{1.2718}^{1.2092}$ | ${ }_{1}^{1.2776}$ | 1.2746 | ${ }_{1}^{1.3516}$ | $\begin{aligned} & 1.2298 \\ & 1.2363 \end{aligned}$ |
| Ausust 2023September 2023 | $\begin{aligned} & 1.2472 \\ & { }_{1.2341} \end{aligned}$ | $\begin{aligned} & 1.2528 \\ & 1.2396 \end{aligned}$ | $\begin{aligned} & 1.249 \\ & 1.2367 \end{aligned}$ | ${ }_{1}^{1.3637}$ | 1.24291.2495 |
|  |  |  |  |  |  |
| October 2023 | ${ }_{1.2918}^{1.231}$ | ${ }^{1.22996}$ | ${ }_{1.2947}^{1.257}$ | 1.3856 | 1.2562 |
| November 2023 <br> Deeember 2023 | $\begin{aligned} & 1.3033 \\ & 1.3072 \end{aligned}$ | $\begin{aligned} & 1.3093 \\ & 1.3132 \end{aligned}$ | $\begin{aligned} & 1.3066 \\ & 1.3101 \end{aligned}$ | ${ }_{1.4108}^{1.392}$ | 1.2628 |
|  |  |  |  |  | 1.2696 |
| January 2024 | ${ }^{1.3262}$ | 1.3314 | 1.3290 | 1.3758 | 1.2763 |
| February 2024 | ${ }^{1.3298}$ | 1.3350 | ${ }^{1.3327}$ | ${ }^{1.3883}$ | 1.2831 |
| March 2024 | 1.3338 | 1.3390 | 1.3366 | 1.4008 | 1.2899 |
| April 2024 | 1.3373 | 1.3426 | 1.3402 | 1.4135 | 1.2968 |
| May 2024 | ${ }^{1.3408}$ | 1.3461 | 1.3437 | 1.4262 | 1.3037 |
| June 2024 | ${ }^{1.3443}$ | ${ }^{1.3496}$ | 1.3472 | ${ }^{1.4391}$ | ${ }^{1.3106}$ |
| July 2024 | 1.3650 | ${ }^{1.3703}$ | 1.3679 | 1.4521 | ${ }^{1.3176}$ |
| August 2024 | ${ }^{1.3685}$ | ${ }^{1.3739}$ | ${ }^{1.3775}$ | 1.4652 | ${ }^{1.13246}$ |
| September 2024 | +1.3721 | 1.3775 1.3896 | 1.3751 13871 | ${ }^{1.4785}$ | ${ }_{1}^{1.33387}$ |
| November 2024 | ${ }_{1}^{1.3964}$ | ${ }_{1}^{1.4015}$ | ${ }_{1}^{1.3990}$ | ${ }_{1.5053}$ | ${ }_{1.3459}$ |
| December 2024 | 1.4003 | 1.4055 | 1.4030 | 1.5189 | 1.3530 |
| Januar 2025 | 1.4337 | 1.4394 | 1.4365 | ${ }^{1.5327}$ | 1.3602 |
| February 2025 | ${ }_{1}^{1.4375}$ | 1.4433 | ${ }^{1} .4404$ | ${ }^{1.5465}$ | ${ }^{1.3675}$ |
| March 2025 <br> April 2025 | -1.4413 | 1.4470 1.4509 | 1.4441 1.4479 | 1.5605 1.5746 | 1.3747 1.3820 |
| May 2025 | 1.4489 | ${ }_{1.4547}$ | ${ }_{1.4517}$ | 1.5588 | 1.3894 |
| June 2025 | 1.4526 | 1.4584 | 1.4555 | 1.6032 | ${ }_{1} .3968$ |
| Jul 2025 | 1.4757 | 1.4816 | 1.4786 | 1.6177 | 1.4042 |
| Augus 2025 | ${ }^{1.4795}$ | 1.4854 | ${ }^{1.48824}$ | ${ }^{1.6323}$ | ${ }_{1}^{1.4117}$ |
| September 2025 | ${ }_{1.4971}^{1.4833}$ | 1.4892 1.5030 | 1.4862 1.5000 | 1.6470 1.6619 | ${ }_{1.4268}^{1.4192}$ |
| November 2025 | ${ }_{1}^{1.5097}$ | ${ }_{1.5157}$ | ${ }_{1.5127}$ | 1.6769 | ${ }_{1.4343}^{1.4283}$ |
| December 2025 | 1.5139 | 1.5200 | 1.5169 | 1.6921 | 1.4420 |
| January 2026 | 1.5502 | 1.5569 | 1.5532 | 1.7074 | 1.4496 |
| February 2026 | 1.5542 | 1.5609 | ${ }^{1.5573}$ | 1.7228 | 1.4574 |
| March 2026 | 1.5582 | 1.5650 | 1.5613 | 1.7384 | 1.4651 |
| April 2026 | 1.5623 | 1.5691 | 1.5654 | 1.7541 | 1.4729 |
| May 2026 | 1.5664 | ${ }^{1.5731}$ | ${ }^{1.5695}$ | 1.7699 | 1.4887 |
| June 2226 | 1.5774 | 1.5772 | 1.5735 | 1.7859 | ${ }^{1.4886}$ |
| July 2026 | 1.5959 | 1.6028 | 1.5991 | 1.8021 | 1.4965 |
|  |  |  |  |  |  |
| YE 202309 Factor | 1.24 | 1.25 | 1.24 | 1.29 | 1.21 |
| YE 202512 factor | 1.47 | 1.47 | 1.47 | 1.61 | 1.40 |
| Allowed Trend fator | 1.1839 | 1.1833 | 1.1837 | 1.2461 | 1.1544 |
| Annual $T$ Tend | 7.8\% | 7.8\% | 7.8\% | 10.3\% | 6.6\% |

AMP Cap Factor Development


| Ingredient Cost Change | $(\$ 2,148,447)$ |
| :--- | ---: |
| Member Months | 378,552 |
| Non-Specialty Adjustment | $(\$ 5.68)$ |


| Rebate Change | $(\$ 2,373,874)$ |
| :--- | ---: |
| Member Months | 378,552 |
| Rebate Adjustment | $\$ 6.27$ |

Claims are from pharmacy trend base members with incurred dates from January 2023 - September 2023, converted to an annual amount as the PBM modeling was based off 2023 costs.

Vermont Freedom Plan (VFP) and Comprehensive (COMP)

|  |  | In-Network Benefits |  |  |  |  |  |  | Out-of-Network Benefits |  |  | Relativity Factor |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| index | Product | Deductible | Coinsurance | Out-of-Pocket | Office Copay | Specialist Copay | $E R^{1}$ Copay | AMB <br> Copay | Deductible | Coinsurance | Out-ofPocket | Active |
| 1 | VFP | \$200 | 20\% | \$800 | \$20 | \$20 |  |  | \$400 | 30\% | \$1,600 | 1.0071 |
| 2 | VFP | \$300 | 10\% | \$1,300 | \$10 | \$30 | \$100 | \$50 | \$600 | 30\% | \$2,600 | 0.9919 |
| 3 | VFP | \$500 | 20\% | \$1,500 | \$20 | \$20 |  |  | \$1,000 | 30\% | \$3,000 | 0.9541 |
| 4 | VFP | \$500 | 20\% | \$1,500 | \$20 | \$40 | \$250 | \$250 | \$1,000 | 30\% | \$3,000 | 0.9542 |
| 5 | VFP | \$500 | 20\% | \$1,750 | \$20 | \$20 |  |  | \$1,000 | 30\% | \$3,500 | 0.9440 |
| 6 | VFP | \$1,000 | 20\% | \$2,300 | \$20 | \$20 | \$100 |  | \$2,000 | 30\% | \$4,600 | 0.9161 |
| 7 | VFP | \$1,000 | 0\% | \$2,350 | \$25 | \$25 | \$50 | \$50 | \$2,000 | 30\% | \$3,500 | 0.9576 |
| 8 | VFP | \$1,000 | 20\% | \$3,500 | \$25 | \$40 |  |  | \$2,000 | 30\% | \$7,000 | 0.8596 |
| 9 | VFP | \$1,000 | 0\% | \$2,000 | \$30 | \$50 | \$150 |  | \$2,000 | 30\% | \$4,000 | 0.9368 |
| 10 | VFP | \$1,500 | 20\% | \$3,000 | \$25 | \$45 | \$250 | \$250 | \$3,000 | 30\% | \$6,000 | 0.8712 |
| 11 | VFP | \$2,000 | 30\% | \$3,500 | \$20 | \$20 | \$500 |  | \$3,000 | 50\% | \$6,000 | 0.8454 |
| 12 | VFP | \$2,000 | 20\% | \$4,000 | \$40 | \$40 | \$150 |  | \$4,000 | 30\% | \$8,000 | 0.8315 |
| 13 | VFP | \$2,500 | 20\% | \$5,000 | \$20 | \$20 |  |  | \$5,000 | 30\% | \$10,000 | 0.8005 |
| 14 | VFP | \$2,500 | 20\% | \$5,150 | \$20 | \$40 |  |  | \$5,000 | 30\% | \$10,300 | 0.7810 |
| 15 | VFP | \$2,500 | 20\% | \$6,000 | \$20 | \$30 |  |  | \$5,000 | 30\% | \$12,000 | 0.7731 |
| 16 | VFP | \$3,000 | 0\% | \$3,000 | \$30 | \$40 | \$200 |  | \$6,000 | 30\% | \$6,000 | 0.8587 |
| 17 | VFP | \$3,000 | 0\% | \$4,000 | \$30 | \$50 | \$150 |  | \$6,000 | 30\% | \$8,000 | 0.8361 |
| 18 | VFP | \$4,000 | 0\% | \$5,000 | \$30 | \$50 | \$150 |  | \$8,000 | 30\% | \$10,000 | 0.8015 |
| 19 | VFP | \$4,000 | 20\% | \$6,000 | \$40 | \$40 | \$150 |  | \$8,000 | 30\% | \$12,000 | 0.7632 |
| 20 | VFP | \$5,000 | 0\% | \$5,000 | \$25 | \$25 |  |  | \$10,000 | 30\% | \$10,000 | 0.7586 |
| 21 | COMP | \$2,000 | 10\% | \$3,000 |  |  |  |  |  |  |  | 0.8234 |
| 22 | COMP | \$3,000 | 0\% | \$3,000 |  |  |  |  |  |  |  | 0.7970 |
| 23 | COMP | \$5,000 | 0\% | \$5,000 |  |  |  |  |  |  |  | 0.7074 |
| 24 | COMP | \$6,550 | 0\% | \$6,550 |  |  |  |  |  |  |  | 0.6578 |
| 25 | COMP | \$6,850 | 0\% | \$6,850 |  |  |  |  |  |  |  | 0.6495 |
| 26 | COMP | \$7,350 | 0\% | \$7,350 |  |  |  |  |  |  |  | 0.6366 |

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at $100 \%$.

Vermont Health Partnership (VHP) Medical Plans

|  |  | VHP In-Network Benefits |  |  |  |  |  |  | VHP Out-of-Network Benefits |  |  | Relativity Factor |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| index | Product | IP | OP | PCP | SCP | ER | AMB | OOPM | Deductible | Coinsurance | Out-of-Pocket | Active |
| 1 | VHP ${ }^{1}$ | \$0 | \$0 | \$10 | \$20 | \$50 | \$50 | \$9,450 | \$500 | 30\% | \$18,900 | 0.9644 |
| 2 | VHP ${ }^{1}$ | \$250 | \$100 | \$15 | \$25 | \$50 | \$50 | \$9,450 | \$500 | 30\% | \$18,900 | 0.9527 |
| 3 | $V H P^{1}$ | \$250 | \$125 | \$20 | \$40 | \$150 | \$0 | \$9,450 | \$500 | 30\% | \$18,900 | 0.9317 |
| 4 | $V H P^{1}$ | \$250 | \$250 | \$20 | \$20 | \$200 | \$100 | \$9,450 | \$1,000 | 30\% | \$18,900 | 0.9389 |
| 5 | $V H P^{1}$ | \$500 | \$250 | \$20 | \$30 | \$100 | \$0 | \$9,450 | \$500 | 30\% | \$18,900 | 0.9379 |
| 6 | VHP ${ }^{1}$ | \$750 | \$750 | \$20 | \$30 | \$50 | \$50 | \$9,450 | \$500 | 30\% | \$18,900 | 0.9281 |


| PCP | Primary Care Physician Copay |
| :--- | :--- |
| SCP | Specialist Physician Copay |
| IP | Inpatient Care Deductible (max of 3/yr per family) |
| OP | Outpatient Surgery Copay |
| ER | Emergency Room Copay |
| AMB | Ambulance Copay |
| OOPM | Per ACA, all copays accumulate toward the Out of Pocket Maximum |

1. All VHP Plans have a DME rider benefit of: $\$ 100$ deductible, $20 \%$ coinsurance, built into the relativity
2. ER Copay: the displayed member copay goes toward the facility allowed charges

Associated physician and ancillary charges are the covered at $100 \%$.

BENEFIT PLAN RELATIVE VALUE FACTORS
Prescription Drug Cards

|  |  |  | Copay (\$) / Coinsurance (\%) |  |  |  |  |  |  |  | Relativity |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Index | Type | Deductible | Retail <br> Generic | Retail Preferred Brand | Retail NonPreferred Brand | Mail Order Generic | Mail Order <br> Preferred Brand | Mail Order NonPreferred Brand | OOPM | Diabetic Supplies | Active |
| 1 | CM1 | \$100 | \$5 | 40\% | 60\% | \$10 | 40\% | 60\% | \$1,600 | SAAO | 0.2588 |
| 2 | CM2 | \$0 | \$5 | \$50 | 50\% | \$10 | \$100 | 50\% | \$1,600 | SAAO | 0.2559 |
| 3 | CM2 | \$100 | \$5 | \$50 | 50\% | \$10 | \$100 | 50\% | \$1,600 | SAAO | 0.2489 |
| 4 | COI | \$0 | 30\% | 30\% | 40\% | 30\% | 30\% | 40\% | \$1,600 | SAAO | 0.2696 |
| 5 | COI | \$0 | 50\% | 50\% | 50\% | 50\% | 50\% | 50\% | \$1,600 | SAAO | 0.2583 |
| 6 | COP | \$0 | \$10 | \$20 | \$40 | \$20 | \$40 | \$80 | \$1,600 | SAAO | 0.2834 |
| 7 | COP | \$0 | \$10 | \$25 | \$50 | \$20 | \$50 | \$100 | \$1,600 | SAAO | 0.2773 |
| 8 | COP | \$0 | \$10 | \$30 | \$50 | \$20 | \$60 | \$100 | \$1,600 | SAAO | 0.2716 |
| 9 | COP | \$0 | \$10 | \$30 | \$60 | \$20 | \$60 | \$120 | \$1,600 | SAAO | 0.2714 |
| 10 | COP | \$0 | \$10 | \$35 | \$60 | \$20 | \$70 | \$120 | \$1,600 | SAAO | 0.2660 |
| 11 | COP | \$0 | \$15 | \$25 | \$40 | \$30 | \$50 | \$80 | \$1,600 | SAAO | 0.2777 |
| 12 | COP | \$0 | \$15 | \$30 | \$45 | \$30 | \$60 | \$90 | \$1,600 | SAAO | 0.2719 |
| 13 | COP | \$0 | \$15 | \$35 | \$50 | \$30 | \$70 | \$100 | \$1,600 | SAAO | 0.2663 |
| 14 | COP | \$0 | \$20 | \$40 | \$60 | \$40 | \$80 | \$120 | \$1,600 | SAAO | 0.2628 |
| 15 | COP | \$0 | \$20 | \$40 | \$80 | \$40 | \$80 | \$160 | \$1,600 | SAAO | 0.2626 |
| 16 | COP | \$0 | \$25 | \$50 | \$75 | \$50 | \$100 | \$150 | \$1,600 | SAAO | 0.2551 |
| 17 | COP | \$0 | \$5 | \$15 | \$30 | \$10 | \$30 | \$60 | \$1,600 | SAAO | 0.2937 |
| 18 | COP | \$0 | \$5 | \$30 | \$50 | \$10 | \$60 | \$100 | \$1,600 | SAAO | 0.2755 |
| 19 | COP | \$50 | \$10 | \$25 | \$50 | \$20 | \$50 | \$100 | \$1,600 | SAAO | 0.2743 |
| 20 | COP | \$50 | \$5 | \$10 | \$25 | \$10 | \$20 | \$50 | \$1,600 | SAAO | 0.2956 |
| 21 | COP | \$100 | \$10 | \$15 | \$30 | \$20 | \$30 | \$60 | \$1,600 | SAAO | 0.2836 |
| 22 | COP | \$100 | \$10 | \$25 | \$45 | \$20 | \$50 | \$90 | \$1,600 | SAAO | 0.2716 |
| 23 | COP | \$100 | \$10 | \$30 | \$45 | \$20 | \$60 | \$90 | \$1,600 | SAAO | 0.2662 |
| 24 | COP | \$100 | \$10 | \$30 | \$50 | \$20 | \$60 | \$100 | \$1,600 | 100\% | 0.2712 |
| 25 | COP | \$100 | \$10 | \$30 | \$50 | \$20 | \$60 | \$100 | \$1,600 | SAAO | 0.2661 |
| 26 | COP | \$100 | \$10 | \$40 | \$60 | \$20 | \$80 | \$120 | \$1,600 | SAAO | 0.2557 |
| 27 | COP | \$100 | \$15 | \$30 | \$45 | \$30 | \$60 | \$90 | \$1,600 | SAAO | 0.2673 |
| 28 | COP | \$100 | \$15 | \$40 | \$60 | \$30 | \$80 | \$120 | \$1,600 | SAAO | 0.2568 |
| 29 | COP | \$100 | \$5 | \$20 | \$40 | \$10 | \$40 | \$80 | \$1,600 | SAAO | 0.2789 |
| 30 | COP | \$150 | \$20 | \$80 | \$100 | \$40 | \$160 | \$200 | \$1,600 | SAAO | 0.2362 |

[^15] If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

Blue Cross VT Indemnity Consumer Driven Health Plans (CDHPs)

|  |  | In-Network |  |  |  |  |  |  | Relativity Factor |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| index | Product | Deductible | Coinsurance | Out-of-Pocket | RX OOPM Limit $^{1}$ | Wellness Rx ${ }^{2}$ | Drugs After <br> Deductible ${ }^{3}$ | Diabetic Supplies | Active |
| 1 | CDHP | \$1,500 | 0\% | \$1,500 | \$1,600 | N/A | N/A | SAAO | 1.1600 |
| 2 | CDHP | \$1,500 | 20\% | \$2,500 | \$1,600 | N/A | N/A | SAAO | 1.0962 |
| 3 | CDHP | \$2,000 | 0\% | \$2,000 | \$1,600 | N/A | N/A | SAAO | 1.1130 |
| 4 | CDHP | \$2,000 | 20\% | \$4,000 | \$1,600 | N/A | N/A | SAAO | 1.0289 |
| 5 | CDHP | \$2,500 | 0\% | \$2,500 | \$1,600 | 0\% | N/A | SAAO | 1.0878 |
| 6 | CDHP | \$2,500 | 0\% | \$2,500 | \$1,600 | N/A | N/A | SAAO | 1.0735 |
| 7 | CDHP | \$2,500 | 0\% | \$3,500 | \$1,600 | 0\% | \$10/\$30/\$50 | SAAO | 1.0832 |
| 8 | CDHP | \$2,500 | 10\% | \$3,500 | \$1,600 | 0\% | N/A | SAAO | 1.0510 |
| 9 | CDHP | \$2,500 | 20\% | \$3,500 | \$1,600 | N/A | N/A | SAAO | 1.0252 |
| 10 | CDHP | \$2,500 | 20\% | \$5,000 | \$1,600 | 0\% | N/A | SAAO | 1.0064 |
| 11 | CDHP | \$2,600 | 20\% | \$5,000 | \$1,600 | 0\% | N/A | SAAO | 1.0030 |
| 12 | CDHP | \$2,700 | 20\% | \$5,000 | \$1,600 | 0\% | N/A | SAAO | 0.9997 |
| 13 | CDHP | \$3,000 | 0\% | \$3,000 | \$1,600 | N/A | \$10/\$35/\$50 | SAAO | 1.0397 |
| 14 | CDHP | \$3,000 | 0\% | \$3,000 | \$1,600 | 0\% | N/A | SAAO | 1.0557 |
| 15 | CDHP | \$3,000 | 0\% | \$3,000 | \$1,600 | N/A | N/A | SAAO | 1.0397 |
| 16 | CDHP | \$3,000 | 20\% | \$5,000 | \$1,600 | 0\% | N/A | SAAO | 0.9906 |
| 17 | CDHP | \$3,500 | 0\% | \$3,500 | \$1,600 | 0\% | N/A | SAAO | 1.0277 |
| 18 | CDHP | \$4,000 | 0\% | \$4,000 | \$1,600 | 0\% | N/A | SAAO | 1.0027 |
| 19 | CDHP | \$4,000 | 20\% | \$6,650 | \$1,600 | 0\% | N/A | SAAO | 0.9376 |
| 20 | CDHP | \$5,000 | 0\% | \$5,000 | \$1,600 | 0\% | N/A | SAAO | 0.9603 |
| 21 | CDHP | \$5,000 | 0\% | \$5,000 | \$1,600 | N/A | N/A | SAAO | 0.9402 |
| 22 | CDHP | \$6,000 | 0\% | \$6,000 | \$1,600 | 0\% | N/A | SAAO | 0.9251 |
| 23 | CDHP | \$6,000 | 0\% | \$6,000 | \$1,600 | N/A | N/A | SAAO | 0.9037 |
| 24 | CDHP | \$6,500 | 0\% | \$6,500 | \$1,600 | 0\% | N/A | SAAO | 0.9096 |
| 25 | CDHP | \$6,500 | 0\% | \$6,500 | \$1,600 | N/A | N/A | SAAO | 0.8875 |
| 26 | CDHP | \$7,000 | 0\% | \$7,000 | \$1,600 | 0\% | N/A | SAAO | 0.8953 |
| 27 | CDHP | \$7,000 | 0\% | \$7,000 | \$1,600 | N/A | N/A | SAAO | 0.8728 |
| 28 | CDHP | \$8,050 | 0\% | \$8,050 | \$1,600 | 0\% | N/A | SAAO | 0.8685 |
| 29 | CDHP | \$8,050 | 0\% | \$8,050 | \$1,600 | N/A | N/A | SAAO | 0.8450 |

1. The Rx OOPM Limit is as described in Vermont Act 171.
2. Wellness Rx: if applicable, cost sharing rules apply before the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.
3. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

Medicare Secondary Vermont Freedom Plan (VFP) and Indemnity J-Plan (JPLAN)

|  |  | In-Network Benefits |  |  |  |  |  |  | Out-of-Network Benefits |  |  | Relativity Factor |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| index | Product | Deductible | Coinsurance | Out-of-Pocket | Office Copay | Specialist Copay | ER ${ }^{1}$ Copay | AMB <br> Copay | Deductible | Coinsurance | Out-of- <br> Pocket | Medicare <br> Secondary |
| 1 | JPLAN ${ }^{2}$ | \$100 | 20\% | \$9,450 | \$10 | \$10 |  |  |  |  |  | 0.3702 |
| 2 | JPLAN ${ }^{2}$ | \$100 | 20\% | \$9,450 | \$20 | \$20 |  |  |  |  |  | 0.3583 |
| 3 | VFP | \$0 | 0\% | \$0 | \$20 | \$20 | \$50 |  | \$250 | 20\% | \$1,000 | 0.3895 |
| 4 | VFP | \$100 | 20\% | \$500 | \$10 | \$10 |  |  | \$200 | 30\% | \$1,000 | 0.3434 |
| 5 | VFP | \$1,000 | 0\% | \$2,350 | \$25 | \$25 | \$50 | \$50 | \$2,000 | 30\% | \$3,500 | 0.2713 |
| 6 | VFP | \$1,000 | 20\% | \$3,500 | \$25 | \$40 |  |  | \$2,000 | 30\% | \$7,000 | 0.2335 |
| 7 | VFP | \$500 | 20\% | \$1,600 | \$10 | \$10 |  |  | \$1,000 | 30\% | \$3,000 | 0.2896 |

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at $100 \%$.
2. The J Plan deductible applies only to infusion therapy, DME and prosthetics ambulance.

Medicare Secondary Prescription Drug Cards

|  |  |  | Copay (\$) / Coinsurance (\%) |  |  |  |  |  |  |  | Relativity |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Index | Type | Deductible | Retail <br> Generic | Retail Preferred Brand | Retail Non- <br> Preferred Brand | Mail Order Generic | Mail Order <br> Preferred Brand | Mail Order <br> NonPreferred Brand | OOPM | Diabetic <br> Supplies | Medicare <br> Secondary |
| 1 | COP | \$0 | \$10 | \$20 | \$40 | \$20 | \$40 | \$80 | \$1,600 | SAAO | 0.8036 |
| 2 | COP | \$0 | \$15 | \$30 | \$45 | \$30 | \$60 | \$90 | \$1,600 | SAAO | 0.7683 |
| 3 | COP | \$0 | \$5 | \$30 | \$50 | \$10 | \$60 | \$100 | \$1,600 | SAAO | 0.7855 |
| 4 | COP | \$50 | \$5 | \$10 | \$25 | \$10 | \$20 | \$50 | \$1,600 | SAAO | 0.8435 |
| 5 | COP | \$100 | \$10 | \$30 | \$45 | \$20 | \$60 | \$90 | \$1,600 | SAAO | 0.7612 |
| 6 | COP | \$100 | \$15 | \$30 | \$45 | \$30 | \$60 | \$90 | \$1,600 | SAAO | 0.7594 |

* Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COP/COI)
* Diabetic: If " $100 \%$ " then Diabetic medications and supplies are covered at $100 \%$ of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

## Medicare Secondary Consumer Driven Health Plans (CDHPs)



1. The Rx OOPM Limit is as described in Vermont Act 171.
2. Wellness $\mathbf{R x}$ : if applicable, cost sharing rules apply before the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.
3. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs

After Deductible cost share until the Out-of-Pocket Maximum is met.

## Vermont Freedom Plan (VFP) and Comprehensive (COMP)

|  |  | In-Network Benefits |  |  |  |  |  |  | Out-of-Network Benefits |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| index | Product | Deductible | Coinsurance | Out-of-Pocket | Office Copay | Specialist Copay | ER ${ }^{1}$ Copay | AMB Copay | Deductible | Coinsurance | Out-of- <br> Pocket | Leverage <br> Factor |
| 1 | VFP | \$200 | 20\% | \$800 | \$20 | \$20 |  |  | \$400 | 30\% | \$1,600 | 1.0041 |
| 2 | VFP | \$300 | 10\% | \$1,300 | \$10 | \$30 | \$100 | \$50 | \$600 | 30\% | \$2,600 | 1.0047 |
| 3 | VFP | \$500 | 20\% | \$1,500 | \$20 | \$20 |  |  | \$1,000 | 30\% | \$3,000 | 1.0060 |
| 4 | VFP | \$1,000 | 20\% | \$3,500 | \$25 | \$40 |  |  | \$2,000 | 30\% | \$7,000 | 1.0097 |
| 5 | VFP | \$1,000 | 0\% | \$2,000 | \$30 | \$50 | \$150 |  | \$2,000 | 30\% | \$4,000 | 1.0067 |
| 6 | VFP | \$1,500 | 20\% | \$3,000 | \$25 | \$45 | \$250 | \$250 | \$3,000 | 30\% | \$6,000 | 1.0092 |
| 7 | VFP | \$2,000 | 30\% | \$3,500 | \$20 | \$20 | \$500 |  | \$3,000 | 50\% | \$6,000 | 1.0102 |
| 8 | VFP | \$3,000 | 0\% | \$4,000 | \$30 | \$50 | \$150 |  | \$6,000 | 30\% | \$8,000 | 1.0106 |
| 9 | VFP | \$4,000 | 0\% | \$5,000 | \$30 | \$50 | \$150 |  | \$8,000 | 30\% | \$10,000 | 1.0121 |
| 10 | VFP | \$5,000 | 0\% | \$5,000 | \$25 | \$25 |  |  | \$10,000 | 30\% | \$10,000 | 1.0140 |
| 11 | COMP | \$2,000 | 10\% | \$3,000 |  |  |  |  |  |  |  | 1.0113 |
| 12 | COMP | \$5,000 | 0\% | \$5,000 |  |  |  |  |  |  |  | 1.0166 |

1. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are the covered at $100 \%$.

Vermont Health Partnership (VHP) Medical Plans

|  |  | VHP In-Network Benefits |  |  |  |  |  |  | VHP Out-of-Network Benefits |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| index | Product | Inpatient Care Deductible ${ }^{2}$ | Outpatient Surgery Copay | Office Copay | Specialist Copay | ER ${ }^{3}$ Copay | AMB Copay | Out-of- <br> Pocket | Deductible | Coinsurance | Out-of- <br> Pocket | Leverage Factor |
| 1 | VHP ${ }^{1}$ | \$0 | \$0 | \$10 | \$20 | \$50 | \$50 | \$9,450 | \$500 | 30\% | \$18,900 | 1.0022 |
| 2 | $V H P^{1}$ | \$250 | \$100 | \$15 | \$25 | \$50 | \$50 | \$9,450 | \$500 | 30\% | \$18,900 | 1.0026 |
| 3 | $V H P^{1}$ | \$250 | \$250 | \$20 | \$20 | \$200 | \$100 | \$9,450 | \$1,000 | 30\% | \$18,900 | 1.0030 |
| 4 | VHP ${ }^{1}$ | \$750 | \$750 | \$20 | \$30 | \$50 | \$50 | \$9,450 | \$500 | 30\% | \$18,900 | 1.0036 |

1. All VHP Plans have a DME rider benefit of: $\$ 100$ deductible, $20 \%$ coinsurance, built into the relativity.
2. Maximum of $3 / y r$ per family
3. ER Copay: the displayed member copay goes toward the facility allowed charges. Associated physician and ancillary charges are then covered at $100 \%$.

Blue Cross VT Comprehensive Consumer Driven Health Plans (CDHPs)

|  |  | In-Network |  |  |  |  |  |  | Leverage Factor |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| index | Product | Deductible | Coinsurance | Out-of-Pocket | $\begin{gathered} \hline \text { RX OOPM } \\ \text { Limit }^{1} \end{gathered}$ | $\begin{gathered} \hline \text { Wellness } \\ \mathrm{Rx}^{2} \\ \hline \end{gathered}$ | Drugs After Deductible ${ }^{3}$ | Diabetic Supplies | Medical | Rx |
| 1 | CDHP | \$1,500 | 0\% | \$1,500 | \$1,600 | N/A | N/A | SAAO | 1.0073 | 1.0065 |
| 2 | CDHP | \$2,500 | 20\% | \$5,000 | \$1,600 | 0\% | N/A | SAAO | 1.0141 | 1.0043 |
| 3 | CDHP | \$3,000 | 0\% | \$3,000 | \$1,600 | N/A | N/A | SAAO | 1.0117 | 1.0086 |
| 4 | CDHP | \$5,000 | 0\% | \$5,000 | \$1,600 | 0\% | N/A | SAAO | 1.0163 | 1.0044 |
| 5 | CDHP | \$6,000 | 0\% | \$6,000 | \$1,600 | 0\% | N/A | SAAO | 1.0180 | 1.0045 |
| 6 | CDHP | \$8,050 | 0\% | \$8,050 | \$1,600 | N/A | N/A | SAAO | 1.0207 | 1.0102 |

1. The $\mathbf{R x}$ OOPM Limit is as described in Vermont Act 171.
2. Wellness $\mathbf{R x}$ : if applicable, cost sharing rules apply before the deductible is satisfied.

The member's cost share for Wellness Rx accumulates toward the Out-of-Pocket Maximum.
3. All other drugs are subject to deductible. Once the deductible is met, drugs are subject to the Drugs After Deductible cost share until the Out-of-Pocket Maximum is met.

Prescription Drug Cards

|  |  |  | Copay (\$) / Coinsurance (\%) |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Index | Type | Deductible | Retail Generic | Retail Preferred Brand | Retail NonPreferred Brand | Mail Order Generic | Mail Order Preferred Brand | Mail Order NonPreferred Brand | OOPM | Diabetic Supplies | Leverage <br> Factor |
| 1 | CM1 | \$100 | \$5 | 40\% | 60\% | \$10 | 40\% | 60\% | \$1,600 | SAAO | 1.0093 |
| 2 | CM2 | \$0 | \$5 | \$50 | 50\% | \$10 | \$100 | 50\% | \$1,600 | SAAO | 1.0062 |
| 3 | CM2 | \$100 | \$5 | \$50 | 50\% | \$10 | \$100 | 50\% | \$1,600 | SAAO | 1.0073 |
| 4 | COI | \$0 | 30\% | 30\% | 40\% | 30\% | 30\% | 40\% | \$1,600 | SAAO | 1.0076 |
| 5 | COI | \$0 | 50\% | 50\% | 50\% | 50\% | 50\% | 50\% | \$1,600 | SAAO | 1.0094 |
| 6 | COP | \$0 | \$10 | \$20 | \$40 | \$20 | \$40 | \$80 | \$1,600 | SAAO | 1.0053 |
| 7 | COP | \$0 | \$10 | \$25 | \$50 | \$20 | \$50 | \$100 | \$1,600 | SAAO | 1.0057 |
| 8 | COP | \$0 | \$10 | \$30 | \$50 | \$20 | \$60 | \$100 | \$1,600 | SAAO | 1.0060 |
| 9 | COP | \$0 | \$10 | \$30 | \$60 | \$20 | \$60 | \$120 | \$1,600 | SAAO | 1.0060 |
| 10 | COP | \$0 | \$10 | \$35 | \$60 | \$20 | \$70 | \$120 | \$1,600 | SAAO | 1.0063 |
| 11 | COP | \$0 | \$15 | \$25 | \$40 | \$30 | \$50 | \$80 | \$1,600 | SAAO | 1.0062 |
| 12 | COP | \$0 | \$15 | \$30 | \$45 | \$30 | \$60 | \$90 | \$1,600 | SAAO | 1.0065 |
| 13 | COP | \$0 | \$15 | \$35 | \$50 | \$30 | \$70 | \$100 | \$1,600 | SAAO | 1.0068 |
| 14 | COP | \$0 | \$20 | \$40 | \$60 | \$40 | \$80 | \$120 | \$1,600 | SAAO | 1.0073 |
| 15 | COP | \$0 | \$20 | \$40 | \$80 | \$40 | \$80 | \$160 | \$1,600 | SAAO | 1.0074 |
| 16 | COP | \$0 | \$25 | \$50 | \$75 | \$50 | \$100 | \$150 | \$1,600 | SAAO | 1.0080 |
| 17 | COP | \$0 | \$5 | \$15 | \$30 | \$10 | \$30 | \$60 | \$1,600 | SAAO | 1.0038 |
| 18 | COP | \$0 | \$5 | \$30 | \$50 | \$10 | \$60 | \$100 | \$1,600 | SAAO | 1.0048 |
| 19 | COP | \$50 | \$10 | \$25 | \$50 | \$20 | \$50 | \$100 | \$1,600 | SAAO | 1.0061 |
| 20 | COP | \$50 | \$5 | \$10 | \$25 | \$10 | \$20 | \$50 | \$1,600 | SAAO | 1.0041 |
| 21 | COP | \$100 | \$10 | \$15 | \$30 | \$20 | \$30 | \$60 | \$1,600 | SAAO | 1.0058 |
| 22 | COP | \$100 | \$10 | \$25 | \$45 | \$20 | \$50 | \$90 | \$1,600 | SAAO | 1.0065 |
| 23 | COP | \$100 | \$10 | \$30 | \$45 | \$20 | \$60 | \$90 | \$1,600 | SAAO | 1.0068 |
| 24 | COP | \$100 | \$10 | \$30 | \$50 | \$20 | \$60 | \$100 | \$1,600 | 100\% | 1.0060 |
| 25 | COP | \$100 | \$10 | \$30 | \$50 | \$20 | \$60 | \$100 | \$1,600 | SAAO | 1.0068 |
| 26 | COP | \$100 | \$10 | \$40 | \$60 | \$20 | \$80 | \$120 | \$1,600 | SAAO | 1.0074 |
| 27 | COP | \$100 | \$15 | \$30 | \$45 | \$30 | \$60 | \$90 | \$1,600 | SAAO | 1.0072 |
| 28 | COP | \$100 | \$15 | \$40 | \$60 | \$30 | \$80 | \$120 | \$1,600 | SAAO | 1.0077 |
| 29 | COP | \$100 | \$5 | \$20 | \$40 | \$10 | \$40 | \$80 | \$1,600 | SAAO | 1.0054 |
| 30 | COP | \$150 | \$20 | \$80 | \$100 | \$40 | \$160 | \$200 | \$1,600 | SAAO | 1.0094 |

[^16]* Diabetic: If " $100 \%$ " then Diabetic medications and supplies are covered at $100 \%$ of allowed charges;

If "SAAO" then Diabetic medications and supplies are subject to cost sharing same as any other prescription drug.

Tier Factors for Benefits with Separate Medical and Pharmacy Deductibles

| Out-of-Pocket | Type | 2-Tier |  | 3-Tier |  |  | 4-Tier |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Single | Family | Single | 2-Person | Family | Subscriber \& Subscriber \& |  |  |  |
| Range |  |  |  |  |  |  | Single | Spouse | Children | Family |
| NA/Stacked | 2 F Family | 1.000 | 2.341 | 1.000 | 2.000 | 2.782 | 1.000 | 2.000 | 1.706 | 2.871 |
| NA/Stacked | 2.5x Family | 1.000 | 2.335 | 1.000 | 2.000 | 2.771 | 1.000 | 2.000 | 1.704 | 2.860 |
| NA/Stacked | 3x Family | 1.000 | 2.333 | 1.000 | 2.000 | 2.768 | 1.000 | 2.000 | 1.704 | 2.856 |
| \$0-\$3,499 | Hybrid | 1.000 | 2.290 | 1.000 | 1.847 | 2.725 | 1.000 | 1.932 | 1.650 | 2.812 |
| \$3,500-\$4,999 | Hybrid | 1.000 | 2.243 | 1.000 | 1.787 | 2.663 | 1.000 | 1.877 | 1.619 | 2.748 |
| \$5,000+ | Hybrid | 1.000 | 2.251 | 1.000 | 1.801 | 2.677 | 1.000 | 1.893 | 1.635 | 2.766 |

Tier Factors for Benefits with Integrated Medical and Pharmacy Deductibles

| Out-of-Pocket Range | Type | 2-Tier |  | 3-Tier |  |  | 4-Tier |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Single | Family | Single | 2-Person | Family | Subscriber \& Subscriber \& |  |  |  |
|  |  |  |  |  |  |  | Single | Spouse | Children | Family |
| NA/Stacked | $2 \times$ Family | 1.000 | 2.341 | 1.000 | 2.000 | 2.782 | 1.000 | 2.000 | 1.706 | 2.871 |
| NA/Stacked | 2.5x Family | 1.000 | 2.335 | 1.000 | 2.000 | 2.771 | 1.000 | 2.000 | 1.704 | 2.860 |
| NA/Stacked | 3x Family | 1.000 | 2.333 | 1.000 | 2.000 | 2.768 | 1.000 | 2.000 | 1.704 | 2.856 |
| \$0-\$3,499 | Aggregate | 1.000 | 2.229 | 1.000 | 1.764 | 2.697 | 1.000 | 1.850 | 1.577 | 2.791 |
| \$3,500-\$4,999 | Aggregate | 1.000 | 2.185 | 1.000 | 1.753 | 2.609 | 1.000 | 1.839 | 1.537 | 2.699 |
| \$5,000-\$9,150 | Aggregate | 1.000 | 2.158 | 1.000 | 1.702 | 2.589 | 1.000 | 1.794 | 1.523 | 2.678 |
| \$0-\$3,499 | Hybrid | 1.000 | 2.229 | 1.000 | 1.783 | 2.697 | 1.000 | 1.870 | 1.577 | 2.791 |
| \$3,500-\$4,999 | Hybrid | 1.000 | 2.209 | 1.000 | 1.760 | 2.632 | 1.000 | 1.854 | 1.559 | 2.722 |
| \$5,000+ | Hybrid | 1.000 | 2.206 | 1.000 | 1.778 | 2.625 | 1.000 | 1.865 | 1.557 | 2.714 |

## Example of Manual Rate Adjustment

## Manual Rate

Average Age/Gender Factor
Average Industry Factor
Projection Period
Trend Factor
Benefit Normalization Factor

Group Information
Age/Gender Factor
Industry Factor
Projection Period

Contract Conversion
Single
Two-Person
Family

Manual Rate
Adjustment for Age/Gender
Adjustment for Industry
Adjustment for Trend
Contract Conversion Factor
Benefit Normalization Factor
Adjusted Manual Rate
\$817.24
1.000
1.000

1/1/2025
9.90\%
0.9885

Active $\quad$| Medicare Primary |  |
| :---: | :---: |
|  |  |
| 0.940 |  |

| Contract Distribution | Members | Tier Factor | "Contract Tiers" |
| :---: | :---: | :---: | :---: |
| 25 | 25 | 1 | 25 |
| 25 | 50 | 2.000 | 50 |
| 50 | 197 | 2.782 | 139.09 |
| 100 | 272 |  | 214.09 |


| Active | Medicare Primary |
| :---: | :---: |
| $\$ 817.24$ | $\$ 547.95$ |
| 0.9400 | 1.0300 |
| 0.9650 | 1.0000 |
| 1.0483 | 1.0239 |
| 1.2705 | 1.0000 |
| 0.9885 | N/A |
| $\$ 976.02$ | $\$ 577.86$ |

Industry Factors

| 2-Digit <br> SIC Code Industry Description | Normalized Factor |
| :---: | :---: |
| 01 Agricultural Production - Crops | 0.9333 |
| 02 Agricultural Production - Livestock And Animal Specialties | 0.9401 |
| 07 Agricultural Services | 0.9337 |
| 08 Forestry | 0.9390 |
| 09 Fishing, Hunting And Trapping | 1.0147 |
| 10 Metal Mining | 1.0689 |
| 12 Coal Mining | 1.0765 |
| 13 Oil And Gas Extraction | 0.9840 |
| 14 Mining And Quarrying Of Nonmetallic Minerals, Except Fuels | 1.0464 |
| 15 Building Cnstrctn - General Contractors \& Operative Builders | 0.9524 |
| 16 Heavy Cnstrctn, Except Building Construction - Contractors | 0.9467 |
| 17 Construction - Special Trade Contractors | 0.9478 |
| 20 Food And Kindred Products | 0.9027 |
| 21 Tobacco Products | 0.9647 |
| 22 Textile Mill Products | 0.9184 |
| 23 Apparel, Finished Prdcts From Fabrics \& Similar Materials | 0.9304 |
| 24 Lumber And Wood Products, Except Furniture | 0.9629 |
| 25 Furniture And Fixtures | 0.9184 |
| 26 Paper And Allied Products | 0.9281 |
| 27 Printing, Publishing And Allied Industries | 0.9095 |
| 28 Chemicals And Allied Products | 0.9562 |
| 29 Petroleum Refining And Related Industries | 0.9570 |
| 30 Rubber And Miscellaneous Plastic Products | 0.9146 |
| 31 Leather And Leather Products | 0.9434 |
| 32 Stone, Clay, Glass, And Concrete Products | 0.9505 |
| 33 Primary Metal Industries | 0.9364 |
| 34 Fabricated Metal Prdcts, Except Machinery \& Transport Eqpmnt | 0.9174 |
| 35 Industrial And Commercial Machinery And Computer Equipment | 0.9146 |
| 36 Electronic, Elctrcl Eqpmnt \& Cmpnts, Excpt Computer Eqpmnt | 0.9006 |
| 37 Transportation Equipment | 0.9456 |
| 38 Mesr/Anlyz/Cntrl Instrmnts; Photo/Med/Opt Gds; Watchs/Clocks | 0.8991 |
| 39 Miscellaneous Manufacturing Industries | 0.9128 |
| 40 Railroad Transportation | 0.9570 |
| 41 Local, Suburban Transit \& Interurbn Hgwy Passenger Transport | 0.9971 |
| 42 Motor Freight Transportation | 0.9979 |
| 43 United States Postal Service | 0.9261 |
| 44 Water Transportation | 0.9763 |
| 45 Transportation By Air | 0.9242 |
| 46 Pipelines, Except Natural Gas | 0.9416 |
| 47 Transportation Services | 0.9068 |
| 48 Communications | 0.8831 |
| 49 Electric, Gas And Sanitary Services | 0.9493 |
| 50 Wholesale Trade - Durable Goods | 0.9286 |
| 51 Wholesale Trade - Nondurable Goods | 0.9187 |
| 52 Building Matrials, Hrdwr, Garden Supply \& Mobile Home Dealrs | 0.9177 |
| 53 General Merchandise Stores | 0.9171 |
| 54 Food Stores | 0.9195 |
| 55 Automotive Dealers And Gasoline Service Stations | 0.9898 |
| 56 Apparel And Accessory Stores | 0.9184 |
| 57 Home Furniture, Furnishings And Equipment Stores | 0.9107 |
| 58 Eating And Drinking Places | 1.0400 |
| 59 Miscellaneous Retail | 0.9483 |
| 60 Depository Institutions | 0.9030 |
| 61 Nondepository Credit Institutions | 0.8739 |
| 62 Security \& Commodity Brokers, Dealers, Exchanges \& Services | 0.9034 |
| 63 Insurance Carriers | 0.9261 |
| 64 Insurance Agents, Brokers And Service | 0.9261 |
| 65 Real Estate | 0.9493 |
| 67 Holding And Other Investment Offices | 0.9030 |
| 70 Hotels, Rooming Houses, Camps, And Other Lodging Places | 0.9902 |
| 72 Personal Services | 0.9710 |
| 73 Business Services | 0.9160 |
| 75 Automotive Repair, Services And Parking | 0.9628 |
| 76 Miscellaneous Repair Services | 0.9287 |
| 78 Motion Pictures | 0.9410 |
| 79 Amusement And Recreation Services | 1.0108 |
| 80 Health Services | 1.0651 |
| 81 Legal Services | 0.9609 |
| 82 Educational Services | 0.9194 |
| 83 Social Services | 1.0651 |
| 84 Museums, Art Galleries And Botanical And Zoological Gardens | 0.9261 |
| 86 Membership Organizations | 0.9730 |
| 87 Engineering, Accounting, Research, Management \& Related Svcs | 0.8791 |
| 88 Private Households | 0.9261 |
| 89 Services, Not Elsewhere Classified | 0.9300 |
| 91 Executive, Legislative \& General Government, Except Finance | 1.0651 |
| 92 Justice, Public Order And Safety | 1.0651 |
| 93 Public Finance, Taxation And Monetary Policy | 0.9817 |
| 94 Administration Of Human Resource Programs | 0.9879 |
| 95 Administration Of Environmental Quality And Housing Programs | 0.9802 |
| 96 Administration Of Economic Programs | 0.9817 |
| 97 National Security And International Affairs | 1.0119 |
| 99 Nonclassifiable Establishments | 0.9261 |

PROJECTED 2025 MLR CALCULATION

Blue Cross VT
(A) Manual Rate
(B) Rebates
(C) Estimated HCQ
(D) State Mandates and Assessments
(E) MLR Numerator
(F) Projected Claims
(G) Net Cost of Reinsurance
(H) Administrative Charge
(I) GMCB Billbacks
(J) Patient-Centered Outcomes Research Institute
(K) Subtotal
(L) Total Premium
(M) Commissions
(N) Contribution to Reserve
(O) MLR Denominator
(P) MLR

```
$817.24 Exhibit 4A
$43.23 Actuarial Memorandum, Section 2.3
    $1.97 2022 MLR Filing, untrended
    $16.60 Calculation as described on Exhibit 1C, using latest actual PMPM as needed
    $792.58 = (A) - (B) + (C) + (D)
    $790.61 = (A) - (B) + (D)
        $3.08 Actuarial Memorandum, Section 6.4
    $55.03 Exhibit 5A
        $2.08 Actuarial Memorandum, Section 6.8
        $0.31 Actuarial Memorandum, Section 6.9
    $851.11 = (F) +(G) + (H)+(I)+(J)
    $883.01 = (K)/(1-0.005-0.03)
        $5.41 = (L) x 0.5% (from 2022 MLR filing)
    $26.49 = (L) x 3.0% (from Actuarial Memorandum, Section 6.7)
    $883.01 = (L)
    89.8% = (E) / (O)
```

Administrative Charges PUPM

|  |  |  |
| ---: | :---: | :---: |
| Expense PUPM | Member |  |
| Increase for Membership | B | $\$ 50.64$ |
| Updated Expense PUPM | $\mathrm{C}=\mathrm{A} \times(1+\mathrm{B})$ | $-3.4 \%$ |
| Annual Trend | D | $\$ 48.92$ |
| Monthly Trend Factor | $\mathrm{E}=(1+\mathrm{D})(1 / 12)$ | $4.0 \%$ |
|  | F | 1.0033 |
|  |  | 24 |


| Projection Periods Effective Date |  | Member |
| :---: | :---: | :---: |
| Jan-24 | $\mathrm{G}=\mathrm{CxE} \times(\mathrm{F})$ | \$52.92 |
| Feb-24 | $\mathrm{H}=\mathrm{GXE}$ | \$53.09 |
| Mar-24 | $1=\mathrm{HxE}$ | \$53.26 |
| Apr-24 |  | \$53.44 |
| May-24 |  | \$53.61 |
| Jun-24 |  | \$53.79 |
| Jul-24 |  | \$53.96 |
| Aug-24 |  | \$54.14 |
| Sep-24 |  | \$54.32 |
| Oct-24 |  | \$54.50 |
| Nov-24 |  | \$54.67 |
| Dec-24 |  | \$54.85 |
| Jan-25 |  | \$55.03 |
| Feb-25 |  | \$55.21 |
| Mar-25 |  | \$55.39 |
| Apr-25 |  | \$55.58 |
| May-25 |  | \$55.76 |
| Jun-25 |  | \$55.94 |
| Jul-25 |  | \$56.12 |
| Aug-25 |  | \$56.31 |
| Sep-25 |  | \$56.49 |
| Oct-25 |  | \$56.68 |


| Pooling Limit | Member Months |
| :---: | :---: |
| \$30,000 | 8,325 |
| \$35,000 | 9,182 |
| \$40,000 | 9,990 |
| \$45,000 | 10,747 |
| \$50,000 | 11,462 |
| \$55,000 | 12,142 |
| \$60,000 | 12,786 |
| \$65,000 | 13,406 |
| \$70,000 | 14,002 |
| \$75,000 | 14,573 |
| \$80,000 | 15,117 |
| \$85,000 | 15,633 |
| \$90,000 | 16,127 |
| \$95,000 | 16,600 |
| \$100,000 | 17,055 |
| \$105,000 | 17,497 |
| \$110,000 | 17,923 |
| \$115,000 | 18,338 |
| \$120,000 | 18,745 |
| \$125,000 | 19,140 |
| \$130,000 | 19,523 |
| \$135,000 | 19,897 |
| \$140,000 | 20,266 |
| \$145,000 | 20,624 |
| \$150,000 | 20,974 |
| \$155,000 | 21,313 |
| \$160,000 | 21,643 |
| \$165,000 | 21,969 |
| \$170,000 | 22,289 |
| \$175,000 | 22,600 |
| \$180,000 | 22,905 |
| \$185,000 | 23,199 |
| \$190,000 | 23,486 |
| \$195,000 | 23,766 |
| \$200,000 | 24,039 |
| \$205,000 | 24,307 |
| \$210,000 | 24,570 |
| \$215,000 | 24,827 |
| \$220,000 | 25,077 |
| \$225,000 | 25,323 |
| \$230,000 | 25,563 |
| \$235,000 | 25,799 |
| \$240,000 | 26,032 |
| \$245,000 | 26,259 |
| \$250,000 | 26,480 |
| \$255,000 | 26,695 |
| \$260,000 | 26,905 |
| \$265,000 | 27,111 |
| \$270,000 | 27,316 |
| \$275,000 | 27,517 |
| \$280,000 | 27,712 |
| \$285,000 | 27,903 |
| \$290,000 | 28,086 |
| \$295,000 | 28,262 |
| \$300,000 | 28,438 |
| \$305,000 | 28,613 |
| \$310,000 | 28,786 |
| \$315,000 | 28,955 |
| \$320,000 | 29,123 |
| \$325,000 | 29,284 |
| \$330,000 | 29,438 |
| \$335,000 | 29,586 |
| \$340,000 | 29,732 |
| \$345,000 | 29,876 |
| \$350,000 | 30,019 |
| \$355,000 | 30,161 |
| \$360,000 | 30,305 |
| \$365,000 | 30,445 |
| \$370,000 | 30,579 |
| \$375,000 | 30,709 |
| \$380,000 | 30,839 |
| \$385,000 | 30,967 |
| \$390,000 | 31,087 |
| \$395,000 | 31,201 |
| \$400,000 | 31,311 |
| \$405,000 | 31,418 |
| \$410,000 | 31,521 |
| \$415,000 | 31,620 |
| \$420,000 | 31,718 |
| \$425,000 | 31,816 |
| \$430,000 | 31,912 |
| \$435,000 | 32,005 |
| \$440,000 | 32,097 |
| \$445,000 | 32,188 |
| \$450,000 | 32,280 |
| \$455,000 | 32,370 |
| \$460,000 | 32,459 |
| \$465,000 | 32,550 |
| \$470,000 | 32,639 |
| \$475,000 | 32,726 |
| \$480,000 | 32,813 |
| \$485,000 | 32,899 |
| \$490,000 | 32,984 |
| \$495,000 $\$ 500,000$ | 33,068 33,152 |

POOLING POINT by MEMBERSHIP

| Membership (Current <br> Month) | Pooling Limit |
| :---: | :---: |
| 0 to 299 | $\$ 100,000$ |
| 300 to 499 | $\$ 120,000$ |
| 500 to 999 | $\$ 140,000$ |
| 1,000 to 1,499 | $\$ 175,000$ |
| 1,500 to 1,999 | $\$ 200,000$ |
| 2,000 to 2,499 | $\$ 220,000$ |
| 2,500 to 2,999 | $\$ 250,000$ |
| 3,000 to 3,999 | $\$ 275,000$ |
| 4,000 to 4,999 | $\$ 315,000$ |
| 5,000 to 7,499 | $\$ 350,000$ |
| 7,500 to 9,999 | $\$ 400,000$ |
| $10,000+$ | $\$ 450,000$ |

## COVID-19 DIAGNOSIS and PROCEDURE CODES

| Diagnosis, Procedure, or Vaccine | Diagnosis or Procedure Code |
| :---: | :---: |
| Coronavirus Diagnosis Code | B34.2 |
| Coronavirus Diagnosis Code | B97.21 |
| Coronavirus Diagnosis Code | B97.29 |
| Coronavirus Diagnosis Code | U07.1 |
| Suspected COVID-19, Exposure to Infectious Disease | z03.818 |
| Suspected exposure to COVID-19 | Z20.822 |
| Suspected COVID-19, Exposure to Infectious Disease | Z20.828 |
| Screening for Infectious Disease | Z11.59 |
| COVID-19 Test | U0001 |
| COVID-19 Test | U0002 |
| COVID-19 Test | U0003 |
| COVID-19 Test | U0004 |
| COVID-19 Test | U0005 |
| COVID-19 Test | 87635 |
| Specimen Collection | C9803 |
| Specimen Collection | G2023 |
| Specimen Collection | G2024 |
| COVID-19 Test | 0202 U |
| COVID-19 Test | 0223 U |
| COVID-19 Test | 87426 |
| COVID-19 Test | 0225 U |
| COVID-19 Test | 87636 |
| COVID-19 Test | 87637 |
| COVID-19 Test | 87811 |
| COVID-19 Test | $0240 \cup$ |
| COVID-19 Test | 0241U |
| COVID-19 Antibody Test | 86328 |
| COVID-19 Antibody Test | 86769 |
| COVID-19 Antibody Test | 0224 U |
| COVID-19 Antibody Test | 86408 |
| COVID-19 Antibody Test | 86409 |
| COVID-19 Antibody Test | 86413 |
| COVID-19 Antibody Test | 0226 U |
| Paxlovid | J8499 |
| Evusheld and Evusheld Administration | Q0220 |
| Evusheld and Evusheld Administration | M0220 |
| Evusheld and Evusheld Administration | M0221 |
| Pfizer-BioNTech COVID-19 Vaccine | 91300 |
| Pfizer-BioNTech COVID-19 Vaccine | 0001A |
| Pfizer-BioNTech COVID-19 Vaccine | 0002A |
| Moderna, Inc. Moderna COVID-19 Vaccine | 91301 |
| Moderna, Inc. Moderna COVID-19 Vaccine | 0011A |
| Moderna, Inc. Moderna COVID-19 Vaccine | 0012A |
| J\&J COVID-19 Vaccine | 0031A |
| J\&J COVID-19 Vaccine | 91303 |


[^0]:    ${ }^{1}$ Previous large group filings were applicable to all insured large groups, including Cost Plus. As of January 2024, there is no active Cost Plus membership. As such, this filing does not develop any Cost Plus specific factors, and the factors included herein will not be used to rate prospective Cost Plus business.
    ${ }^{2}$ As of January 2023, there is no active TVHP large group membership. Similar to previous large group filings, we combine historical Blue Cross VT and TVHP large group experience to get a singular view of the market.

[^1]:    ${ }^{3} 2023$ underwriting results are preliminary as of December 31, 2023.
    ${ }^{4}$ This excludes three groups with fewer than 12 months of enrollment in the experience period used to develop the manual rate.

[^2]:    ${ }^{5}$ For first year renewals where twelve months of experience is not available, we typically use claims incurred in nine months with no runout.
    ${ }^{6}$ This corresponds with the conclusion of the state of emergency in Vermont.

[^3]:    ${ }^{7}$ E.g., the number of contracts in a particular tier may be small (or even 0). In such instances, the underwriter should use appropriate values based on total block of business or other appropriate sources.

[^4]:    ${ }^{8}$ This matches the GMCB-ordered methodology in the 2024 Large Group Rating Program filing (BCVT-133551255).
    ${ }^{9}$ Some Blue Cross VT groups have prior experience on TVHP. Since the trend factors are the ratio of the projected to experience trend factors by network, TVHP trend factors for December 2022 and prior may still needed to develop trends for groups affected by this filing. TVHP has no current large group enrollment, and that the trend factors in this filing will not be used to rate prospective TVHP business.

[^5]:    ${ }^{10}$ https://www.soa.org/Research/Research-Projects/Health/research-health-care-birth-death.aspx
    ${ }^{11}$ This curve is $I U=A V^{2}-A V+1.24$, where $A V$ is the actuarial value of the benefit plan.

[^6]:    ${ }^{12}$ https://gmcboard.vermont.gov/sites/gmcb/files/documents/FY 2024 UVMHN budget narrative 6.30 .23 final 1.pdf, pages 4-7
    ${ }^{13}$ https://gmcboard.vermont.gov/sites/gmcb/files/documents/UVMHN\%20additional\%20followup\%20questions\%209.8.23.pdf, question 1

[^7]:    ${ }^{14}$ Using the factors from the 2024 Blue Cross VT Large Group Rating Program Filing (BCVT-133551255).

[^8]:    ${ }^{15}$ The effective non-specialty utilization rate, which includes the GLP-1 adjustment, is 3.2 percent.
    ${ }^{16}$ The non-specialty trend prior to contract adjustments is
    ${ }^{17}$ The total trend prior to the contract adjustment is

[^9]:    ${ }^{18}$ We use claims incurred October 1, 2022, through September 30, 2023, projected to calendar year 2025.
    ${ }^{19}$ The paid trend without the pharmacy contract adjustment is

[^10]:    ${ }^{20}$ Although we will only quote benefits on Blue Cross VT Managed and Non-Managed contracts in all rating periods covered by this filing, some of the benefits in the experience include claims incurred on the TVHP Managed network.

[^11]:    ${ }^{21}$ Selected using the highest level a group in the manual rate membership base would be pooled at using the table in Exhibit 6B.
    ${ }^{22}$ Adjustment for estimated cost sharing on COVID-19 claims.

[^12]:    ${ }^{23}$ https://www.soa.org/Research/Research-Projects/Health/research-health-care-birth-death.aspx
    The factors for the age curve are in Chart 1 (for actives) and Chart 21 (for Medicare Primary) of the databook linked on the page.

[^13]:    ${ }^{24}$ http://www.vtvaccine.org/
    ${ }^{25}$ https://nhvaccine.org/
    ${ }^{26}$ https://www.health.ny.gov/regulations/hcra/gmecl.htm
    ${ }^{27}$ http://www.mgara.org/
    ${ }^{28}$ http://blueprintforhealth.vermont.gov/

[^14]:    a
    b
    $c=(a / b)^{\wedge} 0.5$

[^15]:    * Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COI/COI); CM2 = combined (COP/COP/COI)
    * Diabetic: If " $100 \%$ " then Diabetic medications and supplies are covered at $100 \%$ of allowed charges;

[^16]:    * Type: COI = coinsurance; COP = copay; CM1 = combined (COP/COI/COI); CM2 = combined (COP/COP/COI)

